Age-Related Clonal Hematopoiesis Associated with Adv

New England Journal of Medicine
371, 2488-2498
DOI: 10.1056/nejmoa1408617

Citation Report

#	Article	IF	Citations
1	Acute myeloid leukaemia. Hematology, 2014, 19, 493-494.	0.7	2
2	Clone Wars â€" The Emergence of Neoplastic Blood-Cell Clones with Aging. New England Journal of Medicine, 2014, 371, 2523-2525.	13.9	19
3	The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology American Society of Hematology Education Program, 2015, 2015, 299-307.	0.9	72
4	Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?. Hematology American Society of Hematology Education Program, 2015, 2015, 308-316.	0.9	16
5	Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica, 2015, 100, e434-e437.	1.7	27
6	Game of clones: the genomic evolution of severe congenital neutropenia. Hematology American Society of Hematology Education Program, 2015, 2015, 1-7.	0.9	44
7	Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. Hematology American Society of Hematology Education Program, 2015, 2015, 19-25.	0.9	32
8	Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology American Society of Hematology Education Program, 2015, 2015, 294-298.	0.9	34
9	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. Stem Cells, 2015, 33, 2887-2892.	1.4	8
10	DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica, 2015, 100, e438-e442.	1.7	105
13	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	0.6	207
14	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125, 1367-1376.	0.6	747
15	What came first: MDS or AML?. Blood, 2015, 125, 1357-1358.	0.6	5
16	Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood, 2015, 126, 445-453.	0.6	126
17	Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. Blood, 2015, 126, 1172-1183.	0.6	117
18	Clinical and molecular response to interferon-Î± therapy in essential thrombocythemia patients with CALR mutations. Blood, 2015, 126, 2585-2591.	0.6	127
19	Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood, 2015, 126, 2362-2365.	0.6	157
20	MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood, 2015, 126, 2355-2361.	0.6	280

#	Article	IF	Citations
21	Cytopenias + mutations â^' dysplasia = what?. Blood, 2015, 126, 2349-2351.	0.6	21
22	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	2.3	30
23	Premalignant cell dynamics in indolent B-cell malignancies. Current Opinion in Hematology, 2015, 22, 388-396.	1.2	13
24	The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. Current Opinion in Oncology, 2015, 27, 551-559.	1.1	8
25	Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes. BMC Genomics, 2015, 16, 727.	1.2	42
26	Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?. Haematologica, 2015, 100, 568-571.	1.7	3
27	Myelodysplastic Syndromes, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 261-272.	2.3	40
28	Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 829-832.	2.3	4
29	Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Current Opinion in Oncology, 2015, 27, 532-539.	1.1	19
30	New data shed light on Yâ€lossâ€related pathogenesis in myelodysplastic syndromes. Genes Chromosomes and Cancer, 2015, 54, 717-724.	1.5	42
31	Myelodysplastic syndromes: 2015 Update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2015, 90, 831-841.	2.0	101
32	Clonal Evolution Models of Tumor Heterogeneity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e662-e665.	1.8	28
33	Gene Mutations in Acute Myeloid Leukemia â€" Incidence, Prognostic Influence, and Association with Other Molecular Markers. , 0, , .		2
34	REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015018.	0.5	7
36	Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm. Mediators of Inflammation, 2015, 2015, 1-6.	1.4	36
37	Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis. Cell Reports, 2015, 10, 1239-1245.	2.9	443
38	High burden and pervasive positive selection of somatic mutations in normal human skin. Science, 2015, 348, 880-886.	6.0	1,431
39	Loss of Dnmt3a and endogenous KrasG12D/+ cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia, 2015, 29, 1847-1856.	3.3	38

#	Article	IF	Citations
40	Epigenetic Control of Stem Cell Potential during Homeostasis, Aging, and Disease. Cell Stem Cell, 2015, 16, 613-625.	5.2	144
41	Post-zygotic Point Mutations Are an Underrecognized Source of De Novo Genomic Variation. American Journal of Human Genetics, 2015, 97, 67-74.	2.6	215
42	Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms. Current Hematologic Malignancy Reports, 2015, 10, 104-111.	1.2	35
43	Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. Cell Stem Cell, 2015, 16, 601-612.	5.2	149
44	The Biology of Aging and Lymphoma: a Complex Interplay. Current Oncology Reports, 2015, 17, 32.	1.8	26
45	Minimal Residual Disease in Acute Myeloid Leukemiaâ€"Current Status and Future Perspectives. Current Hematologic Malignancy Reports, 2015, 10, 132-144.	1.2	31
46	Low frequency of mutations in Chinese with acute myeloid leukemia: Different disease or different aetiology?. Leukemia Research, 2015, 39, 646-648.	0.4	7
47	Stem cells and healthy aging. Science, 2015, 350, 1199-1204.	6.0	268
48	Mitochondrial dysfunction and longevity in animals: Untangling the knot. Science, 2015, 350, 1204-1207.	6.0	213
49	Leukemogenic Activity of Cohesin Rings True. Cell Stem Cell, 2015, 17, 642-644.	5.2	6
50	Aging, clonal hematopoiesis and preleukemia: not just bad luck?. International Journal of Hematology, 2015, 102, 513-522.	0.7	27
51	Modeling Normal and Disordered Human Hematopoiesis. Trends in Cancer, 2015, 1, 199-210.	3.8	10
52	The inflammatory microenvironment in MDS. Cellular and Molecular Life Sciences, 2015, 72, 1959-1966.	2.4	56
53	Multistep tumorigenesis in peripheral T cell lymphoma. International Journal of Hematology, 2015, 102, 523-527.	0.7	31
54	DNMT3A in haematological malignancies. Nature Reviews Cancer, 2015, 15, 152-165.	12.8	379
55	Do Mutational Dynamics in Stem Cells Explain the Origin of Common Cancers?. Cell Stem Cell, 2015, 16, 111-112.	5.2	7
56	Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. Leukemia, 2015, 29, 1600-1602.	3.3	16
57	Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genetics, 2015, 208, 115-128.	0.2	102

#	Article	IF	Citations
58	Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?. Current Hematologic Malignancy Reports, 2015, 10, 309-317.	1.2	9
59	Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?. Current Hematologic Malignancy Reports, 2015, 10, 282-291.	1.2	35
60	Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemia. International Journal of Hematology, 2015, 102, 278-288.	0.7	5
61	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?. Oncologist, 2015, 20, 1069-1076.	1.9	20
62	Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. Experimental Hematology, 2015, 43, 609-624.	0.2	47
64	Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 249-255.	1.8	5
65	Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8914-8921.	3.3	96
66	Advances in the diagnosis and classification of myelodysplastic syndromes. Diagnostic Histopathology, 2015, 21, 203-211.	0.2	2
67	Application of single-cell genomics in cancer: promise and challenges. Human Molecular Genetics, 2015, 24, R74-R84.	1.4	60
68	Insights into cell ontogeny, age, and acute myeloid leukemia. Experimental Hematology, 2015, 43, 745-755.	0.2	28
69	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 35-47.	13.9	508
70	New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Experimental Hematology, 2015, 43, 661-672.	0.2	7
71	Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 969-983.	1.4	78
72	Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to <scp>DNA</scp> Âdamage. EMBO Journal, 2015, 34, 624-640.	3.5	82
73	Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Seminars in Hematology, 2015, 52, 150-164.	1.8	55
74	Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 184-192.	1.8	32
75	Somatic mosaicism: implications for disease and transmission genetics. Trends in Genetics, 2015, 31, 382-392.	2.9	234
76	Clinical management of patients with ASXL1 mutations and Bohringâ€“Opitz syndrome, emphasizing the need for Wilms tumor surveillance. American Journal of Medical Genetics, Part A, 2015, 167, 2122-2131.	0.7	52

#	Article	IF	Citations
77	Distinguishing clonal evolution from so-called secondary acute myelogenous leukemia: Adhering to unifying concepts of the genetic basis of leukemogenesis. Blood Cells, Molecules, and Diseases, 2015, 55, 1-2.	0.6	3
78	TET proteins and the control of cytosine demethylation in cancer. Genome Medicine, 2015, 7, 9.	3.6	176
79	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 2015, 126, 9-16.	0.6	1,493
80	Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment. Leukemia and Lymphoma, 2015, 56, 3022-3030.	0.6	7
81	Myeloproliferative Neoplasms. JAMA Oncology, 2015, 1, 97.	3.4	266
82	Telomerase abrogates aneuploidyâ€induced telomere replication stress, senescence and cell depletion. EMBO Journal, 2015, 34, 1371-1384.	3.5	65
83	Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 264-275.	3.3	48
85	Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 502-515.	7.7	191
86	Genomic medicine at the heart of diabetes management. Diabetologia, 2015, 58, 1725-1729.	2.9	17
87	Genetics and genomics of psychiatric disease. Science, 2015, 349, 1489-1494.	6.0	337
88	Somatic mutation in cancer and normal cells. Science, 2015, 349, 1483-1489.	6.0	996
89	Aging as a driver of leukemogenesis. Science Translational Medicine, 2015, 7, 306fs38.	5.8	42
90	Aging of Human Haematopoietic Stem Cells. , 2015, , 127-147.		2
91	Why germline variations in ALL can matter. Lancet Oncology, The, 2015, 16, 1577-1578.	5.1	1
93	Frequent Somatic Mutation in Adult Intestinal Stem Cells Drives Neoplasia and Genetic Mosaicism during Aging. Cell Stem Cell, 2015, 17, 663-674.	5.2	79
94	Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia. Journal of Experimental and Clinical Cancer Research, 2015, 34, 55.	3.5	12
95	Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse. Frontiers of Medicine, 2015, 9, 412-420.	1.5	10
96	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 1673-1676.	13.9	32

#	Article	IF	Citations
97	The utility of nextâ€generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes. International Journal of Laboratory Hematology, 2015, 37, 115-121.	0.7	44
98	Clonal Hematopoiesis and Blood-Cancer Risk. New England Journal of Medicine, 2015, 372, 1071-1072.	13.9	57
99	The Fanconi anemia pathway is required for efficient repair of stress-induced DNA damage in haematopoietic stem cells. Cell Cycle, 2015, 14, 2734-2742.	1.3	18
100	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. Journal of Experimental Medicine, 2015, 212, 1819-1832.	4.2	137
101	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	0.5	47
102	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. Leukemia, 2015, 29, 2069-2074.	3.3	13
103	A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia, 2015, 29, 2101-2104.	3.3	32
105	Molecular Pathogenesis of Peripheral T Cell Lymphoma. Current Hematologic Malignancy Reports, 2015, 10, 429-437.	1.2	13
106	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nature Genetics, 2015, 47, 1334-1340.	9.4	152
107	DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. Clinical Chemistry, 2015, 61, 1354-1362.	1.5	9
108	Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. International Journal of Hematology, 2015, 102, 553-557.	0.7	16
109	Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 778.	3.8	14
110	Deconstructing innate immune signaling in myelodysplastic syndromes. Experimental Hematology, 2015, 43, 587-598.	0.2	29
111	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature Genetics, 2015, 47, 1131-1140.	9.4	107
112	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. Leukemia Research, 2015, 39, 1034-1040.	0.4	8
113	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	3.8	302
114	Acute Myeloid Leukemia. New England Journal of Medicine, 2015, 373, 1136-1152.	13.9	2,466
115	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	3.2	136

#	Article	IF	Citations
116	Pediatric myelodysplastic syndromes. Journal of Hematopathology, 2015, 8, 127-141.	0.2	8
117	Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer Journal, 2015, 5, e337-e337.	2.8	100
118	Fantastic voyage: the future of cancer diagnostics. Lancet Oncology, The, 2015, 16, 1596-1598.	5.1	6
119	Biologie des syndromes myÃ©loprolifÃ©ratifs : classifications diagnostiques et nouveaux marqueurs molÃ©culaires. Revue Francophone Des Laboratoires, 2015, 2015, 35-45.	0.0	1
120	Reasons for optimism in the therapy of acute leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 69-72.	0.7	9
121	AML evolution from preleukemia to leukemia and relapse. Best Practice and Research in Clinical Haematology, 2015, 28, 81-89.	0.7	20
122	Somatic mutations linked to future disease risk. Nature Reviews Genetics, 2015, 16, 69-69.	7.7	8
123	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. Blood Advances, 2016, 1, 160-169.	2.5	12
124	Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Advances, 2016, 1, 193-204.	2.5	63
125	Obesity and neoplasms of lymphohematopoietic cells. Blood Advances, 2016, 1, 101-103.	2.5	4
128	Myelodysplastic syndroms: epidemiology, diagnosis and treatment. Hematologie, 2016, 22, 288-296.	0.0	0
129	Stem Cell Epigenetics in Medical Therapy. , 2016, , 877-887.		0
130	Molecular landscape in acute myeloid leukemia: where do we stand in 2016. Cancer Biology and Medicine, 2016, 13, 474.	1.4	9
131	Clonal Hematopoiesis of Indeterminate Potential. Deutsches Ärzteblatt International, 2016, 113, 317-22.	0.6	65
132	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Frontiers in Immunology, 2016, 7, 94.	2.2	26
133	Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. Frontiers in Immunology, 2016, 7, 502.	2.2	272
134	Personalized Cancer Risk Assessments for Space Radiation Exposures. Frontiers in Oncology, 2016, 6, 38.	1.3	10
135	DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. Frontiers in Oncology, 2016, 6, 187.	1.3	38

#	Article	IF	Citations
136	The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) â€“ Mechanisms and Opportunities. Frontiers in Pediatrics, 2016, 4, 49.	0.9	11
137	Immune Mechanisms in Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2016, 17, 944.	1.8	48
138	Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients. PLoS ONE, 2016, 11, e0146264.	1.1	79
139	The Emerging Potential for Epigenetic Therapeutics in Noncancer Disorders. , 2016, , 437-456.		2
140	Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Research, 2016, 5, 700.	0.8	39
141	Therapy-related myeloid neoplasms. Current Opinion in Hematology, 2016, 23, 161-166.	1.2	17
142	Regulation of hematopoietic stem cell integrity through p53 and its related factors. Annals of the New York Academy of Sciences, 2016, 1370, 45-54.	1.8	23
143	Role of CSF3R mutations in the pathomechanism of congenital neutropenia and secondary acute myeloid leukemia. Annals of the New York Academy of Sciences, 2016, 1370, 119-125.	1.8	19
144	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer. EBioMedicine, 2016, 10, 117-123.	2.7	153
145	A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. Blood Cancer Journal, 2016, 6, e439-e439.	2.8	16
146	Novel therapeutic strategies in myelodysplastic syndromes. Current Opinion in Hematology, 2016, 23, 79-87.	1.2	2
147	Molecular landscapes of human hematopoietic stem cells in health and leukemia. Annals of the New York Academy of Sciences, 2016, 1370, 5-14.	1.8	24
148	Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance. Modern Pathology, 2016, 29, 1183-1199.	2.9	14
149	Aging, Clonality, and Rejuvenation of Hematopoietic Stem Cells. Trends in Molecular Medicine, 2016, 22, 701-712.	3.5	135
150	Genetically distinct leukemic stem cells in human CD34â˜ acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. Journal of Experimental Medicine, 2016, 213, 1513-1535.	4.2	120
151	Nextâ€generation sequencing in systemic mastocytosis: Derivation of a mutationâ€augmented clinical prognostic model for survival. American Journal of Hematology, 2016, 91, 888-893.	2.0	60
152	New challenges in evaluating anemia in older persons in the era of molecular testing. Hematology American Society of Hematology Education Program, 2016, 2016, 67-73.	0.9	15
153	The Mediator of Hematopoietic Stem Cell Homeostasis. Cell Stem Cell, 2016, 19, 677-678.	5.2	0

#	Article	IF	Citations
154	New insights into the generation and role of de novo mutations in health and disease. Genome Biology, 2016, 17, 241.	3.8	339
155	Molecular pathogenesis of chronic myelomonocytic leukemia. Memo - Magazine of European Medical Oncology, 2016, 9, 172-177.	0.3	2
156	SETD2andDNMT3Ascreen in the Sotos-like syndrome French cohort. Journal of Medical Genetics, 2016, 53, 743-751.	1.5	54
157	Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives. International Journal of Hematologic Oncology, 2016, 5, 143-164.	0.7	6
158	Single cell transcriptomics reveals unanticipated features of early hematopoietic precursors. Nucleic Acids Research, 2017, 45, gkw1214.	6.5	40
159	Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. Nature Communications, 2016, 7, 12157.	5.8	81
160	Reconciling Smooth Muscle Cell Oligoclonality and Proliferative Capacity in Experimental Atherosclerosis. Circulation Research, 2016, 119, 1262-1264.	2.0	23
161	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15084-15089.	3.3	96
162	Mutations in AML: prognostic and therapeutic implications. Hematology American Society of Hematology Education Program, 2016, 2016, 348-355.	0.9	136
163	Case 37-2016. New England Journal of Medicine, 2016, 375, 2273-2282.	13.9	3
164	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	0.9	32
165	Update from the latest WHO classification of MPNs: a userâ€™s manual. Hematology American Society of Hematology Education Program, 2016, 2016, 534-542.	0.9	42
166	Aplastic anemia and clonal evolution: germ line and somatic genetics. Hematology American Society of Hematology Education Program, 2016, 2016, 74-82.	0.9	35
167	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes. Journal of Oncology Practice, 2016, 12, 786-792.	2.5	10
168	Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment. Genome Medicine, 2016, 8, 100.	3.6	6
169	A physical mechanism of cancer heterogeneity. Scientific Reports, 2016, 6, 20679.	1.6	25
170	Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nature Communications, 2016, 7, 12484.	5.8	523
171	Role of TET enzymes in DNA methylation, development, and cancer. Genes and Development, 2016, 30, 733-750.	2.7	781

#	Article	IF	Citations
172	Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia, 2016, 30, 1924-1926.	3.3	44
173	Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Experimental Hematology, 2016, 44, 740-744.	0.2	48
174	Pathogenesis of Myeloproliferative Disorders. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 101-126.	9.6	38
175	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	2.9	104
176	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. American Journal of Human Genetics, 2016, 98, 1208-1219.	2.6	164
177	Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. Leukemia Research, 2016, 47, 41-46.	0.4	12
178	The curious origins of angioimmunoblastic T-cell lymphoma. Current Opinion in Hematology, 2016, 23, 434-443.	1.2	49
180	Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics, 2016, 48, 563-568.	9.4	134
181	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6005-6010.	3.3	135
183	Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. American Journal of Clinical Pathology, 2016, 145, 497-506.	0.4	36
184	Clinical significance of acquired somatic mutations in aplastic anaemia. International Journal of Hematology, 2016, 104, 159-167.	0.7	13
185	Frequent reconstitution of IDH2R140Q mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia. Leukemia, 2016, 30, 1946-1950.	3.3	10
186	Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current Opinion in Genetics and Development, 2016, 36, 100-106.	1.5	130
187	Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes and Development, 2016, 30, 989-1001.	2.7	95
188	Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood, 2016, 128, 1121-1128.	0.6	200
189	Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood, 2016, 127, 29-41.	0.6	356
190	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 2016, 127, 333-342.	0.6	149
191	An update of current treatments for adult acute myeloid leukemia. Blood, 2016, 127, 53-61.	0.6	444

#	Article	IF	Citations
192	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	0.6	94
193	Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML. Blood, 2016, 127, 2638-2641.	0.6	13
194	Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2. Blood, 2016, 127, 1512-1515.	0.6	38
195	Clonal hematopoiesis in acquired aplastic anemia. Blood, 2016, 128, 337-347.	0.6	158
196	Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood, 2016, 127, 2361-2364.	0.6	115
197	Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?. Leukemia, 2016, 30, 2127-2130.	3.3	14
200	Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood, 2016, 128, 1246-1259.	0.6	111
201	New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 279-280.	0.7	0
202	The Evolution of Lifespan and Age-Dependent Cancer Risk. Trends in Cancer, 2016, 2, 552-560.	3.8	83
203	Biology of peripheral T cell lymphomas â€“ Not otherwise specified: Is something finally happening?. Pathogenesis, 2016, 3, 9-18.	0.8	12
204	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology, 2016, 146, 408-422.	0.4	30
205	Tissue-specific mutation accumulation in human adult stem cells during life. Nature, 2016, 538, 260-264.	13.7	759
206	Molecular Testing in Patients with Suspected Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 441-448.	1.2	6
207	Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells. Experimental Hematology, 2016, 44, 1188-1196.e6.	0.2	11
208	Cardiovascular Toxic Effects of Targeted Cancer Therapies. New England Journal of Medicine, 2016, 375, 1457-1467.	13.9	470
209	Correlation of an epigenetic mitotic clock with cancer risk. Genome Biology, 2016, 17, 205.	3.8	197
210	Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia. Cell Stem Cell, 2016, 19, 613-627.	5.2	277
211	Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2. Experimental Hematology, 2016, 44, 1072-1084.	0.2	40

#	Article	IF	Citations
212	Persistence of <scp>DNMT</scp>3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 226-236.	1.2	49
213	Can exome scans be expected to be part of realâ€time decisionâ€making in patients with haematological cancers?. British Journal of Haematology, 2016, 174, 486-492.	1.2	0
214	Chronic lymphocytic leukemia: Time to go past genomics?. American Journal of Hematology, 2016, 91, 518-528.	2.0	13
215	RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell, 2016, 19, 599-612.	5.2	97
216	Aging of hematopoietic stem cells: DNA damage and mutations?. Experimental Hematology, 2016, 44, 895-901.	0.2	65
217	Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia, 2016, 30, 2422-2426.	3.3	6
218	Oncometabolite <scp>d</scp> -2-hydroxyglutarate impairs Î±-ketoglutarate dehydrogenase and contractile function in rodent heart. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10436-10441.	3.3	105
219	Cancer Prevention in the Older Individual. Seminars in Oncology Nursing, 2016, 32, 314-324.	0.7	15
220	The Role of Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026526.	2.9	48
221	Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2041-2049.	1.2	13
222	Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms. Current Hematologic Malignancy Reports, 2016, 11, 408-415.	1.2	19
223	MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis. Current Stem Cell Reports, 2016, 2, 183-196.	0.7	20
224	Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics, 2016, 48, 1193-1203.	9.4	952
225	Prognosis of Primary Myelofibrosis in the Genomic Era. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S105-S113.	0.2	12
226	Molecular Pathology. Surgical Pathology Clinics, 2016, 9, 475-488.	0.7	4
227	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
228	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	13.9	663
229	Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. American Journal of Hematology, 2016, 91, 1234-1238.	2.0	32

#	Article	IF	Citations
230	Critical Updates to the Leukemia Stem Cell Model. , 2016, , 101-119.		2
231	Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission. Leukemia Research, 2016, 49, 102-107.	0.4	18
232	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cellâ€“derived lymphomas. Blood, 2016, 128, 1490-1502.	0.6	255
233	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	3.3	57
234	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405.	0.6	7,429
235	Established and emerging targeted therapies in the myelodysplastic syndromes. Expert Review of Hematology, 2016, 9, 997-1005.	1.0	2
236	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood, 2016, 127, 749-760.	0.6	36
237	Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood, 2016, 127, 42-52.	0.6	234
238	Evaluating Elevated Hemoglobin. JAMA - Journal of the American Medical Association, 2016, 316, 1114.	3.8	0
239	Evaluating Elevated Hemoglobinâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 1115.	3.8	0
240	Immunohistochemical loss of 5â€hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways. Histopathology, 2016, 69, 1055-1065.	1.6	9
241	DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nature Genetics, 2016, 48, 1014-1023.	9.4	200
242	Inflammatory signals in HSPC development and homeostasis: Too much ofÂaÂgood thing?. Experimental Hematology, 2016, 44, 908-912.	0.2	14
243	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. British Journal of Haematology, 2016, 174, 847-858.	1.2	25
244	Acute myeloid leukaemia. Nature Reviews Disease Primers, 2016, 2, 16010.	18.1	277
245	How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood, 2016, 128, 1800-1813.	0.6	149
246	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	5.8	177
247	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	15.2	195

#	Article	IF	Citations
248	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	5.8	86
249	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer Journal, 2016, 6, e472-e472.	2.8	42
250	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell, 2016, 30, 750-763.	7.7	173
251	Leukemic Stem Cells S(p)liced Off. Cell Stem Cell, 2016, 19, 561-563.	5.2	0
252	Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nature Communications, 2016, 7, 12475.	5.8	95
253	The fetal thymus has a unique genomic copy number profile resulting from physiological T cell receptor gene rearrangement. Scientific Reports, 2016, 6, 23500.	1.6	3
254	Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, 2016, 374, 2209-2221.	13.9	3,067
255	Regulation of hematopoietic development by ZBTB transcription factors. International Journal of Hematology, 2016, 104, 310-323.	0.7	67
256	â€˜CHIPâ€™ping away at clonal hematopoiesis. Leukemia, 2016, 30, 1633-1635.	3.3	48
257	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	15.2	322
258	Terminal differentiation induction as DNA damage response in hematopoietic stem cells by GADD45A. Experimental Hematology, 2016, 44, 561-566.	0.2	15
259	Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. Experimental Hematology, 2016, 44, 857-865.e5.	0.2	5
260	Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development. Cancer Cell, 2016, 30, 92-107.	7.7	130
261	Molecular pathogenesis of pancreatic ductal adenocarcinoma. Diagnostic Histopathology, 2016, 22, 226-235.	0.2	1
262	Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Modern Pathology, 2016, 29, 996-1003.	2.9	12
263	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica, 2016, 101, 757-763.	1.7	75
264	Never too old to treat cancer?. Memo - Magazine of European Medical Oncology, 2016, 9, 2-3.	0.3	0
265	Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 89-95.	0.6	37

#	Article	IF	Citations
266	When Genome Maintenance Goes Badly Awry. Molecular Cell, 2016, 62, 777-787.	4.5	64
267	Epilogue: What the Future Holds: Genomic Medicine at the Heart of Diabetes Management. , 2016, , 561-570.		0
268	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	6.9	78
269	BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Annals of Hematology, 2016, 95, 1211-1221.	0.8	72
270	Incorporating measurable (â€˜minimalâ€™) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1527-1533.	0.6	7
271	Mutations of myelodysplastic syndromes (MDS): An update. Mutation Research - Reviews in Mutation Research, 2016, 769, 47-62.	2.4	87
272	p21 shapes cancer evolution. Nature Cell Biology, 2016, 18, 722-724.	4.6	22
273	JAK2 V617F mutation in immune thrombocytopenia. Thrombosis Research, 2016, 144, 149-151.	0.8	5
274	The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia. Tumor Biology, 2016, 37, 10107-10114.	0.8	20
275	Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. Therapeutic Advances in Hematology, 2016, 7, 3-16.	1.1	66
276	Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Expert Review of Hematology, 2016, 9, 447-469.	1.0	12
277	Somatic mosaicism: on the road to cancer. Nature Reviews Cancer, 2016, 16, 43-55.	12.8	113
278	Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia, 2016, 30, 248-250.	3.3	51
279	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	3.4	270
280	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
281	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	7.7	282
282	Age-related mutations and chronic myelomonocytic leukemia. Leukemia, 2016, 30, 906-913.	3.3	119
283	Roles of IDH1/2 and TET2 mutations in myeloid disorders. International Journal of Hematology, 2016, 103, 627-633.	0.7	44

#	Article	IF	Citations
284	Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation. Leukemia, 2016, 30, 1756-1759.	3.3	25
285	Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?. Acta Haematologica, 2016, 135, 39-42.	0.7	6
286	Understanding the physiology of the ageing individual: computational modelling of changes in metabolism and endurance. Interface Focus, 2016, 6, 20150079.	1.5	49
287	The Case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prevention Research, 2016, 9, 119-124.	0.7	85
288	Visualizing the origins of selfish de novo mutations in individual seminiferous tubules of human testes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2454-2459.	3.3	45
289	Leukaemia 'firsts' in cancer research and treatment. Nature Reviews Cancer, 2016, 16, 163-172.	12.8	67
290	The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer, 2016, 16, 145-162.	12.8	227
291	The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection. Nucleic Acids Research, 2016, 44, 2075-2084.	6.5	47
292	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia, 2016, 30, 1916-1920.	3.3	79
293	Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology, 2016, 21, 387-391.	0.7	14
294	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surgical Pathology Clinics, 2016, 9, 143-163.	0.7	14
295	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 496-508.	5.1	142
296	Rosaiâ€“Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation. Head and Neck Pathology, 2016, 10, 394-399.	1.3	60
297	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prevention Research, 2016, 9, 2-10.	0.7	130
298	Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1050-1055.	3.3	28
299	When stem cells grow old: phenotypes and mechanisms of stem cell aging. Development (Cambridge), 2016, 143, 3-14.	1.2	267
300	Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leukemia and Lymphoma, 2016, 57, 520-536.	0.6	96
301	Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia, 2016, 30, 285-294.	3.3	64

#	Article	IF	Citations
302	Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia, 2016, 30, 666-673.	3.3	177
303	Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1â€“PDFGRB fusion gene. Leukemia, 2016, 30, 1402-1405.	3.3	8
304	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. Annual Review of Medicine, 2016, 67, 59-72.	5.0	42
305	Long-term follow-up of the AML97 study for patients aged 60Âyears and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). Journal of Cancer Research and Clinical Oncology, 2016, 142, 305-315.	1.2	19
306	Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia, 2017, 31, 1-10.	3.3	63
307	Detection of activatingMAP2K1mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leukemia and Lymphoma, 2017, 58, 233-236.	0.6	39
308	Patientâ€tailored analysis of minimal residual disease in acute myeloid leukemia using nextâ€generation sequencing. European Journal of Haematology, 2017, 98, 26-37.	1.1	28
309	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	0.8	339
310	The clonal origins of leukemic progression of myelodysplasia. Leukemia, 2017, 31, 1928-1935.	3.3	41
311	Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science, 2017, 355, 842-847.	6.0	999
312	Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leukemia Research, 2017, 54, 55-58.	0.4	14
313	Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. American Journal of Clinical Pathology, 2017, 147, aqw203.	0.4	2
314	Recent advances in understanding clonal haematopoiesis in aplastic anaemia. British Journal of Haematology, 2017, 177, 509-525.	1.2	52
315	Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Cancer Genetics, 2017, 211, 5-8.	0.2	45
316	Biological and clinical consequences of NPM1 mutations in AML. Leukemia, 2017, 31, 798-807.	3.3	134
317	Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia, 2017, 31, 1238-1240.	3.3	37
318	Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 341-354.	1.2	6
319	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2017, 23, 612-617.	2.0	17

#	Article	IF	Citations
320	The ageing genome, clonal mosaicism and chronic disease. Current Opinion in Genetics and Development, 2017, 42, 8-13.	1.5	28
321	Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia. Leukemia Research, 2017, 56, 7-12.	0.4	51
322	Changing mutational and adaptive landscapes and the genesis of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 84-94.	3.3	27
323	The JAK2V617F mutation in normal individuals takes place in differentiating cells. Blood Cells, Molecules, and Diseases, 2017, 63, 45-51.	0.6	2
324	The feasibility of using mutation detection in ctDNA to assess tumor dynamics. International Journal of Cancer, 2017, 140, 2642-2647.	2.3	82
325	Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood, 2017, 129, 2266-2279.	0.6	152
326	Commonality with cancer. Nature, 2017, 543, 45-47.	13.7	22
327	Clonal reversal of ageing-associated stem cell lineage bias via a pluripotent intermediate. Nature Communications, 2017, 8, 14533.	5.8	36
328	Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 51.	6.9	85
329	Hematopoietic stem cells gone rogue. Science, 2017, 355, 798-799.	6.0	4
330	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	13.5	177
331	Myelodysplastic Syndromes. Medical Clinics of North America, 2017, 101, 333-350.	1.1	9
332	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	5.2	114
333	Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. Journal of Clinical Oncology, 2017, 35, 934-946.	0.8	372
334	The origin and evolution of the term â€œcloneâ€• Leukemia Research, 2017, 57, 97-101.	0.4	3
335	Molecular features of early onset adult myelodysplastic syndrome. Haematologica, 2017, 102, 1028-1034.	1.7	20
336	Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Human Mutation, 2017, 38, 517-523.	1.1	49
337	Reprint of: Aging: Treating the Older Patient. Biology of Blood and Marrow Transplantation, 2017, 23, S10-S17.	2.0	4

#	Article	IF	Citations
338	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Reviews, 2017, 31, 185-192.	2.8	83
339	Somatic clonal evolution: A selection-centric perspective. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 139-150.	3.3	61
340	Myeloproliferative neoplasm stem cells. Blood, 2017, 129, 1607-1616.	0.6	133
341	Biology and relevance of human acute myeloid leukemia stem cells. Blood, 2017, 129, 1577-1585.	0.6	328
342	Progenitor genotyping reveals a complex clonal architecture in a subset of <scp>CALR</scp>â€«mutated myeloproliferative neoplasms. British Journal of Haematology, 2017, 177, 55-66.	1.2	3
343	Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Blood, 2017, 129, 484-496.	0.6	22
344	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. Blood, 2017, 129, 2587-2591.	0.6	44
345	Mutation and catastrophe in the aging genome. Experimental Gerontology, 2017, 94, 34-40.	1.2	28
346	Quantitative stability of hematopoietic stem and progenitor cell clonal output in rhesus macaques receiving transplants. Blood, 2017, 129, 1448-1457.	0.6	53
347	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discovery, 2017, 7, 494-505.	7.7	94
348	Hematopoiesis Lineage Tree Uprooted: Every Cell Is a Rainbow. Developmental Cell, 2017, 41, 7-9.	3.1	8
349	The Aging Cardiovascular System. Journal of the American College of Cardiology, 2017, 69, 1952-1967.	1.2	400
350	The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 131-135.	2.3	7
351	Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129, 3371-3378.	0.6	379
352	Therapy-related myeloid neoplasms. Current Opinion in Hematology, 2017, 24, 152-158.	1.2	30
353	Clonal evolution in myelodysplastic syndromes. Nature Communications, 2017, 8, 15099.	5.8	118
354	Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiarDNMT3AR882 mutation. Journal of Medical Genetics, 2017, 54, 805-808.	1.5	30
355	Implications of molecular genetic diversity in myelodysplastic syndromes. Current Opinion in Hematology, 2017, 24, 73-78.	1.2	44

#	Article	IF	Citations
356	Characterization of TP53 mutations in clonal cytopenia of undetermined significance. American Journal of Hematology, 2017, 92, E175-E177.	2.0	4
357	Mutational signatures and mutable motifs in cancer genomes. Briefings in Bioinformatics, 2017, 19, 1085-1101.	3.2	32
358	Expression and Activity of the Small RhoGTPase Cdc42 in Blood Cells of Older Adults Are Associated With Age and Cardiovascular Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1196-1200.	1.7	20
359	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leukemia Research, 2017, 59, 47-54.	0.4	58
361	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood, 2017, 130, 91-94.	0.6	78
362	Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood, 2017, 130, 742-752.	0.6	582
363	Differences between germline and somatic mutation rates in humans and mice. Nature Communications, 2017, 8, 15183.	5.8	309
364	Telomere length is an independent prognostic marker in <scp>MDS</scp> but not in de novo <scp>AML</scp>. British Journal of Haematology, 2017, 178, 240-249.	1.2	21
365	Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders. Genetics in Medicine, 2017, 19, 1300-1308.	1.1	58
366	Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature, 2017, 545, 229-233.	13.7	409
367	Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. Cancer Science, 2017, 108, 553-562.	1.7	44
368	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.4	25
369	Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes. Methods in Molecular Biology, 2017, 1541, 209-222.	0.4	5
370	Preleukemia: one name, many meanings. Leukemia, 2017, 31, 534-542.	3.3	51
371	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	5.1	296
372	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncology, The, 2017, 18, 112-121.	5.1	249
373	Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. Blood Reviews, 2017, 31, 139-150.	2.8	9
374	Therapy of older persons with acute myeloid leukaemia. Leukemia Research, 2017, 60, 1-10.	0.4	11

#	Article	IF	Citations
375	DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppression. Carcinogenesis, 2017, 38, 367-377.	1.3	39
376	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	5.8	55
377	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood, 2017, 130, 167-175.	0.6	136
378	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 111-121.	13.9	1,738
379	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nature Communications, 2017, 8, 15869.	5.8	83
380	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
381	CHIP-ping Away at Atherosclerosis. New England Journal of Medicine, 2017, 377, 184-185.	13.9	8
382	Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nature Reviews Cancer, 2017, 17, 425-440.	12.8	117
383	CHIP, ICUS, CCUS and other four-letter words. Leukemia, 2017, 31, 1869-1871.	3.3	71
384	The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity. Expert Review of Hematology, 2017, 10, 649-657.	1.0	14
385	Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes. Journal of Leukocyte Biology, 2017, 102, 209-219.	1.5	12
386	Myelodysplasia in younger adults: outlier or unique molecular entity?. Haematologica, 2017, 102, 967-968.	1.7	5
387	Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. Experimental Hematology, 2017, 53, 48-58.	0.2	15
388	Using Zebrafish to Study Pathways that Regulate Hematopoietic Stem Cell Self-Renewal and Migration. Stem Cell Reports, 2017, 8, 1465-1471.	2.3	15
389	Targeting Aberrant Signaling in Myeloid Malignancies. Hematology/Oncology Clinics of North America, 2017, 31, 565-576.	0.9	3
390	Myeloid neoplasms with germ line RUNX1 mutation. International Journal of Hematology, 2017, 106, 183-188.	0.7	26
391	Molecular and physiological manifestations and measurement of aging in humans. Aging Cell, 2017, 16, 624-633.	3.0	323
392	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq1 1 0.784314 rgBT /Overlock 10 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	2.9	52

#	Article	IF	Citations
393	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	3.3	242
394	Epigenetic dysregulation of hematopoietic stem cells and preleukemic state. International Journal of Hematology, 2017, 106, 34-44.	0.7	24
395	Liâ€Fraumeni versus Pseudoâ€Liâ€Fraumeni Syndrome: Key Insights for Interpreting Nextâ€Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes. Oncologist, 2017, 22, 1084-1085.	1.9	0
396	The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood, 2017, 130, 433-439.	0.6	50
397	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood, 2017, 130, 440-452.	0.6	66
398	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica, 2017, 102, 968-971.	1.7	28
399	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.4	116
400	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. American Journal of Hematology, 2017, 92, 555-561.	2.0	12
402	Measurable residual disease testing in acute myeloid leukaemia. Leukemia, 2017, 31, 1482-1490.	3.3	197
403	Molecular Analysis of Genetic Markers for Nonâ€Hodgkin Lymphomas. Current Protocols in Human Genetics, 2017, 93, 10.14.1-10.14.29.	3.5	1
404	How do messenger RNA splicing alterations drive myelodysplasia?. Blood, 2017, 129, 2465-2470.	0.6	28
405	Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia, 2017, 31, 1637-1640.	3.3	34
406	Detecting and Monitoring Circulating Stromal Cells from Solid Tumors Using Blood-Based Biopsies in the Twenty-First Century: Have Circulating Stromal Cells Come of Age?. Cancer Drug Discovery and Development, 2017, , 81-104.	0.2	2
407	Runx Family Genes in Tissue Stem Cell Dynamics. Advances in Experimental Medicine and Biology, 2017, 962, 117-138.	0.8	6
408	The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science, 2017, 355, 1147-1152.	6.0	289
409	Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia. Haematologica, 2017, 102, 1227-1237.	1.7	45
410	HSPCs are marathon and not sprint relay athletes. Blood, 2017, 129, 1406-1407.	0.6	1
411	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature, 2017, 543, 714-718.	13.7	229

#	Article	IF	Citations
412	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	0.6	4,375
413	PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. Leukemia, 2017, 31, 1975-1986.	3.3	10
414	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017, 129, 667-679.	0.6	444
415	Genomics of chronic neutrophilic leukemia. Blood, 2017, 129, 715-722.	0.6	74
416	Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica, 2017, 102, 7-17.	1.7	74
417	How â€œpreciseâ€•is precision medicine in hematology?. Haematologica, 2017, 102, 4-6.	1.7	7
418	From the bedside to the bench: new discoveries on blood cell fate and function. Experimental Hematology, 2017, 47, 24-30.	0.2	0
419	Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Therapeutic Advances in Hematology, 2017, 8, 107-118.	1.1	40
420	Mosaicism in health and disease â€” clones picking up speed. Nature Reviews Genetics, 2017, 18, 128-142.	7.7	200
421	Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood, 2017, 129, 38-47.	0.6	95
422	Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 97-99.	0.2	3
423	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	9.4	348
424	DNMT3A in Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030320.	2.9	135
425	A novel class of somatic mutations in blood detected preferentially in CD8 + cells. Clinical Immunology, 2017, 175, 75-81.	1.4	35
426	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Journal of Molecular Diagnostics, 2017, 19, 4-23.	1.2	1,267
427	Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways. Science Translational Medicine, 2017, 9, .	5.8	19
428	NLRP3 inflammasome pathways in atherosclerosis. Atherosclerosis, 2017, 267, 127-138.	0.4	167
429	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	9.4	470

#	Article	IF	Citations
430	Individual risk assessment in MDS in the era of genomic medicine. Seminars in Hematology, 2017, 54, 133-140.	1.8	2
431	Untangling the Web of Lymphoma Somatic Mutations. Cell, 2017, 171, 270-272.	13.5	1
432	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell, 2017, 21, 547-555.e8.	5.2	71
433	Clonal Hematopoiesis and Atherosclerosis. New England Journal of Medicine, 2017, 377, 1400-1402.	13.9	33
434	The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. Journal of Translational Internal Medicine, 2017, 5, 139-143.	1.0	50
435	Measurement of Residual Disease in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 574-581.	1.2	9
436	The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. Best Practice and Research in Clinical Haematology, 2017, 30, 295-300.	0.7	7
437	Familial myelodysplastic syndrome/acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2017, 30, 287-289.	0.7	25
438	Distinguishing CHIP from Myeloid Neoplasia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S215-S216.	0.2	0
439	Clonal evolution in leukemia. Nature Medicine, 2017, 23, 1135-1145.	15.2	93
440	Selective and Sensitive Detection of Methylcytosine by Aerolysin Nanopore under Serum Condition. Analytical Chemistry, 2017, 89, 11685-11689.	3.2	52
441	Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clinical Cancer Research, 2017, 23, 7351-7359.	3.2	74
442	Taking control of spin currents. Nature, 2017, 549, 464-465.	13.7	1
443	Bad blood promotes tumour progression. Nature, 2017, 549, 465-466.	13.7	4
444	The spectrum of DNMT3A variants in Tattonâ€“Brownâ€“Rahman syndrome overlaps with that in hematologic malignancies. American Journal of Medical Genetics, Part A, 2017, 173, 3022-3028.	0.7	42
445	Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender. Current Hematologic Malignancy Reports, 2017, 12, 424-431.	1.2	11
446	The Prognostic Significance of Measurable (â€œMinimalâ€) Residual Disease in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 547-556.	1.2	19
447	Monocyte-Macrophages and T Cells in Atherosclerosis. Immunity, 2017, 47, 621-634.	6.6	462

#	Article	IF	Citations
448	Case 32-2017. New England Journal of Medicine, 2017, 377, 1569-1578.	13.9	2
449	Clonality in context: hematopoietic clones in their marrow environment. Blood, 2017, 130, 2363-2372.	0.6	74
450	The potential of liquid biopsies for the early detection of cancer. Npj Precision Oncology, 2017, 1, 36.	2.3	126
451	Stem cells and heart disease - Brake or accelerator?. Advanced Drug Delivery Reviews, 2017, 120, 2-24.	6.6	29
452	Cytogenetic changes in the Bhopal population exposed to methyl isocyanate (MIC) in 1984: Then and 30 years later. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2017, 824, 9-19.	0.9	8
453	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	12.8	270
454	ICUS/CCUS/CHIP: basics & beyond. Expert Review of Hematology, 2017, 10, 915-920.	1.0	14
455	Increased risk of leukemia among sickle cell disease patients in California. Blood, 2017, 130, 1597-1599.	0.6	95
456	Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature, 2017, 549, 476-481.	13.7	398
457	Genomic and functional integrity of the hematopoietic system requires tolerance of oxidative DNA lesions. Blood, 2017, 130, 1523-1534.	0.6	29
458	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	2.2	132
459	Tet2 restrains inflammatory gene expression in macrophages. Experimental Hematology, 2017, 55, 56-70.e13.	0.2	210
460	Clonal chromosomal abnormalities appearing in Philadelphia chromosomeâ€“negative metaphases during CML treatment. Blood, 2017, 130, 2084-2091.	0.6	65
461	Exonic Mosaic Mutations Contribute Risk for Autism Spectrum Disorder. American Journal of Human Genetics, 2017, 101, 369-390.	2.6	151
462	Detection of structural mosaicism from targeted and whole-genome sequencing data. Genome Research, 2017, 27, 1704-1714.	2.4	44
463	Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. Journal of the American Society of Echocardiography, 2017, 30, 1111-1118.	1.2	27
464	Mutations in myeloproliferative neoplasms â€“ their significance and clinical use. Expert Review of Hematology, 2017, 10, 961-973.	1.0	19
465	New Advances and Challenges of Targeting Cancer Stem Cells. Cancer Research, 2017, 77, 5222-5227.	0.4	28

#	Article	IF	Citations
466	The management and treatment of acute leukemias in the elderly population. Expert Review of Hematology, 2017, 10, 975-985.	1.0	7
467	Characterization of <scp>TP</scp>53 mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. European Journal of Haematology, 2017, 99, 536-543.	1.1	20
468	The maturation of a â€˜neuralâ€“hematopoieticâ€™ inflammatory axis in cardiovascular disease. Current Opinion in Lipidology, 2017, 28, 507-512.	1.2	8
469	Higher-than-expected population prevalence of potentially pathogenic germlineTP53variants in individuals unselected for cancer history. Human Mutation, 2017, 38, 1723-1730.	1.1	40
470	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
471	State of the Art Update: Molecular Genetics of MPN. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S88-S90.	0.2	0
472	Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood, 2017, 130, 1693-1698.	0.6	286
473	Vitamin C regulates stem cells and cancer. Nature, 2017, 549, 462-464.	13.7	11
474	A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. Journal of Molecular Diagnostics, 2017, 19, 711-721.	1.2	7
475	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. Cell Reports, 2017, 20, 572-585.	2.9	99
476	Design and Application of Multiplex PCR Seq for the Detection of Somatic Mutations Associated with Myeloid Malignancies. Methods in Molecular Biology, 2017, 1633, 87-99.	0.4	1
477	Pathophysiology of Acquired Bone Marrow Failure. , 2017, , 13-33.		0
478	Acquired Overlap Bone Marrow Failure Disorders. , 2017, , 51-56.		1
479	Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia, 2017, 31, 2388-2397.	3.3	110
480	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	5.2	578
481	The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression. Immunity, 2017, 47, 284-297.e5.	6.6	115
482	Characterization of breakpoint regions of large structural autosomal mosaic events. Human Molecular Genetics, 2017, 26, 4388-4394.	1.4	2
483	Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197.	2.0	27

#	Article	IF	Citations
484	Prevalent premalignancy. Blood, 2017, 130, 695-696.	0.6	2
485	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 2017, 26, 17-24.	2.7	24
486	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2017, , .	3.3	9
487	Myeloproliferative neoplasms: from origins to outcomes. Blood, 2017, 130, 2475-2483.	0.6	107
488	Reducing medical comorbidities associated with long-term HIV infection. Aids, 2017, 31, 2547-2549.	1.0	1
489	Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms. Klinische Padiatrie, 2017, 229, 329-334.	0.2	13
490	Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!. Oncologist, 2017, 22, 1125-1134.	1.9	21
491	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 1736-1743.	2.0	44
492	CHIPs and engraftment dips. Blood, 2017, 130, 7-9.	0.6	0
493	Absence of driver mutations in persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. Blood, 2017, 130, 1267-1269.	0.6	10
494	High prevalence of myeloid neoplasms in adults with nonâ€“Langerhans cell histiocytosis. Blood, 2017, 130, 1007-1013.	0.6	98
495	Mosaic mutations in blood DNA sequence are associated with solid tumor cancers. Npj Genomic Medicine, 2017, 2, 22.	1.7	10
496	Guest editorial: Connecting multiple aspects of hematologic malignancies toward creation of new therapeutics. International Journal of Hematology, 2017, 105, 547-548.	0.7	0
497	Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia. International Journal of Hematology, 2017, 106, 847-851.	0.7	1
498	Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. AIDS Research and Human Retroviruses, 2017, 33, 889-897.	0.5	6
499	Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia. Annals of Hematology, 2017, 96, 1457-1461.	0.8	18
500	Acute myeloid leukaemia genomics. British Journal of Haematology, 2017, 179, 530-542.	1.2	82
501	DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood, 2017, 130, 753-762.	0.6	283

#	Article	IF	Citations
502	Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. American Journal of Human Genetics, 2017, 101, 50-64.	2.6	210
503	The role of mutations in the cohesin complex in acute myeloid leukemia. International Journal of Hematology, 2017, 105, 31-36.	0.7	17
504	Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia, 2017, 31, 520-522.	3.3	71
505	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nature Reviews Cancer, 2017, 17, 5-19.	12.8	542
506	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia, 2017, 31, 872-881.	3.3	87
507	DNMT3A mutations are associated with inferior overall and leukemiaâ€free survival in chronic myelomonocytic leukemia. American Journal of Hematology, 2017, 92, 56-61.	2.0	60
508	High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. International Journal of Cancer, 2017, 140, 555-564.	2.3	77
509	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. Annual Review of Cancer Biology, 2017, 1, 223-240.	2.3	20
510	Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. Stem Cells Translational Medicine, 2017, 6, 840-850.	1.6	5
511	Dysregulation of TET2 in hematologic malignancies. International Journal of Hematology, 2017, 105, 17-22.	0.7	42
512	Aging: Treating the Older Patient. Biology of Blood and Marrow Transplantation, 2017, 23, 193-200.	2.0	23
513	The aging hematopoietic stem cell niche: Phenotypic and functional changes and mechanisms that contribute to hematopoietic aging. Seminars in Hematology, 2017, 54, 25-32.	1.8	50
514	Clonal hematopoiesis. Seminars in Hematology, 2017, 54, 43-50.	1.8	100
515	Age-associated changes in human hematopoietic stem cells. Seminars in Hematology, 2017, 54, 39-42.	1.8	89
516	Do hematopoietic stem cells get old?. Leukemia, 2017, 31, 529-531.	3.3	5
517	Hematopoiesis in aging: Current concepts and challenges. Seminars in Hematology, 2017, 54, 1-3.	1.8	9
518	Rejuvenation of aged hematopoietic stem cells. Seminars in Hematology, 2017, 54, 51-55.	1.8	23
519	The epigenetic basis of hematopoietic stem cell aging. Seminars in Hematology, 2017, 54, 19-24.	1.8	37

#	Article	IF	Citations
520	Rapid parallel acquisition of somatic mutations after <i><scp>NPM</scp>1</i> in acute myeloid leukaemia evolution. British Journal of Haematology, 2017, 176, 825-829.	1.2	3
521	Sixty as the new forty: considerations on older related stem cell donors. Bone Marrow Transplantation, 2017, 52, 15-19.	1.3	10
522	Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications. Stem Cell Reviews and Reports, 2017, 13, 7-16.	5.6	198
523	Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia, 2017, 31, 720-727.	3.3	105
524	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 7-13.	0.2	5
525	Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Reviews, 2017, 31, 63-75.	2.8	128
526	Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia, 2017, 31, 861-871.	3.3	22
527	Accumulation of DNA damage in the aged hematopoietic stem cell compartment. Seminars in Hematology, 2017, 54, 12-18.	1.8	41
528	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia, 2017, 31, 1286-1295.	3.3	44
529	Molecular mechanisms underlying lineage bias in aging hematopoiesis. Seminars in Hematology, 2017, 54, 4-11.	1.8	58
530	Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations. Annual Review of Medicine, 2017, 68, 127-137.	5.0	6
531	ãƒ“ã,¿ãƒŸãƒ³Cã€å¹¹ç´°èƒžãŒã‚“ã,'èª¿ç¯€ã™ã‚‹. Nature Digest, 2017, 14, 36-37.	0.0	0
532	ASXL1 c.1934dup;p.Gly646Trpfs*12â€"a true somatic alteration requiring a new approach. Blood Cancer Journal, 2017, 7, 656.	2.8	18
533	Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer Journal, 2017, 7, e516-e516.	2.8	66
535	Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 109-119.	0.3	23
536	Aging, hematopoiesis, and the myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2017, 2017, 73-78.	0.9	17
537	Not So Typical: Development of Atypical Chronic Myeloid Leukemia in a Patient With Chronic Myeloid Leukemia. JCO Precision Oncology, 2017, 1, 1-5.	1.5	1
538	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 480-494.	1.8	9

#	Article	IF	Citations
539	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	9
540	Myeloproliferative neoplasms: from origins to outcomes. Hematology American Society of Hematology Education Program, 2017, 2017, 470-479.	0.9	29
541	How and when to decide between epigenetic therapy and chemotherapy in patients with AML. Hematology American Society of Hematology Education Program, 2017, 2017, 45-53.	0.9	28
542	Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Advances, 2017, 1, 2572-2578.	2.5	35
543	Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age. Hematology American Society of Hematology Education Program, 2017, 2017, 66-72.	0.9	13
544	Now I cuss less about ICUS. Blood, 2017, 129, 3282-3283.	0.6	0
545	Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. Blood Advances, 2017, 1, 401-406.	2.5	17
546	Mosaic chromosome 20q deletions are more frequent in the aging population. Blood Advances, 2017, 1, 380-385.	2.5	15
547	JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. Blood Advances, 2017, 1, 968-971.	2.5	42
548	Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?. Journal of Clinical Medicine, 2017, 6, 57.	1.0	28
549	Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia. Frontiers in Oncology, 2017, 7, 241.	1.3	21
550	RUNX1 Mutations in Inherited and Sporadic Leukemia. Frontiers in Cell and Developmental Biology, 2017, 5, 111.	1.8	62
551	Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicismâ€"UK Single Center Experience. Frontiers in Immunology, 2017, 8, 1410.	2.2	109
552	Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. Frontiers in Oncology, 2017, 7, 263.	1.3	39
553	Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells. Frontiers in Oncology, 2017, 7, 265.	1.3	79
554	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. Frontiers in Pediatrics, 2017, 5, 252.	0.9	16
555	Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis. BioMed Research International, 2017, 2017, 1-13.	0.9	29
556	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. JCI Insight, 2017, 2, .	2.3	32

#	Article	IF	Citations
557	Erythropoietin Receptor Signaling and Lipid Rafts. Vitamins and Hormones, 2017, 105, 79-100.	0.7	16
558	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Medicine, 2017, 9, 89.	3.6	39
559	SG-ADVISER mtDNA: a web server for mitochondrial DNA annotation with data from 200 samples of a healthy aging cohort. BMC Bioinformatics, 2017, 18, 373.	1.2	11
560	MosaicHunter: accurate detection of postzygotic single-nucleotide mosaicism through next-generation sequencing of unpaired, trio, and paired samples. Nucleic Acids Research, 2017, 45, e76-e76.	6.5	51
561	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology American Society of Hematology Education Program, 2017, 2017, 37-44.	0.9	49
562	Aging, Somatic Evolution, and Cancer. , 2017, , 193-209.		0
563	Somatic HLA mutations expose the role of class Iâ€“mediated autoimmunity in aplastic anemia and its clonal complications. Blood Advances, 2017, 1, 1900-1910.	2.5	69
564	Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches. Oncotarget, 2017, 8, 72621-72632.	0.8	51
565	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget, 2017, 8, 73483-73500.	0.8	153
566	Precancerous Clonal Expansion: A New Therapeutic Target?. Journal of Clinical Oncology, 2017, 35, 1503-1505.	0.8	0
567	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Advances, 2017, 1, 2032-2040.	2.5	53
568	Genomics of Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2017, 35, 947-954.	0.8	62
569	La prÃ©sence dâ€™hÃ©matopoÃ¯ses clonales de signification indÃ©terminÃ©es permet-elle de prÃ©dire la survenue dâ€™une hÃ©mopathie secondaire Ã un traitement pour cancer chez les patients de plus de 70 ansÂ?. Hematologie, 2017, 23, 20-21.	0.0	0
570	Established and Novel Prognostic Biomarkers in Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 548-560.	1.8	21
571	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2017, 35, 968-974.	0.8	117
572	Uncoding the genetic heterogeneity of myelodysplastic syndrome. Hematology American Society of Hematology Education Program, 2017, 2017, 447-452.	0.9	26
573	Tet2 Rescues Age-Related Regenerative Decline and Enhances Cognitive Function in the Adult Mouse Brain. Cell Reports, 2018, 22, 1974-1981.	2.9	147
574	Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through aÂMechanism Involving the IL-1Î²/NLRP3Âlnflammasome. Journal of the American College of Cardiology, 2018, 71, 875-886.	1.2	452

#	Article	IF	Citations
575	Clonal Hematopoiesis Wages War on the Myocardium. Journal of the American College of Cardiology, 2018, 71, 887-889.	1.2	1
576	Cancer detection: Seeking signals in blood. Science, 2018, 359, 866-867.	6.0	58
577	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	1.2	120
578	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biology of Blood and Marrow Transplantation, 2018, 24, 1049-1056.	2.0	98
579	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 11.	1.3	3
580	The interplay of leukemia cells and the bone marrow microenvironment. Blood, 2018, 131, 1507-1511.	0.6	87
581	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia, 2018, 32, 1908-1919.	3.3	137
582	Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing. Journal of the National Cancer Institute, 2018, 110, 863-870.	3.0	69
583	Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national populationâ€based caseâ€control study. British Journal of Haematology, 2018, 181, 205-214.	1.2	18
584	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood, 2018, 131, 2501-2505.	0.6	57
585	Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes. Cell Transplantation, 2018, 27, 754-764.	1.2	36
586	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	2.3	43
587	Methylation in cell-free DNA for early cancer detection. Annals of Oncology, 2018, 29, 1351-1353.	0.6	22
588	Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Experimental Hematology, 2018, 63, 1-11.	0.2	12
589	Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia, 2018, 32, 1762-1767.	3.3	27
590	Effect of age at exposure on chromosome abnormalities in MIC-exposed Bhopal population detected 30â€¯years post-disaster. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 809, 32-50.	0.4	3
591	Large-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment. Cell Stem Cell, 2018, 22, 600-607.e4.	5.2	132
592	Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. International Journal of Laboratory Hematology, 2018, 40, 408-418.	0.7	12

#	Article	IF	Citations
593	Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells InÂVivo. Cell Reports, 2018, 23, 1-10.	2.9	159
594	Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Critical Reviews in Oncology/Hematology, 2018, 126, 64-79.	2.0	12
595	Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Journal of Experimental Medicine, 2018, 215, 1729-1747.	4.2	113
596	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	5.8	299
597	The role of JAK2 inhibitors in MPNs 7 years after approval. Blood, 2018, 131, 2426-2435.	0.6	40
598	TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis. DNA and Cell Biology, 2018, 37, 517-523.	0.9	42
600	Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell, 2018, 22, 157-170.	5.2	345
601	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	5.8	150
602	Shedding New Light on the Magnitude of Thrombosis Risk in Patients With Myeloproliferative Neoplasms. Annals of Internal Medicine, 2018, 168, 363.	2.0	2
603	Cardiac macrophages promote diastolic dysfunction. Journal of Experimental Medicine, 2018, 215, 423-440.	4.2	314
604	Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant. Bone Marrow Transplantation, 2018, 53, 499-502.	1.3	3
605	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	6.0	1,872
606	Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations. Bone Marrow Transplantation, 2018, 53, 661-663.	1.3	0
607	Liquid biopsy and its role in an advanced clinical trial for lung cancer. Experimental Biology and Medicine, 2018, 243, 262-271.	1.1	38
608	ASXL1mutations in AML are associated with specific clinical and cytogenetic characteristics. Leukemia and Lymphoma, 2018, 59, 2439-2446.	0.6	20
609	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	2.8	404
610	Somatic Mutations and Clonal Hematopoiesis. Circulation Research, 2018, 122, 523-532.	2.0	129
611	Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG. Annals of Hematology, 2018, 97, 977-988.	0.8	15

#	Article	IF	Citations
612	Donor Cellâ€“Derived Hematologic Neoplasms after Hematopoietic Stem Cell Transplantation: A Systematic Review. Biology of Blood and Marrow Transplantation, 2018, 24, 1505-1513.	2.0	22
613	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2018, 131, 1820-1832.	0.6	40
614	Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2018, 100, 687-694.	0.4	4
615	Cohesin mutations in myeloid malignancies made simple. Current Opinion in Hematology, 2018, 25, 61-66.	1.2	34
616	Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53. Leukemia, 2018, 32, 850-854.	3.3	26
617	The emerging significance of secondary germline testing in cancer genomics. Journal of Pathology, 2018, 244, 610-615.	2.1	37
618	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. Current Opinion in Hematology, 2018, 25, 120-128.	1.2	4
619	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell, 2018, 33, 44-59.e8.	7.7	71
620	From clonal haematopoiesis to the CANTOS trial. Nature Reviews Cardiology, 2018, 15, 79-80.	6.1	25
621	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	0.6	796
622	Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing. Blood Cells, Molecules, and Diseases, 2018, 69, 10-22.	0.6	10
623	Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients. Clinical Cancer Research, 2018, 24, 1716-1726.	3.2	63
624	The differential diagnosis of a TP53 genetic testing result. Genetics in Medicine, 2018, 20, 806-808.	1.1	1
625	The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nature Reviews Clinical Oncology, 2018, 15, 219-233.	12.5	120
626	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. Blood, 2018, 131, 1846-1857.	0.6	35
627	Management of older adults with myelodysplastic syndromes (MDS). Journal of Geriatric Oncology, 2018, 9, 302-307.	0.5	12
628	The impact of aging on primate hematopoiesis as interrogated by clonal tracking. Blood, 2018, 131, 1195-1205.	0.6	39
629	DNA Hydroxymethylation Levels Are Altered in Blood Cells From Down Syndrome Persons Enrolled in the MARK-AGE Project. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 737-744.	1.7	16

#	Article	IF	Citations
630	Haploidentical Transplants for Acute Myeloid Leukemia in Adults. , 2018, , 231-243.		0
631	BCR/ABL1-negative, triple-negative, myeloproliferative neoplasm with a hitherto undescribed, isolated, SH2B3 (LNK) gene mutation: A case report. Human Pathology: Case Reports, 2018, 13, 4-8.	0.2	0
632	Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes. Hematology/Oncology Clinics of North America, 2018, 32, 643-655.	0.9	16
633	Causes and Consequences of Hematopoietic Stem Cell Heterogeneity. Cell Stem Cell, 2018, 22, 627-638.	5.2	233
634	CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease. Circulation Research, 2018, 123, 335-341.	2.0	282
635	Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Molecular Cancer, 2018, 17, 49.	7.9	146
636	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	1.8	36
637	Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association?. Haematologica, 2018, 103, 751-752.	1.7	6
638	Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. International Journal of Hematology, 2018, 108, 447-451.	0.7	7
639	Cancer stem cells modulate patterns and processes of evolution in cancers. Biology and Philosophy, 2018, 33, 1.	0.7	4
640	Cohesin in haematopoiesis and leukaemia. Current Opinion in Hematology, 2018, 25, 259-265.	1.2	2
641	Aterosclerosis y hematopoyesis clonal: un nuevo factor de riesgo. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2018, 30, 133-136.	0.4	3
642	Vitamin C in Stem Cell Reprogramming and Cancer. Trends in Cell Biology, 2018, 28, 698-708.	3.6	139
643	New Insights from Studies of Clonal Hematopoiesis. Clinical Cancer Research, 2018, 24, 4633-4642.	3.2	76
644	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
645	Myeloid cells regulate plasma LDL-cholesterol levels. Current Opinion in Lipidology, 2018, 29, 233-239.	1.2	3
646	Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood, 2018, 131, 2682-2697.	0.6	36
647	New genetic tools for the in vivo study of hematopoietic stem cell function. Experimental Hematology, 2018, 61, 26-35.	0.2	12

#	Article	IF	Citations
648	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica, 2018, 103, 1198-1208.	1.7	34
649	Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation, 2018, 138, 898-912.	1.6	208
650	Time to repeal and replace response criteria for acute myeloid leukemia?. Blood Reviews, 2018, 32, 416-425.	2.8	51
651	Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 1244-1245.	13.9	17
652	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 1189-1199.	13.9	605
653	The role of IDH mutations in acute myeloid leukemia. Future Oncology, 2018, 14, 979-993.	1.1	100
654	Diagnosis and Treatment of Acute Myeloid Leukemia in Children. , 2018, , 359-374.		0
655	JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biology and Therapy, 2018, 19, 664-668.	1.5	4
656	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clinical Cancer Research, 2018, 24, 4437-4443.	3.2	321
657	Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nature Reviews Genetics, 2018, 19, 269-285.	7.7	374
658	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
659	Immunobiology of Acute Leukemia. , 2018, , 237-279.		3
660	Mutation analysis of therapy-related myeloid neoplasms. Cancer Genetics, 2018, 222-223, 38-45.	0.2	11
661	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 32.	2.8	12
662	Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nature Cell Biology, 2018, 20, 413-421.	4.6	41
663	Cardiac stem cell aging and heart failure. Pharmacological Research, 2018, 127, 26-32.	3.1	12
664	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. Leukemia, 2018, 32, 139-148.	3.3	28
665	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia, 2018, 32, 30-37.	3.3	50

#	Article	IF	Citations
666	Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia, 2018, 32, 450-461.	3.3	54
667	Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. Blood Cells, Molecules, and Diseases, 2018, 69, 90-100.	0.6	24
668	Replication stress in hematopoietic stem cells in mouse and man. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 808, 74-82.	0.4	13
669	Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. Genes Chromosomes and Cancer, 2018, 57, 80-88.	1.5	55
670	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. European Heart Journal, 2018, 39, 4150-4158.	1.0	79
671	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2021-2039.	0.6	8
672	Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood, 2018, 131, 408-416.	0.6	91
673	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 2018, 39, 3521-3527.	1.0	44
674	The GNASR201C mutation associated with clonal hematopoiesis supports transplantable hematopoietic stem cell activity. Experimental Hematology, 2018, 57, 14-20.	0.2	5
675	Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. Seminars in Cancer Biology, 2018, 51, 89-100.	4.3	21
676	Atypical haematological presentation in a case of polycythaemia vera with a new variant mutation detected in exon 12: c.1605G>T (p.Met535Ile). Journal of Clinical Pathology, 2018, 71, 180-184.	1.0	1
677	Phenome and genome based studies into human ageing and longevity: An overview. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2742-2751.	1.8	36
678	Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. Leukemia, 2018, 32, 550-553.	3.3	10
679	Genomic Approaches to Hematology. , 2018, , 25-36.		0
680	Comprehensive genetic analysis of donor cell derived leukemia with KMT2A rearrangement. Pediatric Blood and Cancer, 2018, 65, e26823.	0.8	4
681	Genomeâ€wide <scp>DNA</scp> methylation analysis of senescence in repetitively infected memory cytotoxic T lymphocytes. Immunology, 2018, 153, 253-267.	2.0	3
682	Mechanisms underlying the heterogeneity of myelodysplastic syndromes. Experimental Hematology, 2018, 58, 17-26.	0.2	16
683	Somatic TP53 variants frequently confound germ-line testing results. Genetics in Medicine, 2018, 20, 809-816.	1.1	91

#	Article	IF	Citations
684	Myelodysplastic syndromes: 2018 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2018, 93, 129-147.	2.0	154
685	Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic Tâ€cell lymphoma. Cancer Science, 2018, 109, 490-496.	1.7	37
686	Modernizing Human Cancer Risk Assessment of Therapeutics. Trends in Pharmacological Sciences, 2018, 39, 232-247.	4.0	17
687	Hematopoietic Stem Cell Biology. , 2018, , 95-110.e13.		0
688	Muscle Stem Cells Exhibit Distinct Clonal Dynamics in Response to Tissue Repair and Homeostatic Aging. Cell Stem Cell, 2018, 22, 119-127.e3.	5.2	68
689	A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Experimental Hematology, 2018, 59, 9-13.	0.2	4
690	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	7.7	243
691	Normal variation of bone marrow Bâ€cell precursors according to age â€“ reference ranges for studies in myelodysplastic syndromes in Brazil. Cytometry Part B - Clinical Cytometry, 2018, 94, 800-806.	0.7	9
692	An inflammatory environment containing TNFÎ± favors Tet2-mutant clonal hematopoiesis. Experimental Hematology, 2018, 59, 60-65.	0.2	141
693	Aging of hematopoietic stem cells. Blood, 2018, 131, 479-487.	0.6	266
694	Anemia at older age: etiologies, clinical implications, and management. Blood, 2018, 131, 505-514.	0.6	266
695	Age-related clonal hematopoiesis. Blood, 2018, 131, 496-504.	0.6	215
696	Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood, 2018, 131, 621-635.	0.6	64
697	The Loss of TET2 Promotes CD8+ T Cell Memory Differentiation. Journal of Immunology, 2018, 200, 82-91.	0.4	112
698	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood, 2018, 131, 717-732.	0.6	240
699	Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?. Biology of Blood and Marrow Transplantation, 2018, 24, 649-658.	2.0	13
700	Readers of DNA methylation, the MBD family as potential therapeutic targets. , 2018, 184, 98-111.		54
701	DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. Seminars in Cancer Biology, 2018, 51, 68-79.	4.3	42

#	Article	IF	Citations
702	Novel epigenetic therapies in hematological malignancies: Current status and beyond. Seminars in Cancer Biology, 2018, 51, 198-210.	4.3	22
703	Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes. Leukemia and Lymphoma, 2018, 59, 803-812.	0.6	13
704	Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer. Journal of Clinical Oncology, 2018, 36, 2206-2215.	0.8	99
705	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1788-1797.	0.8	156
706	Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 764-774.	1.8	18
707	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	0.8	668
708	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 555-573.	1.8	71
709	Circulating Tumor DNAâ€“Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. Journal of Clinical Oncology, 2018, 36, 3437-3440.	0.8	47
710	Rare TP53 variant associated with Li-Fraumeni syndrome exhibits variable penetrance in a Saudi family. Npj Genomic Medicine, 2018, 3, 35.	1.7	6
711	Molecular Hematopathology. , 2018, , 712-760.e18.		4
712	ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells. Oncotarget, 2018, 9, 35203-35204.	0.8	6
714	Loss of heterogeneity, quiescence, and differentiation in muscle stem cells. Stem Cell Investigation, 2018, 5, 9-9.	1.3	25
715	Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. Blood Advances, 2018, 2, 1000-1012.	2.5	20
716	A brief, but comprehensive, guide to clonal evolution in aplastic anemia. Hematology American Society of Hematology Education Program, 2018, 2018, 457-466.	0.9	20
717	Myeloproliferative and â€œOverlapâ€•Myelodysplastic/Myeloproliferative Neoplasms. , 2018, , 488-538.e4.		5
718	I. Understanding the Pathogenesis of Acute Myeloid Leukemia through Leukemic Stem Cells. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1272-1278.	0.0	0
719	Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. JCO Precision Oncology, 2018, 2, 0-0.	1.5	0
720	Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation. Current Opinion in Hematology, 2018, 25, 441-445.	1.2	6

#	Article	IF	Citations
721	Emerging Concepts in Liquid Biopsy. Advances in Molecular Pathology, 2018, 1, 183-191.	0.2	0
722	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. Blood Cancer Journal, 2018, 8, 114.	2.8	16
723	Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis. Cell Reports, 2018, 25, 2308-2316.e4.	2.9	170
724	Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer Journal, 2018, 8, 113.	2.8	90
725	Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 ^{V617F} Mice. Circulation Research, 2018, 123, e35-e47.	2.0	173
726	Aging, inflammation and cancer. Seminars in Immunology, 2018, 40, 74-82.	2.7	103
727	Accelerating myelofibrosis through loss of Dnmt3a. Blood, 2018, 132, 2703-2704.	0.6	2
728	Â¿Es la hematopoyesis clonal un nuevo factor de riesgo en enfermedades cardiovasculares?: evidencias clÃnicas y experimentales. Medicina ClÃnica, 2018, 151, 207-209.	0.3	0
729	Distinctive types of postzygotic single-nucleotide mosaicisms in healthy individuals revealed by genome-wide profiling of multiple organs. PLoS Genetics, 2018, 14, e1007395.	1.5	31
730	The Clinical and Laboratory Features of Clonal Hematopoiesis of Indeterminate Potential. Advances in Molecular Pathology, 2018, 1, 37-42.	0.2	1
731	Tropism of PCNSL: is it all about autoantigens?. Blood, 2018, 132, 2704-2706.	0.6	3
732	Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease. International Journal of Molecular Sciences, 2018, 19, 3850.	1.8	24
733	Myelodysplastic syndromes and acute myeloid leukemias in the elderly. European Journal of Internal Medicine, 2018, 58, 28-32.	1.0	5
734	Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. Cell Stem Cell, 2018, 23, 833-849.e5.	5.2	242
735	Clonal Hematopoiesis Leading to AITL and NPM1-Mutated AML. New England Journal of Medicine, 2018, 379, 2184-2185.	13.9	0
736	Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging. Cells, 2018, 7, 237.	1.8	15
737	Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML. Cancer Cell, 2018, 34, 533-535.	7.7	2
738	NLRP3 inflammasome activation in inflammaging. Seminars in Immunology, 2018, 40, 61-73.	2.7	109

#	Article	IF	Citations
739	Mechanisms of Hematopoietic Stem Cell Ageing and Targets for Hematopoietic Tumour Prevention. Advances in Experimental Medicine and Biology, 2018, 1086, 117-140.	0.8	2
740	An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Oncotarget, 2018, 9, 19079-19099.	0.8	11
741	Is it time to routinely incorporate MRD into practice?. Best Practice and Research in Clinical Haematology, 2018, 31, 396-400.	0.7	7
742	Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. Clinical Interventions in Aging, 2018, Volume 13, 1675-1690.	1.3	5
743	Therapy-related myeloid neoplasms: clinical perspectives. OncoTargets and Therapy, 2018, Volume 11, 5909-5915.	1.0	12
744	Genetics of Human Longevity Within an Eco-Evolutionary Nature-Nurture Framework. Circulation Research, 2018, 123, 745-772.	2.0	75
745	Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood, 2018, 132, 2201-2205.	0.6	4
746	Patterns of mutations in TP53 mutated AML. Best Practice and Research in Clinical Haematology, 2018, 31, 379-383.	0.7	43
747	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	13.9	442
748	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
749	The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence. Gynecologic Oncology, 2018, 151, 187-189.	0.6	4
750	A CHIP mutation to battle cancer: potential or hazard for cardiovascular disease?. Cardiovascular Research, 2018, 114, e96-e98.	1.8	0
751	Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes. Genome Research, 2018, 28, 1779-1790.	2.4	56
752	Inflammation, Immunity, and Infection in Atherothrombosis. Journal of the American College of Cardiology, 2018, 72, 2071-2081.	1.2	389
753	High prevalence of focal and multi-focal somatic genetic variants in the human brain. Nature Communications, 2018, 9, 4257.	5.8	54
754	Radioactive Iodine Therapy Is Associated with Clonal Hematopoiesis, a Precursor for Hematologic Malignancies. Clinical Thyroidology, 2018, 30, 443-446.	0.0	0
755	Functional genomic landscape of acute myeloid leukaemia. Nature, 2018, 562, 526-531.	13.7	907
756	Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10437-E10446.	3.3	59

#	Article	IF	Citations
758	Application of Cell-free DNA Analysis to Cancer Treatment. New England Journal of Medicine, 2018, 379, 1754-1765.	13.9	634
759	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell, 2018, 23, 700-713.e6.	5.2	272
760	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Current Hematologic Malignancy Reports, 2018, 13, 467-476.	1.2	4
761	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults. , 2018, , 970-980.e4.		0
762	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.2	25
763	Aging and Malignant Hemopathies: A Complex Multistep Process. , 2018, , 1-13.		1
764	CHIPing out PPM1D-mutant hematopoiesis. Blood, 2018, 132, 1087-1088.	0.6	1
765	Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis. Human Mutation, 2018, 39, 2040-2046.	1.1	20
766	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, 2018, 132, 1703-1713.	0.6	237
767	Population dynamics of normal human blood inferred from somatic mutations. Nature, 2018, 561, 473-478.	13.7	427
768	High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML. New England Journal of Medicine, 2018, 379, 981-984.	13.9	53
769	How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. Blood, 2018, 132, 1657-1663.	0.6	32
770	Radioactive Iodineâ€“Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4216-4223.	1.8	33
771	Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. Scientific Reports, 2018, 8, 12316.	1.6	105
772	Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. Circulation Journal, 2018, 83, 2-11.	0.7	42
773	Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis. Clinical Science, 2018, 132, 1889-1899.	1.8	14
774	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	3.2	292
775	Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS ONE, 2018, 13, e0204218.	1.1	23

#	Article	IF	Citations
776	Aging and Aging-Related Diseases. Advances in Experimental Medicine and Biology, 2018, , .	0.8	15
777	Acute myeloid leukemiaâ€"current data from the 2017 American Society of Hematology meeting. Memo - Magazine of European Medical Oncology, 2018, 11, 97-100.	0.3	0
778	Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. Cancer Cell, 2018, 34, 674-689.e8.	7.7	71
780	State of the Art Update: On the Origins of MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S30-S31.	0.2	0
781	Is clonal hematopoiesis a new risk factor for cardiovascular diseases?: Clinical and experimental evidences. Medicina ClÃnica (English Edition), 2018, 151, 207-209.	0.1	0
782	The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. Yearbook of Medical Informatics, 2018, 27, 211-222.	0.8	21
783	Molecular Genetics of MDS. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S45-S47.	0.2	0
784	Macrophages and Cardiovascular Health. Physiological Reviews, 2018, 98, 2523-2569.	13.1	79
785	JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology American Society of Hematology Education Program, 2018, 2018, 110-117.	0.9	7
786	Clinical consequences of clonal hematopoiesis of indeterminate potential. Hematology American Society of Hematology Education Program, 2018, 2018, 264-269.	0.9	83
787	Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Advances, 2018, 2, 481-491.	2.5	41
788	Cell-lineage levelâ€"targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. Blood Advances, 2018, 2, 2513-2521.	2.5	10
789	Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Advances, 2018, 2, 3404-3410.	2.5	149
790	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Advances, 2018, 2, 2814-2828.	2.5	42
791	NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Advances, 2018, 2, 3118-3125.	2.5	62
792	Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood, 2018, 132, 277-280.	0.6	101
793	Quantitative competitive allele-specific TaqMan duplex PCR (qCAST-Duplex PCR) assay: a refined method for highly sensitive and specific detection of JAK2V617F mutant allele burdens. Haematologica, 2018, 103, e450-e454.	1.7	4
794	A causal mechanism for childhood acute lymphoblastic leukaemia. Nature Reviews Cancer, 2018, 18, 471-484.	12.8	342

#	Article	IF	Citations
795	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2018, 32, 2604-2616.	3.3	137
796	Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia, 2018, 32, 1751-1761.	3.3	54
797	Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 495-500.	0.2	1
798	Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Annals of Internal Medicine, 2018, 169, 116.	2.0	26
799	Cellular and epigenetic drivers of stem cell ageing. Nature Reviews Molecular Cell Biology, 2018, 19, 594-610.	16.1	196
800	Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasmâ€”a comparison of 756 cases. Leukemia, 2018, 32, 2295-2298.	3.3	18
801	Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature, 2018, 557, 580-584.	13.7	296
802	Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 636-647.	0.2	6
803	Incident adverse events following therapy for acute promyelocytic leukemia. Leukemia Research Reports, 2018, 9, 79-83.	0.2	4
804	Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia, 2018, 32, 1679-1696.	3.3	10
805	The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Therapeutic Advances in Hematology, 2018, 9, 163-173.	1.1	50
806	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood, 2018, 132, 1095-1105.	0.6	160
807	Atherosclerosis and clonal hematopoiesis: A new risk factor. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2018, 30, 133-136.	0.1	5
808	Acute myeloid leukemia in very old patients. Haematologica, 2018, 103, e578-e580.	1.7	17
809	The Value of T-Cell Receptor Î³ (TRG) Clonality Evaluation by Next-Generation Sequencing in Clinical Hematolymphoid Tissues. American Journal of Clinical Pathology, 2018, 150, 193-223.	0.4	9
810	Stem Cell Model of Hematologic Diseases. , 2018, , 111-118.		0
811	Hematology in Aging. , 2018, , 2328-2331.		0
812	Acute myeloid leukaemia. Lancet, The, 2018, 392, 593-606.	6.3	512

#	Article	IF	Citations
813	AML: Predicting the Unpredictable. Cell Stem Cell, 2018, 23, 162-163.	5.2	1
814	Tracing human stem cell lineage during development using DNA methylation. Genome Research, 2018, 28, 1285-1295.	2.4	27
815	Multi-Modality Imaging in the Assessment of Cardiovascular Toxicity inÂthe Cancer Patient. JACC: Cardiovascular Imaging, 2018, 11, 1173-1186.	2.3	102
816	Lymphohematopoietic Stem Cells and Their Aging. , 2018, , 1-16.		0
818	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood, 2018, 132, 1526-1534.	0.6	90
819	Mutation Detection in Tumor-Derived Cell Free DNA Anticipates Progression in a Patient With Metastatic Colorectal Cancer. Frontiers in Oncology, 2018, 8, 306.	1.3	9
820	A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs. Annals of Hematology, 2018, 97, 2299-2308.	0.8	50
821	Clonal Hematopoiesis in Aging. Current Stem Cell Reports, 2018, 4, 209-219.	0.7	18
822	Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis, 2018, 276, 98-108.	0.4	289
823	Conventional and Molecular Cytogenomic Basis of Hematologic Malignancies. , 2018, , 774-848.		0
825	Genomic Instabilities, Cellular Senescence, and Aging: In Vitro, In Vivo and Aging-Like Human Syndromes. Frontiers in Medicine, 2018, 5, 104.	1.2	60
826	Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 41.	1.3	56
827	Clonal Hematopoiesis. Circulation Genomic and Precision Medicine, 2018, 11, e001926.	1.6	43
828	Bridging Strategies to Allogeneic Transplant for Older AML Patients. Cancers, 2018, 10, 232.	1.7	6
829	Tuning of the Hematopoietic Stem Cell Compartment in its Inflammatory Environment. Current Stem Cell Reports, 2018, 4, 189-200.	0.7	2
830	Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. Diagnostics, 2018, 8, 31.	1.3	94
831	Advances in understanding the pathogenesis of acquired aplastic anaemia. British Journal of Haematology, 2018, 182, 758-776.	1.2	91
832	Clinical Implications of Clonal Hematopoiesis. Mayo Clinic Proceedings, 2018, 93, 1122-1130.	1.4	81

#	Article	IF	Citations
833	Diagnosis and Prognosis: Molecular. Hematologic Malignancies, 2018, , 15-37.	0.2	0
834	Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404.	13.7	617
835	Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature Medicine, 2018, 24, 1015-1023.	15.2	447
836	Predicting progression to AML. Nature Medicine, 2018, 24, 904-906.	15.2	22
837	Microbiome metabolomics reveals new drivers of human liver steatosis. Nature Medicine, 2018, 24, 906-907.	15.2	25
838	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10Âyears and future perspectives. Wiener Klinische Wochenschrift, 2018, 130, 517-529.	1.0	3
839	Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nature Communications, 2018, 9, 2733.	5.8	88
840	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nature Communications, 2018, 9, 2670.	5.8	79
841	Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal. Blood, 2018, 132, 791-803.	0.6	24
842	Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature, 2018, 559, 350-355.	13.7	279
843	Evolutionary Stem Cell Poker and Cancer Risks: the Paradox of the Large and Small Intestines. Current Pathobiology Reports, 2018, 6, 193-198.	1.6	2
844	The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. Trends in Cancer, 2018, 4, 523-536.	3.8	36
845	Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. Atherosclerosis, 2018, 276, 39-43.	0.4	45
846	A CRISPR Take on Clonal Hematopoiesis. Circulation Research, 2018, 123, 313-314.	2.0	1
847	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2018, 6, 56.	1.8	54
848	Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Molecular Cancer, 2018, 17, 40.	7.9	30
849	Identification of somatic mutations in monozygotic twins discordant for psychiatric disorders. NPJ Schizophrenia, 2018, 4, 7.	2.0	16
850	Skewed megakaryopoiesis in human induced pluripotent stemÂcellâ€derived haematopoietic progenitor cells harbouring calreticulin mutations. British Journal of Haematology, 2018, 181, 791-802.	1.2	19

#	Article	IF	Citations
851	Signaling Pathways Regulating Hematopoietic Stem Cell and Progenitor Aging. Current Stem Cell Reports, 2018, 4, 166-181.	0.7	15
853	DNA Methylation Patterns in Normal Tissue Correlate more Strongly with Breast Cancer Status than Copy-Number Variants. EBioMedicine, 2018, 31, 243-252.	2.7	27
854	Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. Experimental Hematology, 2018, 64, 33-44.e5.	0.2	17
855	Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. Leukemia, 2018, 32, 2399-2411.	3.3	39
856	Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. Oncology Letters, 2018, 15, 7132-7138.	0.8	1
857	Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to atherlosclerotic cardio/cerebro-vascular diseases?. Genes and Diseases, 2018, 5, 75-76.	1.5	6
858	Additional germline findings from a tumor profiling program. BMC Medical Genomics, 2018, 11, 65.	0.7	16
859	CHIP (Clonal Hematopoiesis of Indeterminate Potential). Circulation, 2018, 138, 666-668.	1.6	71
860	Relationship between Aging and Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1965-1970.	2.0	10
861	Clonal hematopoiesis in patients with rheumatoid arthritis. Blood Cancer Journal, 2018, 8, 69.	2.8	62
862	Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium. Cell Reports, 2018, 24, 1777-1789.	2.9	296
863	Near Tetraploidy Acute Myeloid Leukemia in Long-term Remission with Persistent Clonal Hematopoiesis with del(20)(q12q13). Internal Medicine, 2018, , .	0.3	0
864	Impacts of demographic and laboratory parameters on key hematological indices in an adult population of southern Taiwan: A cohort study. PLoS ONE, 2018, 13, e0201708.	1.1	4
865	Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms. Journal of Molecular Diagnostics, 2018, 20, 717-737.	1.2	49
866	Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia. Journal of Physical Education and Sports Management, 2018, 4, a002980.	0.5	7
867	New insights in the pathogenesis of T-cell lymphomas. Current Opinion in Oncology, 2018, 30, 277-284.	1.1	31
868	Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. Expert Review of Hematology, 2018, 11, 805-816.	1.0	10
869	Cytopenias: Reactive and Neoplastic. , 2018, , 17-79.		1

#	Article	IF	Citations
870	Myeloid cell contributions to cardiovascular health and disease. Nature Medicine, 2018, 24, 711-720.	15.2	211
871	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	3.4	139
872	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clinical Cancer Research, 2018, 24, 5918-5924.	3.2	84
873	Chronic Myelomonocytic Leukemia (CMML). Hematologic Malignancies, 2018, , 65-79.	0.2	0
874	Srsf2 P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells. Blood, 2018, 132, 608-621.	0.6	45
875	Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica, 2018, 103, 1853-1861.	1.7	96
876	The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span. GeroScience, 2018, 40, 221-242.	2.1	15
877	Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC). Genomics, Proteomics and Bioinformatics, 2018, 16, 172-186.	3.0	22
878	Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. Stem Cells, 2018, 36, 1287-1294.	1.4	60
879	Mixed Cytoses and Cytopenias. , 2018, , 257-279.		0
880	Somatic Mutations in Aplastic Anemia. Hematology/Oncology Clinics of North America, 2018, 32, 595-607.	0.9	18
881	Anemia in the Elderly. HemaSphere, 2018, 2, e40.	1.2	71
882	Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia, 2018, 32, 2046-2049.	3.3	37
883	Biological pathways underlying the association of red cell distribution width and adverse clinical outcome: Results of a prospective cohort study. PLoS ONE, 2018, 13, e0191280.	1.1	32
884	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood, 2018, 132, 1225-1240.	0.6	168
885	Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genetics, 2018, 14, e1007108.	1.5	162
886	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. Leukemia Research, 2018, 74, 137-143.	0.4	7
887	Differential Responses of Plants to Biotic Stress and the Role of Metabolites. , 2018, , 69-87.		13

#	Article	IF	Citations
888	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 2442-2443.	13.9	7
889	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Pathobiology, 2019, 86, 30-38.	1.9	71
890	The Molecular Pathology of Myelodysplastic Syndrome. Pathobiology, 2019, 86, 24-29.	1.9	30
891	Next generation sequencing in hematolymphoid neoplasia. Seminars in Hematology, 2019, 56, 2-6.	1.8	5
892	Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. Frontiers of Medicine, 2019, 13, 229-237.	1.5	18
893	AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival. Leukemia and Lymphoma, 2019, 60, 69-77.	0.6	16
894	Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification. Leukemia, 2019, 33, 191-204.	3.3	41
895	Genetic and epigenetic determinants of AML pathogenesis. Seminars in Hematology, 2019, 56, 84-89.	1.8	65
896	DNA methylation as a transcriptional regulator of the immune system. Translational Research, 2019, 204, 1-18.	2.2	102
897	Somatic mutations in the human brain: implications for psychiatric research. Molecular Psychiatry, 2019, 24, 839-856.	4.1	29
898	Who is the best donor for haploidentical stem cell transplantation?. Seminars in Hematology, 2019, 56, 194-200.	1.8	15
899	Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group. Pathobiology, 2019, 86, 62-75.	1.9	3
900	Does patient age influence anti-cancer immunity?. Seminars in Immunopathology, 2019, 41, 125-131.	2.8	60
901	Impact of aging on bone, marrow and their interactions. Bone, 2019, 119, 1-7.	1.4	18
903	Inherited Platelet Defects and Mutations in Hematopoietic Transcription Factor RUNX1. , 2019, , 317-325.		0
904	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	6.0	265
905	The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes and Cancer, 2019, 58, 875-888.	1.5	79
906	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer Journal, 2019, 9, 61.	2.8	25

#	Article	IF	Citations
907	Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells, 2019, 8, 854.	1.8	119
908	Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies. Cells, 2019, 8, 868.	1.8	17
909	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 2019, 3, 508-518.	2.5	62
910	Paradoxical association of TET loss of function with genome-wide DNA hypomethylation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16933-16942.	3.3	81
911	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Review of Hematology, 2019, 12, 833-843.	1.0	13
912	HIV portends a poor prognosis in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3529-3535.	0.6	15
913	Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Medicine, 2019, 8, 5609-5618.	1.3	10
914	Discrete Changes in Glucose Metabolism Define Aging. Scientific Reports, 2019, 9, 10347.	1.6	42
915	Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 321-329.	1.0	17
916	Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes. Expert Review of Hematology, 2019, 12, 821-831.	1.0	6
917	Characterizing Mutational Load and Clonal Composition of Human Blood. Journal of Visualized Experiments, 2019, , .	0.2	5
918	Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. Leukemia Research, 2019, 84, 106190.	0.4	9
919	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death and Disease, 2019, 10, 534.	2.7	78
920	Premalignant Clonal Hematopoietic Proliferations. American Journal of Clinical Pathology, 2019, 152, 347-358.	0.4	3
921	The Inflammasome: More Than a Protective Innate Immune Mechanism. Immunity, 2019, 51, 3-5.	6.6	6
922	Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. Annals of Laboratory Medicine, 2019, 39, 509-514.	1.2	10
923	Atherosclerosis Pathogenesis and Microvascular Dysfunction. , 2019, , .		8
924	Clonal Hematopoiesis of IndeterminateÂPotential Reshapes Age-Related CVD. Journal of the American College of Cardiology, 2019, 74, 578-586.	1.2	57

#	Article	IF	Citations
925	Clonal Hematopoiesis. Journal of the American College of Cardiology, 2019, 74, 567-577.	1.2	150
926	Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies. Genes Chromosomes and Cancer, 2019, 58, 889-902.	1.5	41
927	Leukemia Stem Cells in Hematologic Malignancies. Advances in Experimental Medicine and Biology, 2019, , .	0.8	1
928	DNA Damage Response in Quiescent Hematopoietic Stem Cells and Leukemia Stem Cells. Advances in Experimental Medicine and Biology, 2019, 1143, 147-171.	0.8	2
929	The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. American Journal of Hematology, 2019, 94, 1141-1148.	2.0	33
930	Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia. Hematological Oncology, 2019, 37, 456-463.	0.8	11
931	Vulnerable Plaque, Characteristics, Detection, and Potential Therapies. Journal of Cardiovascular Development and Disease, 2019, 6, 26.	0.8	60
932	Inflammation as a Therapeutic Target in Atherosclerosis. Journal of Clinical Medicine, 2019, 8, 1109.	1.0	118
933	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. , 0, , .		0
934	Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. Nature Communications, 2019, 10, 2891.	5.8	36
935	Interactions Between Gut Microbiota and Acute Childhood Leukemia. Frontiers in Microbiology, 2019, 10, 1300.	1.5	26
936	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. Cell Reports, 2019, 28, 132-144.e3.	2.9	72
937	The roles of DNA, RNA and histone methylation in ageing and cancer. Nature Reviews Molecular Cell Biology, 2019, 20, 573-589.	16.1	359
938	Chronic lymphocytic leukaemia: from genetics to treatment. Nature Reviews Clinical Oncology, 2019, 16, 684-701.	12.5	154
939	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. Blood Reviews, 2019, 37, 100587.	2.8	23
940	Aging and Hematopoiesis. Clinics in Geriatric Medicine, 2019, 35, 285-293.	1.0	50
941	Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood, 2019, 134, 469-479.	0.6	139
942	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clinic Proceedings, 2019, 94, 1753-1768.	1.4	21

#	Article	IF	Citations
943	How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. Haematologica, 2019, 104, 1532-1541.	1.7	37
944	Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes and Cancer, 2019, 58, 839-849.	1.5	67
946	JAK2-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine HeartÂFailure. JACC Basic To Translational Science, 2019, 4, 684-697.	1.9	114
947	Immune-Based Therapies in Acute Leukemia. Trends in Cancer, 2019, 5, 604-618.	3.8	32
948	Liquid biopsy tracking of lung tumor evolutions over time. Expert Review of Molecular Diagnostics, 2019, 19, 1099-1108.	1.5	50
949	The cell of origin and the leukemia stem cell in acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 850-858.	1.5	50
950	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. International Journal of Molecular Sciences, 2019, 20, 5362.	1.8	29
951	Clonal hematopoiesis in human aging and disease. Science, 2019, 366, .	6.0	590
953	Assessing Measurable Residual Disease in Acute Myeloid Leukemia. Advances in Molecular Pathology, 2019, 2, 45-58.	0.2	1
954	EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer Journal, 2019, 9, 85.	2.8	24
955	The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia, 2019, 33, 2779-2794.	3.3	28
956	Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Frontiers in Immunology, 2019, 10, 2357.	2.2	99
957	The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS). Current Hematologic Malignancy Reports, 2019, 14, 536-542.	1.2	29
958	Cell cycle dynamics in the reprogramming of cellular identity. FEBS Letters, 2019, 593, 2840-2852.	1.3	24
959	Biological implications of clonal hematopoiesis. Experimental Hematology, 2019, 77, 1-5.	0.2	21
960	Somatic Variants: New Kids on the Block in Human Immunogenetics. Trends in Genetics, 2019, 35, 935-947.	2.9	29
961	Mutations found in cellâ€free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. Cancer Science, 2019, 110, 3375-3381.	1.7	16
962	Quantification of IGFâ€1 receptor is useful in the differential diagnosis of essential thrombocytosis from reactive thrombocytosis. European Journal of Haematology, 2019, 103, 573-577.	1.1	1

#	Article	IF	Citations
963	How Methods of Molecular Biology Shape Our Understanding of the Hematopoietic System. Molecular Biology, 2019, 53, 626-637.	0.4	1
964	A Revised Perspective of Skeletal Stem Cell Biology. Frontiers in Cell and Developmental Biology, 2019, 7, 189.	1.8	143
965	Targeting Metabolic Reprogramming in Acute Myeloid Leukemia. Cells, 2019, 8, 967.	1.8	43
966	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2517-2521.	2.0	19
967	Cancer-Associated Mutations but No Cancer: Insights into the Early Steps of Carcinogenesis and Implications for Early Cancer Detection. Trends in Cancer, 2019, 5, 531-540.	3.8	34
968	Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH). Experimental Hematology and Oncology, 2019, 8, 17.	2.0	3
969	Trisomy 8 in acute myeloid leukemia. Expert Review of Hematology, 2019, 12, 947-958.	1.0	27
970	Circulating Tumor DNA and Biliary Tract Cancer Diagnosis. JCO Precision Oncology, 2019, 3, 1-2.	1.5	0
971	Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. Blood, 2019, 134, 1487-1497.	0.6	95
972	The protective function of non-coding DNA in DNA damage accumulation with age and its roles in age-related diseases. Biogerontology, 2019, 20, 741-761.	2.0	8
973	Age-related clonal haemopoiesis is associated with increased epigenetic age. Current Biology, 2019, 29, R786-R787.	1.8	37
974	Updates in the management of polycythemia vera and essential thrombocythemia. Therapeutic Advances in Hematology, 2019, 10, 204062071987005.	1.1	25
975	CHIPing Away at Breast Cancer. Journal of the National Cancer Institute, 2019, 112, 10-11.	3.0	0
976	Tet inactivation disrupts YY1 binding and long-range chromatin interactions during embryonic heart development. Nature Communications, 2019, 10, 4297.	5.8	44
977	Li-Fraumeni syndrome: not a straightforward diagnosis anymoreâ€"the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 2019, 21, 107.	2.2	51
978	Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 4576.	1.8	54
979	From Focal Lipid Storage to Systemic Inflammation. Journal of the American College of Cardiology, 2019, 74, 1594-1607.	1.2	158
980	Towards a Better Understanding of Cohesin Mutations in AML. Frontiers in Oncology, 2019, 9, 867.	1.3	26

#	Article	IF	Citations
981	Clonal hematopoiesis: Pre-cancer PLUS. Advances in Cancer Research, 2019, 141, 85-128.	1.9	35
982	Evidence of clonality in cases of hypereosinophilia of undetermined significance. Leukemia and Lymphoma, 2019, 60, 2071-2074.	0.6	5
983	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell, 2019, 35, 283-296.e5.	7.7	71
984	Rethinking clinical trial endpoints in myelodysplastic syndromes. Leukemia, 2019, 33, 570-575.	3.3	18
985	Anticytokine Agents. Circulation Research, 2019, 124, 437-450.	2.0	188
986	Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. Frontiers in Oncology, 2018, 8, 669.	1.3	15
987	Genetics of MDS. Blood, 2019, 133, 1049-1059.	0.6	241
988	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood, 2019, 133, 1039-1048.	0.6	172
989	Genetic predisposition to MDS: clinical features and clonal evolution. Blood, 2019, 133, 1071-1085.	0.6	100
990	MDS overlap disorders and diagnostic boundaries. Blood, 2019, 133, 1086-1095.	0.6	58
991	DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, 1617-1625.	1.7	40
992	Mitochondrial Stress-Initiated Aberrant Activation of the NLRP3 Inflammasome Regulates the Functional Deterioration of Hematopoietic Stem Cell Aging. Cell Reports, 2019, 26, 945-954.e4.	2.9	98
993	Premature Aging in Young Cancer Survivors. Journal of the National Cancer Institute, 2019, 111, 226-232.	3.0	61
994	Defining the impact of mutation accumulation on replicative lifespan in yeast using cancer-associated mutator phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3062-3071.	3.3	17
995	Update on the pathologic diagnosis of chronic myelomonocytic leukemia. Modern Pathology, 2019, 32, 732-740.	2.9	18
996	Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms. Current Hematologic Malignancy Reports, 2019, 14, 145-153.	1.2	31
997	Adenocarcinoma in the transposed colon: High grade active inflammation versus low grade chronic inflammation. European Journal of Surgical Oncology, 2019, 45, 1536-1541.	0.5	11
998	Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 177-185.	0.7	15

#	Article	IF	Citations
999	Stem Cells Heterogeneity in Cancer. Advances in Experimental Medicine and Biology, 2019, , .	0.8	2
1000	Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3058-3062.	0.6	4
1001	Evolution of academicâ€“industry partnerships in cardiovascular research and development. Nature Reviews Cardiology, 2019, 16, 449-451.	6.1	1
1002	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
1003	DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern. Leukemia, 2019, 33, 2741-2746.	3.3	15
1004	Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nature Immunology, 2019, 20, 802-811.	7.0	205
1005	Mechanisms of leukemic transformation in congenital neutropenia. Current Opinion in Hematology, 2019, 26, 34-40.	1.2	28
1006	Myeloid malignanciesâ€related somatic mutations in aging individuals. Molecular Genetics & Genomic Medicine, 2019, 7, e683.	0.6	0
1007	Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis. International Journal of Hematology, 2019, 110, 431-437.	0.7	4
1008	Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act. Trends in Immunology, 2019, 40, 598-612.	2.9	67
1009	RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science, 2019, 364, .	6.0	369
1010	Mutated clones are the new normal. Science, 2019, 364, 938-939.	6.0	28
1011	Cell-Free DNA. , 2019, , 11-24.		1
1012	Emerging patterns in clonal haematopoiesis. Journal of Clinical Pathology, 2019, 72, 453-459.	1.0	2
1013	Strategies for minimal residual disease detection: current perspectives . Blood and Lymphatic Cancer: Targets and Therapy, 2019, Volume 9, 1-8.	1.2	5
1014	Mechanisms underlying T cell ageing. Nature Reviews Immunology, 2019, 19, 573-583.	10.6	250
1015	Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity. Advances in Experimental Medicine and Biology, 2019, 1139, 171-185.	0.8	0
1016	Comparative analysis of clonal hematopoiesis of multipotent stem cells in healthy elderly in blood and bone marrow. Leukemia Research, 2019, 82, 15-18.	0.4	1

#	Article	IF	Citations
1017	Somatic mutation and clonal expansions in human tissues. Genome Medicine, 2019, 11, 35.	3.6	100
1018	Illegitimate and Repeated Genomic Integration of Cell-Free Chromatin in the Aetiology of Somatic Mosaicism, Ageing, Chronic Diseases and Cancer. Genes, 2019, 10, 407.	1.0	15
1019	A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis. Cancer Research, 2019, 79, 3583-3594.	0.4	18
1020	Clinical and Therapeutic Implications of Cancer Stem Cells. New England Journal of Medicine, 2019, 380, 2237-2245.	13.9	234
1021	TET2 missense variants in human neoplasia. A proposal of structural and functional classification. Molecular Genetics & Genomic Medicine, 2019, 7, e00772.	0.6	9
1022	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1902-1910.	3.3	37
1023	Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. Biomarker Insights, 2019, 14, 117727191984645.	1.0	87
1025	Molecular genetic testing in the diagnosis of myeloid neoplasms. Diagnostic Histopathology, 2019, 25, 249-259.	0.2	1
1027	Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	18
1028	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 421-432.	1.8	31
1029	Sequencing Lung Cancerâ€™s Sequence. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 657-659.	2.5	0
1030	The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 2019, 33, 2842-2853.	3.3	43
1031	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation. Cell Reports, 2019, 27, 2022-2028.e3.	2.9	44
1032	Genomic testing in myeloid malignancy. International Journal of Laboratory Hematology, 2019, 41, 117-125.	0.7	7
1033	Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease. Revista Espanola De Cardiologia (English Ed), 2019, 72, 760-766.	0.4	3
1034	Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Cancer Discovery, 2019, 9, 1080-1101.	7.7	119
1035	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica, 2019, 104, 2400-2409.	1.7	37
1036	Circulating cell-free DNA use for diagnosing cholangiocarcinoma. Clinical Epigenetics, 2019, 11, 75.	1.8	2

#	Article	IF	Citations
1037	Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation. Trends in Molecular Medicine, 2019, 25, 494-515.	3.5	84
1038	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 400-410.	1.8	58
1039	Evolutionary trajectory of leukemic clones and its clinical implications. Haematologica, 2019, 104, 872-880.	1.7	17
1040	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematological Oncology, 2019, 37, 240-252.	0.8	8
1041	Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nature Communications, 2019, 10, 1252.	5.8	67
1042	The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients. Journal of the American Geriatrics Society, 2019, 67, 884-888.	1.3	11
1043	Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 1158-1167.	1.9	14
1044	Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes. Blood, 2019, 134, 186-198.	0.6	43
1045	Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia. Current Medical Science, 2019, 39, 217-221.	0.7	3
1046	Leukemiaâ€™s Clonal Evolution in Development, Progression, and Relapse. Current Stem Cell Reports, 2019, 5, 73-81.	0.7	3
1047	Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis. Blood, 2019, 134, 227-238.	0.6	23
1048	Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica, 2019, 104, 2410-2417.	1.7	73
1049	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
1050	Cardiotoxicity due to targeted anticancer agents: a growing challenge. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471984343.	1.0	22
1051	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	1.7	93
1053	Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews, 2019, 36, 70-87.	2.8	484
1054	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 2019, 10, 2031.	5.8	87
1055	Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1666-1673.	2.0	13

#	Article	IF	Citations
1056	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genetics, 2019, 235-236, 31-38.	0.2	23
1057	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019, 133, 2575-2585.	0.6	77
1058	Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment. Cells, 2019, 8, 312.	1.8	41
1059	Cytokine Circuits in Cardiovascular Disease. Immunity, 2019, 50, 941-954.	6.6	125
1060	Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience. Cancers, 2019, 11, 570.	1.7	14
1061	Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation. PLoS Computational Biology, 2019, 15, e1006913.	1.5	16
1062	Ultra-High-Frequency Reprogramming of Individual Long-Term Hematopoietic Stem Cells Yields Low Somatic Variant Induced Pluripotent Stem Cells. Cell Reports, 2019, 26, 2580-2592.e7.	2.9	14
1063	Novel Antiatherosclerotic Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 538-545.	1.1	103
1064	DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcoding. Bioinformatics, 2019, 35, 3849-3851.	1.8	3
1065	Replicative senescence of hematopoietic cells in patients with idiopathic cytopenia of undetermined significance. Leukemia Research, 2019, 79, 22-26.	0.4	1
1066	Inflammation: a common contributor to cancer, aging, and cardiovascular diseasesâ€”expanding the concept of cardio-oncology. Cardiovascular Research, 2019, 115, 824-829.	1.8	101
1067	Integration of transcriptional and mutational data simplifies the stratification of peripheral Tâ€cell lymphoma. American Journal of Hematology, 2019, 94, 628-634.	2.0	16
1068	Decoy fitness peaks, tumor suppression, and aging. Aging Cell, 2019, 18, e12938.	3.0	19
1069	On fitness: how do mutations shape the biology of cancer?. Biochemical Society Transactions, 2019, 47, 559-569.	1.6	2
1070	The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Molecular Cancer, 2019, 18, 36.	7.9	48
1071	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. Journal of Human Genetics, 2019, 64, 545-550.	1.1	6
1072	Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Annals of Oncology, 2019, 30, 945-952.	0.6	103
1073	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer. JAMA Cardiology, 2019, 4, 380.	3.0	42

#	Article	IF	Citations
1074	Clonal hematopoiesis of indeterminate potentialâ€“associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer, 2019, 125, 2233-2241.	2.0	19
1075	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. British Journal of Haematology, 2019, 186, e31-e35.	1.2	17
1076	Cellâ€free tumour <scp>DNA</scp> testing for early detection of cancer â€“ a potential future tool. Journal of Internal Medicine, 2019, 286, 118-136.	2.7	50
1077	DNA methylation and hydroxymethylation are associated with the degree of coronary atherosclerosis in elderly patients with coronary heart disease. Life Sciences, 2019, 224, 241-248.	2.0	35
1078	Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology, 2019, 37, 7-11.	0.8	60
1079	Clonal Hematopoiesis of Indeterminate Potential. Journal of Clinical Oncology, 2019, 37, 419-422.	0.8	18
1080	Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. British Journal of Haematology, 2019, 186, 300-310.	1.2	9
1081	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and highâ€risk disease. American Journal of Hematology, 2019, 94, 757-766.	2.0	86
1082	Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology, 2019, 12, 215-224.	1.0	9
1083	Liquid biopsy for cancer diagnosis and screening â€“ The promise and challenges. Annals of Clinical Biochemistry, 2019, 56, 420-423.	0.8	1
1084	RNA-binding proteins in hematopoiesis and hematological malignancy. Blood, 2019, 133, 2365-2373.	0.6	52
1085	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	9.4	97
1086	The role of ASXL1 in hematopoiesis and myeloid malignancies. Cellular and Molecular Life Sciences, 2019, 76, 2511-2523.	2.4	82
1087	Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica, 2019, 104, 868-871.	1.7	40
1088	Clonal hematopoiesis and preleukemiaâ€”Genetics, biology, and clinical implications. Genes Chromosomes and Cancer, 2019, 58, 828-838.	1.5	18
1089	Editorial commentary: Arson in the artery: Who set the atheroma aflame?. Trends in Cardiovascular Medicine, 2019, 29, 473-475.	2.3	2
1090	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia, 2019, 33, 2495-2505.	3.3	61
1091	Detection of Solid Tumor Molecular Residual DiseaseÂ(MRD) Using Circulating Tumor DNA (ctDNA). Molecular Diagnosis and Therapy, 2019, 23, 311-331.	1.6	123

#	Article	IF	Citations
1092	Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. Cell, 2019, 177, 608-621.e12.	13.5	167
1093	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 mutations. Modern Pathology, 2019, 32, 1123-1134.	2.9	54
1094	Targeted, Amplicon-Based, Next-Generation Sequencing to Detect Age-Related Clonal Hematopoiesis. Methods in Molecular Biology, 2019, 2045, 167-180.	0.4	8
1095	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 375-385.	0.8	163
1096	Cardiovascular Disease and Cancer: Is There Increasing Overlap?. Current Oncology Reports, 2019, 21, 47.	1.8	43
1097	TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells. Genome Research, 2019, 29, 564-575.	2.4	66
1098	Next Generation Sequencing in AMLâ€"On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. Cancers, 2019, 11, 252.	1.7	44
1099	Mosaicism, aging and cancer. Current Opinion in Oncology, 2019, 31, 108-113.	1.1	13
1100	Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?. Best Practice and Research in Clinical Haematology, 2019, 32, 104-113.	0.7	5
1101	Clonal approaches to understanding the impact of mutations on hematologic disease development. Blood, 2019, 133, 1436-1445.	0.6	14
1102	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. International Journal of Molecular Sciences, 2019, 20, 789.	1.8	50
1103	TP53 and therapy-related myeloid neoplasms. Best Practice and Research in Clinical Haematology, 2019, 32, 98-103.	0.7	9
1104	Cardiac Complications in the Adult Bone Marrow Transplant Patient. Current Oncology Reports, 2019, 21, 28.	1.8	28
1105	Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation. Immunity, 2019, 50, 288-301.	6.6	106
1106	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	1.0	32
1107	Inflammasomes, neutrophil extracellular traps, and cholesterol. Journal of Lipid Research, 2019, 60, 721-727.	2.0	92
1108	Completing the genetic spectrum influencing coronary artery disease: from germline to somatic variation. Cardiovascular Research, 2019, 115, 830-843.	1.8	14
1109	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Circulation, 2019, 139, e579-e602.	1.6	142

#	Article	IF	Citations
1110	The global clonal complexity of the murine blood system declines throughout life and after serial transplantation. Blood, 2019, 133, 1927-1942.	0.6	45
1111	Clonal Hematopoiesis and therapy related MDS/AML. Best Practice and Research in Clinical Haematology, 2019, 32, 13-23.	0.7	17
1112	Valor terapÃ©utico potencial de las estrategias dirigidas contra la interleucina 1Î² en la enfermedad cardiovascular ateroesclerÃ³tica. Revista Espanola De Cardiologia, 2019, 72, 760-766.	0.6	12
1113	In MDS, is higher risk higher reward?. Hematology American Society of Hematology Education Program, 2019, 2019, 381-390.	0.9	7
1114	Inflammatory bone marrow microenvironment. Hematology American Society of Hematology Education Program, 2019, 2019, 294-302.	0.9	41
1115	Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?. HemaSphere, 2019, 3, e283.	1.2	2
1116	Epigenetic regulation of hematopoietic stem cell homeostasis. Blood Science, 2019, 1, 19-28.	0.4	8
1117	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. Blood Advances, 2019, 3, 3449-3453.	2.5	7
1118	Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Advances, 2019, 3, 2482-2486.	2.5	89
1119	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Advances, 2019, 3, 3406-3418.	2.5	8
1120	The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Advances, 2019, 3, 2949-2961.	2.5	29
1121	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. Blood Advances, 2019, 3, 3454-3460.	2.5	5
1122	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances, 2019, 3, 3962-3967.	2.5	12
1123	Non-del(5q) myelodysplastic syndromesâ€“associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances, 2019, 3, 3579-3589.	2.5	7
1124	Mastering the multitude of monocytoses. Haematologica, 2019, 104, 1912-1914.	1.7	1
1125	When should transplant physicians think about familial blood cancers?. Advances in Cell and Gene Therapy, 2019, 2, e68.	0.6	4
1126	The Ban on US Government Funding Research Using Human Fetal Tissues: How Does This Fit with the NIH Mission to Advance Medical Science for the Benefit of the Citizenry?. Stem Cell Reports, 2019, 13, 777-786.	2.3	23
1127	Molecular Genetics in Myelodysplasia Outcomes Prognostication. Advances in Molecular Pathology, 2019, 2, 35-43.	0.2	0

#	Article	IF	Citations
1129	Somatic mutations in aplastic anemia: Significance for classification, therapy, and outcome. HemaSphere, 2019, 3, 10-12.	1.2	0
1130	Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nature Communications, 2019, 10, 5386.	5.8	53
1131	Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies. , 2019, , .		9
1132	Metcalf Lecture Award: Applying niche biology to engineer T-cell regenerative therapies. Experimental Hematology, 2019, 80, 1-10.	0.2	1
1133	Does early diagnosis and treatment of myelodysplastic syndromes make a difference?. Best Practice and Research in Clinical Haematology, 2019, 32, 101099.	0.7	3
1135	Telomeres as Therapeutic Targets inÂHeart Disease. JACC Basic To Translational Science, 2019, 4, 855-865.	1.9	26
1136	DNA methylation aging clocks: challenges and recommendations. Genome Biology, 2019, 20, 249.	3.8	552
1137	p53 involvement in clonal hematopoiesis of indeterminate potential. Current Opinion in Hematology, 2019, 26, 235-240.	1.2	21
1138	Growing old in the age of heterogeneity: the perils of shifting clonality. Current Opinion in Hematology, 2019, 26, 222-227.	1.2	4
1139	Application of Genomics to Clinical Practice in Haematological Malignancy. Current Genetic Medicine Reports, 2019, 7, 236-252.	1.9	0
1140	Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas. Current Opinion in Oncology, 2019, 31, 369-373.	1.1	6
1141	Symptomatic HeartÂFailure in AcuteÂLeukemia Patients TreatedÂWithÂAnthracyclines. JACC: CardioOncology, 2019, 1, 208-217.	1.7	27
1142	MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors. Nature Communications, 2019, 10, 5767.	5.8	41
1143	Emerging single-cell tools are primed to reveal functional and molecular heterogeneity in malignant hematopoietic stem cells. Current Opinion in Hematology, 2019, 26, 214-221.	1.2	9
1144	Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. Experimental Hematology, 2019, 80, 36-41.e3.	0.2	90
1145	Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. Journal of Oncology, 2019, 2019, 1-8.	0.6	3
1146	Personalized Cardiovascular Regenerative Medicine: Targeting the Extreme Stages of Life. Frontiers in Cardiovascular Medicine, 2019, 6, 177.	1.1	4
1147	The landscape of somatic mutation in normal colorectal epithelial cells. Nature, 2019, 574, 532-537.	13.7	468

#	Article	IF	Citations
1148	The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models. HemaSphere, 2019, 3, e152.	1.2	8
1149	Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia. Current Opinion in Hematology, 2019, 26, 51-57.	1.2	4
1150	Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nature Communications, 2019, 10, 5649.	5.8	77
1151	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	15.2	485
1152	Genome Sequencing during a Patientâ€™s Journey through Cancer. New England Journal of Medicine, 2019, 381, 2145-2156.	13.9	50
1153	Metabolism as master of hematopoietic stem cell fate. International Journal of Hematology, 2019, 109, 18-27.	0.7	71
1154	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica, 2019, 104, 305-311.	1.7	56
1155	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, 488-495.	2.0	21
1156	Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. Haematologica, 2019, 104, 297-304.	1.7	33
1157	Clinical implications of molecular markers in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 20-35.	1.1	44
1158	DNA methylation processes in atherosclerotic plaque. Atherosclerosis, 2019, 281, 168-179.	0.4	49
1159	Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle. Future Oncology, 2019, 15, 65-79.	1.1	4
1160	Acute myeloid leukemia with eosinophilia after cyclinâ€dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. American Journal of Hematology, 2019, 94, E82-E85.	2.0	2
1161	CHIPping Away at the Pathogenesis of Heart Failure. JAMA Cardiology, 2019, 4, 5.	3.0	8
1162	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Human Pathology, 2019, 86, 1-11.	1.1	24
1163	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature, 2019, 565, 312-317.	13.7	476
1164	Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Haematologica, 2019, 104, e200-e203.	1.7	8
1165	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 2019, 133, 1140-1151.	0.6	96

#	Article	IF	Citations
1166	Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiology, 2019, 4, 25.	3.0	313
1167	Myelodysplastic Syndrome and Acute Myeloid Leukemia Risk Associated With Solid Tumor Chemotherapy. JAMA Oncology, 2019, 5, 303.	3.4	6
1168	A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. Human Molecular Genetics, 2019, 28, 1369-1380.	1.4	16
1169	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1204-1213.	0.4	75
1170	Single cell analysis of clonal architecture in acute myeloid leukaemia. Leukemia, 2019, 33, 1113-1123.	3.3	65
1171	The molecular genetics of sideroblastic anemia. Blood, 2019, 133, 59-69.	0.6	68
1172	Spontaneous <i>de novo</i> germline mutations in humans and mice: rates, spectra, causes and consequences. Genes and Genetic Systems, 2019, 94, 13-22.	0.2	19
1173	Current and future perspectives ofÂliquid biopsies in genomics-driven oncology. Nature Reviews Genetics, 2019, 20, 71-88.	7.7	912
1174	Heterogeneity in myeloproliferative neoplasms: Causes and consequences. Advances in Biological Regulation, 2019, 71, 55-68.	1.4	35
1175	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology, 2019, 14, 16-24.	0.5	100
1176	Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal. Experimental Hematology, 2019, 70, 10-23.	0.2	13
1177	Clonal hematopoiesis: Genes and underlying mechanisms in cardiovascular disease development. Journal of Cellular Physiology, 2019, 234, 8396-8401.	2.0	8
1178	Anemia in the Young and Old. , 2019, , .		0
1179	Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma. Cancer Science, 2019, 110, 401-407.	1.7	20
1180	Radiation exposure and longitudinal changes in peripheral monocytes over 50Âyears: the Adult Health Study of atomicâ€bomb survivors. British Journal of Haematology, 2019, 185, 107-115.	1.2	20
1181	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2019, 54, 1281-1286.	1.3	24
1182	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications, 2019, 10, 244.	5.8	111
1183	The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood, 2019, 133, 1325-1334.	0.6	53

#	Article	IF	Citations
1184	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica, 2019, 104, e236-e239.	1.7	18
1185	Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. Expert Review of Hematology, 2019, 12, 99-106.	1.0	5
1186	Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia, 2019, 33, 1723-1735.	3.3	28
1187	Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. International Journal of Molecular Sciences, 2019, 20, 228.	1.8	93
1188	Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience. Haematologica, 2019, 104, e134-e137.	1.7	6
1189	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hautsâ€deâ€France AML observatory. American Journal of Hematology, 2019, 94, E24-E27.	2.0	5
1190	Multisystem Trajectories Over the Adult Life Course and Relations to Cardiovascular Disease and Death. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1778-1785.	1.7	8
1191	Molecular pathogenesis of acquired aplastic anemia. European Journal of Haematology, 2019, 102, 103-110.	1.1	25
1192	Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms. International Journal of Hematology, 2019, 110, 179-186.	0.7	17
1193	Cohesin-mediated NF-ÎºB signaling limits hematopoietic stem cell self-renewal in aging and inflammation. Journal of Experimental Medicine, 2019, 216, 152-175.	4.2	56
1194	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 2019, 25, 103-110.	15.2	169
1195	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology, 2019, 184, 176-191.	1.2	102
1196	Circulating Tumor DNA: Clinical Monitoring and Early Detection. Annual Review of Cancer Biology, 2019, 3, 187-201.	2.3	6
1197	Immunometabolic Crosstalk: An Ancestral Principle of Trained Immunity?. Trends in Immunology, 2019, 40, 1-11.	2.9	92
1198	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplantation, 2019, 54, 1189-1197.	1.3	34
1199	Epigenomic drivers of immune dysfunction in aging. Aging Cell, 2019, 18, e12878.	3.0	60
1200	ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance. Leukemia and Lymphoma, 2019, 60, 756-763.	0.6	6
1201	Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology. International Journal of Laboratory Hematology, 2019, 41, 109-117.	0.7	5

#	Article	IF	Citations
1202	What do the lineage tracing studies tell us? Consideration for hematopoietic stem cell origin, dynamics, and leukemia-initiating cells. International Journal of Hematology, 2019, 109, 35-40.	0.7	9
1203	Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Seminars in Hematology, 2019, 56, 183-189.	1.8	8
1204	ASXL1 mutations in idiopathic cytopenias: determined significance?. Leukemia and Lymphoma, 2019, 60, 568-570.	0.6	0
1205	Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Haematologica, 2020, 105, 358-365.	1.7	5
1206	Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors. Bone Marrow Transplantation, 2020, 55, 665-668.	1.3	7
1207	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 12-24.	1.3	94
1208	Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia. International Journal of Hematology, 2020, 111, 311-316.	0.7	1
1209	Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis. Journal of Geriatric Oncology, 2020, 11, 316-319.	0.5	8
1210	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. Acta Clinica Belgica, 2020, 75, 9-18.	0.5	9
1211	Tumor-Based Genetic Testing and Familial Cancer Risk. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036590.	2.9	27
1212	The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a034876.	2.9	42
1213	Donor-to-Donor Heterogeneity in the Clonal Dynamics of Transplanted Humanâ€Cord Blood Stem Cellsâ€in Murine Xenografts. Biology of Blood and Marrow Transplantation, 2020, 26, 16-25.	2.0	21
1215	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 823-834.	1.2	29
1216	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia, 2020, 34, 957-962.	3.3	32
1217	Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. British Journal of Haematology, 2020, 188, 852-859.	1.2	13
1218	Melt dripping behavior in the process of flame spread over energized electrical wire at different pressures. Fire and Materials, 2020, 44, 58-64.	0.9	2
1219	Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms. Seminars in Cancer Biology, 2020, 60, 191-201.	4.3	15
1220	Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 137-144.	6.1	215

#	Article	IF	Citations
1222	Mechanisms underlying the crossâ€talk between heart and cancer. Journal of Physiology, 2020, 598, 3015-3027.	1.3	14
1223	DNA damage in aging, the stem cell perspective. Human Genetics, 2020, 139, 309-331.	1.8	29
1224	Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. European Heart Journal, 2020, 41, 933-939.	1.0	150
1225	Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036251.	2.9	17
1226	Genetic and epigenetic Mullerâ€™s ratchet as a mechanism of frailty and morbidity during aging: a demographic genetic model. Human Genetics, 2020, 139, 409-420.	1.8	6
1228	Recent advances in MDS mutation landscape: Splicing and signalling. Advances in Biological Regulation, 2020, 75, 100673.	1.4	7
1229	Cardiovascular Disease, Aging, and Clonal Hematopoiesis. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 419-438.	9.6	94
1230	Low prevalence of the BCRâ€“ABL1 fusion gene in a normal population in southern Sarawak. International Journal of Hematology, 2020, 111, 217-224.	0.7	1
1231	Aspects of the normal genome. , 2020, , 525-545.		0
1232	Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia. Expert Review of Hematology, 2020, 13, 55-70.	1.0	35
1233	Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals. European Journal of Human Genetics, 2020, 28, 349-357.	1.4	47
1234	Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. Circulation, 2020, 141, 124-131.	1.6	270
1235	Clonal Hematopoiesis and Premalignant Diseases. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035675.	2.9	10
1236	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2020, 188, 605-622.	1.2	25
1237	Molecular heterogeneity unravelled by singleâ€cell transcriptomics in patients with essential thrombocythaemia. British Journal of Haematology, 2020, 188, 707-722.	1.2	2
1238	A decade with whole exome sequencing in haematology. British Journal of Haematology, 2020, 188, 367-382.	1.2	24
1239	A substantial proportion of apparently heterozygousTP53pathogenic variants detected with a nextâ€generation sequencing hereditary panâ€cancer panel are acquired somatically. Human Mutation, 2020, 41, 203-211.	1.1	19
1240	A new opening on aortic stenosis: predicting prognosis with clonal haematopoiesis. European Heart Journal, 2020, 41, 940-942.	1.0	3

#	Article	IF	Citations
1241	The evolving role of next generation sequencing in myelodysplastic syndromes. British Journal of Haematology, 2020, 188, 224-239.	1.2	11
1243	Somatic selection of poorly differentiating variant stem cell clones could be a key to human ageing. Journal of Theoretical Biology, 2020, 489, 110153.	0.8	5
1245	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
1246	Environmental influences on clonal hematopoiesis. Experimental Hematology, 2020, 83, 66-73.	0.2	45
1247	Age-related disease burden in Indian population. Journal of the National Medical Association, 2020, 112, 57-73.	0.6	3
1248	Genetic predisposition for multiple myeloma. Leukemia, 2020, 34, 697-708.	3.3	25
1249	Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system. FASEB Journal, 2020, 34, 3239-3252.	0.2	9
1250	Cancer-predisposing germline variants and childhood cancer. , 2020, , 221-232.		0
1251	Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. Journal of Molecular Diagnostics, 2020, 22, 396-404.	1.2	17
1252	Evolving Significance of Tumor-Normal Sequencing in Cancer Care. Trends in Cancer, 2020, 6, 31-39.	3.8	30
1253	Autism risk in offspring can be assessed through quantification of male sperm mosaicism. Nature Medicine, 2020, 26, 143-150.	15.2	76
1254	Somatic mosaicism: implications for the cardiovascular system. European Heart Journal, 2020, 41, 2904-2907.	1.0	13
1255	Clonal hematopoiesis, aging, and cardiovascular diseases. Experimental Hematology, 2020, 83, 95-104.	0.2	37
1256	How I investigate chronic myelomonocytic leukemia. International Journal of Laboratory Hematology, 2020, 42, 101-108.	0.7	9
1257	Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells. Leukemia, 2020, 34, 1125-1134.	3.3	10
1258	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	2.0	69
1259	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer, 2020, 20, 158-173.	12.8	181
1260	Atypical CML- the role of morphology and precision genomics. Best Practice and Research in Clinical Haematology, 2020, 33, 101133.	0.7	7

#	Article	IF	Citations
1261	Acute Myeloid Leukemia: Aging and Epigenetics. Cancers, 2020, 12, 103.	1.7	46
1262	Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. International Journal of Hematology, 2020, 111, 634-641.	0.7	12
1263	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€"a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	3.3	68
1264	Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis. Leukemia, 2020, 34, 1689-1693.	3.3	12
1265	Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 145, 102832.	2.0	8
1266	Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. Molecular Diagnosis and Therapy, 2020, 24, 1-13.	1.6	21
1267	Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematology,the, 2020, 7, e73-e81.	2.2	45
1268	Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. Best Practice and Research in Clinical Haematology, 2020, 33, 101137.	0.7	11
1269	Circulating tumor DNA as an early cancer detection tool. , 2020, 207, 107458.		123
1270	Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 407-414.	0.6	10
1271	Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nature, 2020, 577, 254-259.	13.7	202
1272	Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature, 2020, 577, 260-265.	13.7	168
1273	Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. Current Opinion in Hematology, 2020, 27, 2-10.	1.2	7
1274	The power and potential of integrated diagnostics in acute myeloid leukaemia. British Journal of Haematology, 2020, 188, 36-48.	1.2	44
1275	Familial myeloid malignancies with germline TET2 mutation. Leukemia, 2020, 34, 1450-1453.	3.3	36
1276	Clonal hematopoiesis as a model for premalignant changes during aging. Experimental Hematology, 2020, 83, 48-56.	0.2	56
1277	Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. British Journal of Haematology, 2020, 190, 562-572.	1.2	5
1278	Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2020, 95, 238-244.	2.0	4

#	Article	IF	Citations
1279	Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2020, 79, 242-253.	0.5	44
1280	Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology, 2019, 9, 1380.	1.3	187
1281	EBV status has prognostic implication among young patients with angioimmunoblastic Tâ€cell lymphoma. Cancer Medicine, 2020, 9, 678-688.	1.3	23
1282	CRISPR Diagnosis and Therapeutics with Single Base Pair Precision. Trends in Molecular Medicine, 2020, 26, 337-350.	3.5	30
1283	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. Journal of Clinical Oncology, 2020, 38, 1273-1283.	0.8	281
1284	Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS). American Journal of Hematology, 2020, 95, 258-266.	2.0	14
1285	Novel Approaches to Target Mutant FLT3 Leukaemia. Cancers, 2020, 12, 2806.	1.7	13
1286	In vivo clonal analysis of aging hematopoietic stem cells. Mechanisms of Ageing and Development, 2020, 192, 111378.	2.2	3
1287	Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. Journal of Thrombosis and Haemostasis, 2020, 18, 3359-3370.	1.9	21
1288	The old and the new: DNA and RNA methylation in normal and malignant hematopoiesis. Experimental Hematology, 2020, 90, 1-11.	0.2	7
1289	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leukemia Research, 2020, 98, 106454.	0.4	8
1290	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 1027-1033.	1.5	20
1291	Advancing Leukemia Diagnostics: Role of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia. Hematology Reports, 2020, 12, 8957.	0.3	14
1292	Trained Immunity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 55-61.	1.1	21
1293	Putative Mechanisms Underlying Cardiovascular Disease Associated with Clonal Hematopoiesis of Indeterminate Potential. Stem Cell Reports, 2020, 15, 292-306.	2.3	4
1294	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature, 2020, 586, 763-768.	13.7	376
1295	Management of Patients with Acute Coronary Syndrome and Cancer. Current Cardiology Reports, 2020, 22, 159.	1.3	10
1296	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. International Journal of Molecular Sciences, 2020, 21, 7140.	1.8	14

#	Article	IF	Citations
1297	Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis. Experimental Hematology, 2020, 91, 1-9.	0.2	42
1298	Clonal hematopoiesis: Molecular basis and clinical relevance. Leukemia Research, 2020, 98, 106457.	0.4	2
1299	Proliferation: Driver of HSC aging phenotypes?. Mechanisms of Ageing and Development, 2020, 191, 111331.	2.2	7
1300	The genomic landscapes of individual melanocytes from human skin. Nature, 2020, 586, 600-605.	13.7	79
1301	Methylated DNA immunoprecipitation sequencing (MeDIP-seq): Principles and applications. , 2020, , 157-179.		1
1302	Somatic Evolution in Non-neoplastic IBD-Affected Colon. Cell, 2020, 182, 672-684.e11.	13.5	122
1303	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. HemaSphere, 2020, 4, .	1.2	2
1304	A six-attribute classification of geneticmosaicism. Genetics in Medicine, 2020, 22, 1743-1757.	1.1	34
1305	EZH2 in Myeloid Malignancies. Cells, 2020, 9, 1639.	1.8	37
1306	Glycogen accumulation, central carbon metabolism, and aging of hematopoietic stem and progenitor cells. Scientific Reports, 2020, 10, 11597.	1.6	12
1307	Tracking hematopoietic stem cells and their progeny using whole-genome sequencing. Experimental Hematology, 2020, 83, 12-24.	0.2	19
1308	Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion. Cell Stem Cell, 2020, 27, 326-335.e4.	5.2	25
1309	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	1.8	51
1310	A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation. Biology of Sex Differences, 2020, 11, 39.	1.8	7
1311	FOXO activity adaptation safeguards the hematopoietic stem cell compartment in hyperglycemia. Blood Advances, 2020, 4, 5512-5526.	2.5	7
1312	Fundamental Biological Features of Spaceflight: Advancing the Field to Enable Deep-Space Exploration. Cell, 2020, 183, 1162-1184.	13.5	185
1313	Dynamic clonal hematopoiesis and functional T-cell immunity in a supercentenarian. Leukemia, 2021, 35, 2125-2129.	3.3	9
1314	Immuno-Modulation of Hematopoietic Stem and Progenitor Cells in Inflammation. Frontiers in Immunology, 2020, 11, 585367.	2.2	16

#	Article	IF	Citations
1315	Clonal Hematopoiesis Before, During, and After Human Spaceflight. Cell Reports, 2020, 33, 108458.	2.9	30
1316	The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. Cells, 2020, 9, 2512.	1.8	15
1317	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature, 2020, 588, 157-163.	13.7	90
1318	Germline genomic patterns are associated with cancer risk, oncogenic pathways, and clinical outcomes. Science Advances, 2020, 6, .	4.7	12
1319	Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Frontiers in Immunology, 2020, 11, 604142.	2.2	5
1320	Applied genomics in MPN presentation. Hematology American Society of Hematology Education Program, 2020, 2020, 434-439.	0.9	5
1321	Hematopoietic Stem Cell Stress and Regeneration. Current Stem Cell Reports, 2020, 6, 134-143.	0.7	2
1322	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. Cancers, 2020, 12, 3304.	1.7	5
1323	Immunogenetics of Atherosclerosisâ€"Link between Lipids, Immunity, and Genes. Current Atherosclerosis Reports, 2020, 22, 53.	2.0	6
1324	Evidence of Clonal Hematopoiesis and Risk of Heart Failure. Current Heart Failure Reports, 2020, 17, 271-276.	1.3	4
1325	Discovery through clinical sequencing in oncology. Nature Cancer, 2020, 1, 774-783.	5.7	29
1326	Clonal haematopoiesis is increased in early onset inÂsystemic sclerosis. Rheumatology, 2020, 59, 3499-3504.	0.9	22
1327	Molecular and functional characteristics of megakaryocytes and platelets in aging. Current Opinion in Hematology, 2020, 27, 302-310.	1.2	2
1328	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. International Journal of Laboratory Hematology, 2020, 42, 671-684.	0.7	7
1329	High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. Blood Advances, 2020, 4, 3550-3557.	2.5	38
1330	Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia, 2020, 34, 2592-2606.	3.3	91
1331	Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. Biomarker Research, 2020, 8, 27.	2.8	22
1332	A somatic evolutionary model of the dynamics of aneuploid cells during hematopoietic reconstitution. Scientific Reports, 2020, 10, 12198.	1.6	0

#	Article	IF	Citations
1333	TET family dioxygenases and the TET activator vitamin C in immune responses and cancer. Blood, 2020, 136, 1394-1401.	0.6	40
1334	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. Cancers, 2020, 12, 1992.	1.7	24
1335	Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN. Cancers, 2020, 12, 2038.	1.7	7
1336	Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse. Haematologica, 2021, 106, 2325-2333.	1.7	18
1337	Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. Cancers, 2020, 12, 2100.	1.7	19
1338	Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci. Best Practice and Research in Clinical Haematology, 2020, 33, 101191.	0.7	6
1339	Clinical utility of target captureâ€based panel sequencing in hematological malignancies: A multicenter feasibility study. Cancer Science, 2020, 111, 3367-3378.	1.7	11
1340	Clonal hematopoiesis and non-hematologic disorders. Blood, 2020, 136, 1606-1614.	0.6	71
1341	Clonal hematopoiesis in the inherited bone marrow failure syndromes. Blood, 2020, 136, 1615-1622.	0.6	26
1342	Clonal hematopoiesis and risk for hematologic malignancy. Blood, 2020, 136, 1599-1605.	0.6	35
1343	What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. Blood, 2020, 136, 1623-1631.	0.6	23
1344	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 1399-1420.	2.0	119
1345	Thrombosis in hematological malignancies: mechanisms and implications. Thrombosis Research, 2020, 191, S58-S62.	0.8	14
1346	Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones. Blood, 2020, 136, 1590-1598.	0.6	67
1347	Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review. Journal of Clinical Medicine, 2020, 9, 2480.	1.0	16
1348	Sowing the Seeds of Clonal Hematopoiesis. Cell Stem Cell, 2020, 27, 195-197.	5.2	3
1349	Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabineâ€based chemotherapy. International Journal of Laboratory Hematology, 2020, 42, 849-857.	0.7	8
1350	Impact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival. Leukemia and Lymphoma, 2020, 61, 3269-3271.	0.6	0

#	Article	IF	Citations
1351	The role of clonal haematopoiesis in cardiovascular diseases: epidemiology and experimental studies. Journal of Internal Medicine, 2020, 288, 507-517.	2.7	10
1352	Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers, 2020, 12, 2194.	1.7	28
1353	In Vitro Modeling of Non-Solid Tumors: How Far Can Tissue Engineering Go?. International Journal of Molecular Sciences, 2020, 21, 5747.	1.8	16
1355	Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica, 2021, 106, 2397-2404.	1.7	8
1356	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers, 2020, 12, 2228.	1.7	22
1357	Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia. Stem Cell Reports, 2020, 15, 279-291.	2.3	10
1358	Inflammation mediated platelet hyperactivity in aging. Annals of Blood, 2020, 5, 10-10.	0.4	2
1359	Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. Cancers, 2020, 12, 2216.	1.7	17
1360	Controversies on the Consequences of Iron Overload and Chelation in MDS. HemaSphere, 2020, 4, e357.	1.2	19
1362	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
1363	Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy. Blood Advances, 2020, 4, 4798-4801.	2.5	11
1364	Dnmt3a-null hematopoietic stem and progenitor cells expand after busulfan treatment. Experimental Hematology, 2020, 91, 39-45.e2.	0.2	6
1365	Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature, 2020, 587, 477-482.	13.7	304
1366	A mosaic analysis system with Cre or Tomato expression in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28212-28220.	3.3	3
1367	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3112.	1.7	23
1368	Clonal Hematopoiesis, Cardiovascular Diseases and Hematopoietic Stem Cells. International Journal of Molecular Sciences, 2020, 21, 7902.	1.8	10
1369	TET2-Loss-of-Function-Driven Clonal Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity. Cell Reports, 2020, 33, 108326.	2.9	117
1370	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92

#	Article	IF	Citations
1371	Murine Models of Myelofibrosis. Cancers, 2020, 12, 2381.	1.7	14
1372	Targeting Inflammation to Reduce Residual Cardiovascular Risk. Current Atherosclerosis Reports, 2020, 22, 66.	2.0	29
1373	Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. Blood Cancer Journal, 2020, 10, 89.	2.8	20
1374	Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach. Expert Review of Hematology, 2020, 13, 1289-1301.	1.0	3
1375	Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor . OncoTargets and Therapy, 2020, Volume 13, 8581-8591.	1.0	8
1376	The myeloid type I interferon response to myocardial infarction begins in bone marrow and is regulated by Nrf2-activated macrophages. Science Immunology, 2020, 5, .	5.6	43
1377	Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency. Journal of Physical Education and Sports Management, 2020, 6, a005769.	0.5	3
1378	Stem Cell Aging and Regenerative Medicine. Advances in Experimental Medicine and Biology, 2020, 1326, 11-37.	0.8	11
1379	Autophagyâ€Sirt3 axis decelerates hematopoietic aging. Aging Cell, 2020, 19, e13232.	3.0	24
1380	Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation. Haematologica, 2020, 105, 2655-2658.	1.7	1
1381	Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers, 2020, 12, 2277.	1.7	83
1382	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. Journal of Personalized Medicine, 2020, 10, 94.	1.1	12
1383	MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. Cells, 2020, 9, 1901.	1.8	27
1384	Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network. Annals of Hematology, 2020, 99, 2303-2313.	0.8	5
1385	The Role of Age-Related Clonal Hematopoiesis in Genetic Sequencing Studies. American Journal of Human Genetics, 2020, 107, 575-576.	2.6	6
1386	Response to Holstege etÂal.. American Journal of Human Genetics, 2020, 107, 577-578.	2.6	1
1387	Unraveling Hematopoiesis through the Lens of Genomics. Cell, 2020, 182, 1384-1400.	13.5	96
1388	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. Journal of Adolescent and Young Adult Oncology, 2020, 10, 336-341.	0.7	2

#	Article	IF	Citations
1389	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Communications Biology, 2020, 3, 493.	2.0	30
1390	All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells. Cell Cycle, 2020, 19, 2573-2588.	1.3	10
1391	Cytotoxic Therapyâ€“Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 32-47.	2.6	16
1392	Chasing ctDNA in Patients With Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e351-e360.	1.8	8
1393	Crosstalk Between the Heart and Cancer. Circulation, 2020, 142, 684-687.	1.6	28
1394	New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. Oncogenesis, 2020, 9, 73.	2.1	14
1395	Considering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction. Cells, 2020, 9, 1894.	1.8	13
1396	The road ahead in genetics and genomics. Nature Reviews Genetics, 2020, 21, 581-596.	7.7	118
1397	Non-genetic Heterogeneity of Macrophages in Diseasesâ€”A Medical Perspective. Frontiers in Cell and Developmental Biology, 2020, 8, 613116.	1.8	10
1398	Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. Cells, 2020, 9, 2721.	1.8	13
1399	Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. Blood Advances, 2020, 4, 6353-6363.	2.5	36
1400	Clonal Hematopoiesis in Hospitalized Elderly Patients With COVIDâ€19. HemaSphere, 2020, 4, e453.	1.2	23
1401	Dietary patterns and the neoplasticâ€prone tissue landscape of old age. Aging and Cancer, 2020, 1, 45-57.	0.5	2
1402	Donor cellâ€derived chronic myelomonocytic leukemia presenting after allogeneic hematopoietic cell transplantation for Tâ€cell acute lymphoblastic leukemia. Clinical Case Reports (discontinued), 2020, 8, 3225-3228.	0.2	1
1403	Predictors of vascular disease in myelodysplastic syndromes. EJHaem, 2020, 1, 467-472.	0.4	3
1404	Newâ€onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide. EJHaem, 2020, 1, 576-580.	0.4	2
1405	TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis. Journal of Personalized Medicine, 2020, 10, 259.	1.1	6
1406	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	2.5	21

#	Article	IF	Citations
1407	Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes. Blood Advances, 2020, 4, 5232-5245.	2.5	8
1408	Malignant progression of donor-engrafted clonal hematopoiesis in sibling recipients after stem cell transplantation. Blood Advances, 2020, 4, 5631-5634.	2.5	6
1409	Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia, 2020, 35, 2017-2029.	3.3	27
1410	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2441-2453.	1.1	5
1411	Clonal Hematopoiesis in Late-Stage Nonâ€“Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing. JCO Precision Oncology, 2020, 4, 1271-1279.	1.5	19
1412	Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis. Scientific Reports, 2020, 10, 19037.	1.6	4
1413	Fate of Hematopoiesis During Aging. What Do We Really Know, and What are its Implications?. Stem Cell Reviews and Reports, 2020, 16, 1020-1048.	1.7	19
1414	Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer, 2020, 20, 1053.	1.1	10
1415	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood, 2020, 135, 1548-1559.	0.6	58
1416	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in nonâ€“small cell lung cancer: Analysis of over 8000 cases. Cancer, 2020, 126, 3219-3228.	2.0	106
1417	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. Annals of Hematology, 2020, 99, 1341-1350.	0.8	7
1418	MicroRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia. Diabetes Care, 2020, 43, 1520-1529.	4.3	22
1419	TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. International Journal of Molecular Sciences, 2020, 21, 3432.	1.8	25
1420	Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis. Leukemia and Lymphoma, 2020, 61, 2168-2179.	0.6	7
1421	Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology, 2020, 8, 249.	1.8	29
1422	Quantitative and Qualitative QC of Next-Generation Sequencing for Detecting Somatic Variants: An Example of Detecting Clonal Hematopoiesis of Indeterminate Potential. Clinical Chemistry, 2020, 66, 832-841.	1.5	3
1423	Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. Current Oncology Reports, 2020, 22, 61.	1.8	21
1424	Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study. EClinicalMedicine, 2020, 21, 100324.	3.2	2

#	Article	IF	Citations
1425	A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation. Case Reports in Oncology, 2020, 13, 449-455.	0.3	2
1426	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood, 2020, 135, 1729-1738.	0.6	80
1427	Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nature Reviews Cancer, 2020, 20, 365-382.	12.8	87
1428	Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity. Frontiers in Cardiovascular Medicine, 2020, 7, 64.	1.1	39
1429	Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer. Cancer Medicine, 2020, 9, 4501-4511.	1.3	8
1430	Restoring aged stem cell functionality: Current progress and future directions. Stem Cells, 2020, 38, 1060-1077.	1.4	25
1431	Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia, 2020, 34, 2198-2205.	3.3	26
1432	Cancer spectrum and outcomes in the Mendelian short telomere syndromes. Blood, 2020, 135, 1946-1956.	0.6	79
1433	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	0.6	195
1434	Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood, 2020, 136, 36-49.	0.6	59
1435	Genetics of progression from MDS to secondary leukemia. Blood, 2020, 136, 50-60.	0.6	80
1436	The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor. JAMA Cardiology, 2020, 5, 958.	3.0	33
1437	Remethylation of Dnmt3a ^{â^'/â^'} hematopoietic cells is associated with partial correction of gene dysregulation and reduced myeloid skewing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3123-3134.	3.3	27
1438	Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia, 2020, 34, 2660-2672.	3.3	96
1439	Clonality in haematopoietic stem cell ageing. Mechanisms of Ageing and Development, 2020, 189, 111279.	2.2	4
1440	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	5.8	98
1441	Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2020, 98, 399-411.	0.7	24
1442	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182

#	Article	IF	Citations
1443	Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Blood Reviews, 2020, 42, 100708.	2.8	10
1444	Chromosomal alterations among age-related haematopoietic clones in Japan. Nature, 2020, 584, 130-135.	13.7	102
1445	Monogenic and polygenic inheritance become instruments for clonal selection. Nature, 2020, 584, 136-141.	13.7	119
1446	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Advances, 2020, 4, 2430-2438.	2.5	54
1447	Implications of Clonal Hematopoiesis for Precision Oncology. JCO Precision Oncology, 2020, 4, 639-646.	1.5	16
1448	Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. Leukemia and Lymphoma, 2020, 61, 2700-2707.	0.6	21
1449	TET2. Circulation, 2020, 141, 2001-2003.	1.6	8
1450	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes, 2020, 11, 649.	1.0	29
1451	Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms. Rheumatic Disease Clinics of North America, 2020, 46, 429-444.	0.8	12
1452	The role of host environment in cancer evolution. Evolutionary Applications, 2020, 13, 1756-1770.	1.5	15
1453	Intestinal stem cells heterogeneity and clonal dominance during aging: two faces of the same coin?. Mechanisms of Ageing and Development, 2020, 189, 111247.	2.2	2
1454	Clonal haematopoiesis and COVIDâ€19: A possible deadly liaison. International Journal of Immunogenetics, 2020, 47, 329-331.	0.8	5
1455	CML - Not only BCR-ABL1 matters. Best Practice and Research in Clinical Haematology, 2020, 33, 101194.	0.7	6
1456	Donor cell leukemia: reappearance of gene mutations in donor cells - more than an incidental phenomenon?. Haematologica, 2020, 105, 2861-2863.	1.7	6
1457	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. Journal of Hematology and Oncology, 2020, 13, 72.	6.9	123
1458	Germline mutation rates in young adultsÂpredict longevity and reproductive lifespan. Scientific Reports, 2020, 10, 10001.	1.6	16
1459	Inflammation in HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1324-1340.	1.2	273
1460	Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. Frontiers in Oncology, 2020, 10, 230.	1.3	23

#	Article	IF	Citations
1461	Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. Biology of Blood and Marrow Transplantation, 2020, 26, e142-e144.	2.0	7
1462	Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?. Biochemical Pharmacology, 2020, 177, 113895.	2.0	18
1463	Interplay between Clonal Hematopoiesis of Indeterminate Potential and Metabolism. Trends in Endocrinology and Metabolism, 2020, 31, 525-535.	3.1	23
1464	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia, 2020, 34, 3256-3268.	3.3	46
1465	Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 2020, 1, 276-290.	5.7	309
1466	Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation, 2020, 141, 1986-2000.	1.6	75
1467	DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nature Genetics, 2020, 52, 378-387.	9.4	154
1468	The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science, 2020, 367, 1449-1454.	6.0	294
1469	Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035519.	2.9	29
1470	MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus. Blood, 2020, 136, 2764-2773.	0.6	15
1471	Gene mutation profile in patients with acquired pure red cell aplasia. Annals of Hematology, 2020, 99, 1749-1754.	0.8	9
1472	Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status. Blood Advances, 2020, 4, 845-854.	2.5	11
1473	Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis. Haematologica, 2020, 105, e328-e332.	1.7	19
1474	Immunotherapy in Myeloproliferative Diseases. Cells, 2020, 9, 1559.	1.8	17
1475	Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease. Cells, 2020, 9, 1558.	1.8	75
1476	Field Study of the Possible Effect of Parental Irradiation on the Germline of Children Born to Cleanup Workers and Evacuees of the Chornobyl Nuclear Accident. American Journal of Epidemiology, 2020, 189, 1451-1460.	1.6	12
1477	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	12.5	218
1478	The three dimensions of somatic evolution: Integrating the role of genetic damage, lifeâ€history traits, and aging in carcinogenesis. Evolutionary Applications, 2020, 13, 1569-1580.	1.5	5

#	Article	IF	Citations
1479	The Boneâ€™s Role in Myeloid Neoplasia. International Journal of Molecular Sciences, 2020, 21, 4712.	1.8	2
1480	Association of Clonal Hematopoiesis of Indeterminate Potential With Inflammatory Gene Expression in Patients With Severe Degenerative Aortic Valve Stenosis or Chronic Postischemic Heart Failure. JAMA Cardiology, 2020, 5, 1170.	3.0	88
1481	Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer. JAMA Oncology, 2020, 6, 1332.	3.4	2
1482	Pathogenic Mechanisms of Somatic Mutation and Genome Mosaicism in Aging. Cell, 2020, 182, 12-23.	13.5	128
1483	Cellular Therapy in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 701-714.	0.9	1
1484	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Genes, 2020, 11, 749.	1.0	30
1485	Common genetic predisposition for heart failure and cancer. Herz, 2020, 45, 632-636.	0.4	16
1486	Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease. Current Oncology Reports, 2020, 22, 87.	1.8	2
1487	Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors. Leukemia, 2020, 34, 2992-3006.	3.3	14
1488	Clonal hematopoiesis in myeloma: root of all maladies!. Blood, 2020, 135, 2330-2331.	0.6	2
1490	Kinetics of <scp>preâ€myelodysplastic</scp> syndromes blood values correlate with disease risk and survival. Hematological Oncology, 2020, 38, 782-791.	0.8	1
1491	Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. Experimental Hematology, 2020, 83, 85-94.	0.2	77
1492	Clonal hematopoiesis in hematological disorders: Three different scenarios. Experimental Hematology, 2020, 83, 57-65.	0.2	7
1493	A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. Journal of Molecular Medicine, 2020, 98, 1069-1091.	1.7	44
1494	Hematopoietic stem cell regulation by the proteostasis network. Current Opinion in Hematology, 2020, 27, 254-263.	1.2	14
1495	Ten-eleven translocation methyl-cytosine dioxygenase 2 deficiency exacerbates renal ischemia-reperfusion injury. Clinical Epigenetics, 2020, 12, 98.	1.8	8
1496	Clonal hematopoiesis in cancer. Experimental Hematology, 2020, 83, 105-112.	0.2	24
1497	Clonal hematopoiesis driven by somatic mutations: A new player in atherosclerotic cardiovascular disease. Atherosclerosis, 2020, 297, 120-126.	0.4	12

#	Article	IF	Citations
1498	Clonal Hematopoiesis: AÂNewÂStepÂLinking Inflammation toÂHeartÂFailure. JACC Basic To Translational Science, 2020, 5, 196-207.	1.9	33
1499	Driver mutations in acute myeloid leukemia. Current Opinion in Hematology, 2020, 27, 49-57.	1.2	44
1500	A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. Journal of Biomedical Informatics, 2020, 104, 103398.	2.5	5
1501	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.	12.8	270
1502	The Role of ASXL1/2 and Their Associated Proteins in Malignant Hematopoiesis. Current Stem Cell Reports, 2020, 6, 6-15.	0.7	5
1503	Targeting Age-Related Pathways in Heart Failure. Circulation Research, 2020, 126, 533-551.	2.0	111
1504	Genetic basis for iMCD-TAFRO. Oncogene, 2020, 39, 3218-3225.	2.6	14
1505	Somatic mutations and T-cell clonality in patients with immunodeficiency. Haematologica, 2020, 105, 2757-2768.	1.7	18
1506	Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome. JCO Precision Oncology, 2020, 4, 91-95.	1.5	3
1507	Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms. Advances in Cell and Gene Therapy, 2020, 3, e78.	0.6	1
1508	Evolving therapies for lower-risk myelodysplastic syndromes. Annals of Hematology, 2020, 99, 677-692.	0.8	16
1509	The Clinical Management of Clonal Hematopoiesis. Hematology/Oncology Clinics of North America, 2020, 34, 357-367.	0.9	42
1510	Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoeâ^'/â^' Mice. Cardiovascular Drugs and Therapy, 2020, 34, 145-152.	1.3	32
1511	Secondary Acute Myeloid Leukemia. Hematology/Oncology Clinics of North America, 2020, 34, 449-463.	0.9	17
1512	CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance. British Journal of Haematology, 2020, 190, 495-507.	1.2	31
1513	Quantifying Hematopoietic Stem Cell Clonal Diversity by Selecting Informative Amplicon Barcodes. Scientific Reports, 2020, 10, 2153.	1.6	4
1514	The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia. British Journal of Haematology, 2020, 189, e81-e86.	1.2	5
1515	The Contextualized Genetics of HumanÂLongevity. Journal of the American College of Cardiology, 2020, 75, 968-979.	1.2	25

#	Article	IF	Citations
1516	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer Journal, 2020, 10, 7.	2.8	14
1517	Heme oxygenaseâ€1 deficiency triggers exhaustion of hematopoietic stem cells. EMBO Reports, 2020, 21, e47895.	2.0	19
1518	Cancer as a disease of old age: changing mutational and microenvironmental landscapes. British Journal of Cancer, 2020, 122, 943-952.	2.9	153
1519	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine, 2020, 12, .	5.8	41
1520	Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation. Current Oncology Reports, 2020, 22, 4.	1.8	9
1521	The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nature Communications, 2020, 11, 435.	5.8	47
1522	Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. International Journal of Molecular Sciences, 2020, 21, 626.	1.8	42
1523	Genetic cancer predisposition syndromes among older adults. Journal of Geriatric Oncology, 2020, 11, 1054-1060.	0.5	4
1524	ASXL1 mutation in clonal hematopoiesis. Experimental Hematology, 2020, 83, 74-84.	0.2	30
1525	Stem Cell DNA Damage and Genome Mutation in the Context of Aging and Cancer Initiation. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036210.	2.3	25
1526	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	5.8	158
1527	Red Cell Distribution Width Is a Risk Factor for Hip Fracture in Elderly Men Without Anemia. Journal of Bone and Mineral Research, 2020, 35, 869-874.	3.1	19
1528	60 Years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations. Experimental Hematology, 2020, 83, 2-11.	0.2	24
1529	Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science, 2020, 367, 586-590.	6.0	145
1530	A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations. Scientific Reports, 2020, 10, 826.	1.6	11
1531	Mutational Mosaics of Cell-Free DNA from Pancreatic Cyst Fluids. Digestive Diseases and Sciences, 2020, 65, 2294-2301.	1.1	6
1532	Clones assemble! The clonal complexity of blood during ontogeny and disease. Experimental Hematology, 2020, 83, 35-47.	0.2	10
1533	Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. European Heart Journal, 2020, 41, 2974-2982.	1.0	185

#	Article	IF	Citations
1534	Distinctive and common features of moderate aplastic anaemia. British Journal of Haematology, 2020, 189, 967-975.	1.2	10
1535	Understanding intrinsic hematopoietic stem cell aging. Haematologica, 2020, 105, 22-37.	1.7	101
1536	Hematopathology. , 2020, , 1729-2141.		0
1537	An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-Associated Chronic Inflammation and Insulin Resistance. Cell Metabolism, 2020, 31, 580-591.e5.	7.2	213
1538	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genetics in Medicine, 2020, 22, 1366-1373.	1.1	40
1539	Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Advances, 2020, 4, 1700-1710.	2.5	33
1540	The mitochondrial metabolic checkpoint in stem cell aging and rejuvenation. Mechanisms of Ageing and Development, 2020, 188, 111254.	2.2	12
1541	EM-mosaic detects mosaic point mutations that contribute to congenital heart disease. Genome Medicine, 2020, 12, 42.	3.6	17
1542	Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 165-177.	0.4	19
1543	Does clonal hematopoiesis explain unexplained anemia?. Blood, 2020, 135, 1080-1082.	0.6	5
1544	Cancer and myeloid clonal evolution in the short telomere syndromes. Current Opinion in Genetics and Development, 2020, 60, 112-118.	1.5	22
1545	Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma. Haematologica, 2020, 105, e337-e339.	1.7	7
1546	Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1867-1876.	1.2	5
1547	Acquired Aplastic Anemia as a Clonal Disorder of Hematopoietic Stem Cells. Stem Cell Reviews and Reports, 2020, 16, 472-481.	1.7	6
1548	The epigenetically-encoded memory of the innate immune system. Current Opinion in Immunology, 2020, 65, 7-13.	2.4	24
1549	Genetics of age-related clonal hematopoiesis and atherosclerotic cardiovascular disease. Current Opinion in Cardiology, 2020, 35, 219-225.	0.8	7
1550	Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations. Cancers, 2020, 12, 934.	1.7	35
1551	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer Journal, 2020, 10, 42.	2.8	22

#	Article	IF	Citations
1552	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e47-e57.	1.8	30
1553	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1625-1645.	1.2	14
1554	Molecular aberrations in myelodysplastic syndromes. Advances in Cell and Gene Therapy, 2020, 4, e83.	0.6	0
1555	Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation. Blood, 2020, 135, 1185-1188.	0.6	29
1556	The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time. Breast Cancer Management, 2020, 9, .	0.2	12
1557	Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness. Stem Cell Reports, 2020, 14, 551-560.	2.3	53
1558	The mutational landscape of normal human endometrial epithelium. Nature, 2020, 580, 640-646.	13.7	338
1559	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
1560	Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality. Blood, 2020, 135, 261-268.	0.6	47
1561	Concordance for clonal hematopoiesis is limited in elderly twins. Blood, 2020, 135, 269-273.	0.6	38
1562	Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis. Blood, 2020, 135, 845-856.	0.6	27
1563	Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. Blood, 2020, 135, 1161-1170.	0.6	30
1564	Stem cell donors should be screened for CHIP. Blood Advances, 2020, 4, 784-788.	2.5	28
1565	Stem cell donors should not be screened for clonal hematopoiesis. Blood Advances, 2020, 4, 789-792.	2.5	27
1566	Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling. Blood Advances, 2020, 4, 1145-1158.	2.5	39
1567	Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms postâ€“autologous stem cell transplantation. Blood Advances, 2020, 4, 885-892.	2.5	33
1568	Clinical implications of recurrent gene mutations in acute myeloid leukemia. Experimental Hematology and Oncology, 2020, 9, 4.	2.0	47
1569	De Novo Secondary Adenocarcinoma in the Colon Used as Urinary Diversion Not in Contact with the Fecal Stream: Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2020, 27, 2750-2759.	0.7	3

#	Article	IF	Citations
1570	Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes. Cancers, 2020, 12, 903.	1.7	14
1571	Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. Leukemia, 2021, 35, 47-61.	3.3	47
1572	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034975.	2.9	8
1573	Mouse Models of Myeloid Malignancies. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a035535.	2.9	3
1574	The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia. Haematologica, 2021, 106, 1000-1007.	1.7	9
1575	Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. Internal Medicine, 2021, 60, 15-23.	0.3	1
1576	Bone marrow contribution to the heart from development to adulthood. Seminars in Cell and Developmental Biology, 2021, 112, 16-26.	2.3	2
1577	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratificationâ€"an approach to classification of patients with t-MDS. Leukemia, 2021, 35, 835-849.	3.3	54
1578	Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1. Cardiovascular Research, 2021, 117, 162-177.	1.8	28
1579	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta OncolÃ³gica, 2021, 60, 466-474.	0.8	4
1580	Immunometabolic control of hematopoiesis. Molecular Aspects of Medicine, 2021, 77, 100923.	2.7	22
1581	Clonal Hematopoiesisâ€"Driver DNMT3A Mutations Alter Immune Cells in Heart Failure. Circulation Research, 2021, 128, 216-228.	2.0	129
1582	A CHIP in the Armor of Cell-Free DNAâ€"Based Predictive Biomarkers for Prostate Cancer. JAMA Oncology, 2021, 7, 111.	3.4	2
1583	The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Reviews, 2021, 46, 100744.	2.8	16
1584	Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. Circulation, 2021, 143, 410-423.	1.6	87
1585	In Vivo Clonal Analysis of Aged Hematopoietic Stem Cells: Single-Cell Transplantation. Methods in Molecular Biology, 2021, 2185, 181-194.	0.4	0
1586	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. Bone Marrow Transplantation, 2021, 56, 689-691.	1.3	1
1587	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clinical Cancer Research, 2021, 27, 15-23.	3.2	20

#	Article	IF	Citations
1588	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Annals of Surgical Oncology, 2021, 28, 1845-1858.	0.7	5
1589	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 89-95.	1.8	25
1590	The Origin of Ovarian Cancer Species and Precancerous Landscape. American Journal of Pathology, 2021, 191, 26-39.	1.9	102
1591	Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. Blood Reviews, 2021, 47, 100760.	2.8	7
1592	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunctionâ€"a retrospective propensity score analysis. Leukemia, 2021, 35, 1301-1316.	3.3	30
1593	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leukemia and Lymphoma, 2021, 62, 95-103.	0.6	12
1594	Cellular heterogeneity and microenvironmental control of skin cancer. Journal of Internal Medicine, 2021, 289, 614-628.	2.7	8
1595	Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy. British Journal of Haematology, 2021, 192, 137-145.	1.2	6
1596	TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes. Gut, 2021, 70, 1139-1146.	6.1	10
1597	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	0.6	30
1598	Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€â˜†. Annals of Oncology, 2021, 32, 142-156.	0.6	75
1599	Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. European Heart Journal, 2021, 42, 257-265.	1.0	83
1600	Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood, 2021, 137, 1145-1153.	0.6	52
1601	Cause and effect in epigenetics â€“ where lies the truth, and how can experiments reveal it?. BioEssays, 2021, 43, e2000262.	1.2	3
1602	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 199-222.	9.6	16
1603	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 2021, 53, 487-492.	0.3	0
1604	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood, 2021, 137, 2103-2113.	0.6	57
1605	Tumorâ€only sequencing for oncology management: Germlineâ€focused analysis and implications. Genes Chromosomes and Cancer, 2021, 60, 352-357.	1.5	4

#	Article	IF	Citations
1606	Principles of the Molecular and Cellular Mechanisms of Aging. Journal of Investigative Dermatology, 2021, 141, 951-960.	0.3	36
1607	Preleukemic and leukemic evolution at the stem cell level. Blood, 2021, 137, 1013-1018.	0.6	9
1608	The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin. Annals of Oncology, 2021, 32, 412-421.	0.6	29
1609	Clonal tracking of haematopoietic cells: insights and clinical implications. British Journal of Haematology, 2021, 192, 819-831.	1.2	10
1610	TET2: A cornerstone in normal and malignant hematopoiesis. Cancer Science, 2021, 112, 31-40.	1.7	25
1611	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. Ca-A Cancer Journal for Clinicians, 2021, 71, 176-190.	157.7	101
1612	Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response. Experimental Hematology, 2021, 94, 26-30.	0.2	6
1613	Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nature Reviews Rheumatology, 2021, 17, 17-33.	3.5	118
1614	Human hematopoiesis: aging and leukemogenic risk. Current Opinion in Hematology, 2021, 28, 57-63.	1.2	10
1615	Protein phosphatase, Mg 2+ /Mn 2+ â€dependent 1D (PPM1D) mutations in haematological cancer. British Journal of Haematology, 2021, 192, 697-705.	1.2	7
1616	A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression. British Journal of Haematology, 2021, 192, e77-e81.	1.2	1
1617	Genetic complexity of chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2021, 62, 1031-1045.	0.6	4
1618	Clonal haematopoiesis and cardiovascular disease: how low can you go?. European Heart Journal, 2021, 42, 266-268.	1.0	7
1619	Comment on â€œNext-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosisâ€. Journal of Hepatology, 2021, 74, 249-250.	1.8	0
1620	Dynamic analysis of circulating tumor <scp>DNA</scp> to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. International Journal of Cancer, 2021, 148, 921-931.	2.3	13
1621	Alterations to DNMT3A in Hematologic Malignancies. Cancer Research, 2021, 81, 254-263.	0.4	20
1622	Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nature Reviews Genetics, 2021, 22, 3-18.	7.7	228
1623	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia, 2021, 35, 1291-1300.	3.3	5

#	Article	IF	Citations
1624	Unique roles of rare variants in the genetics of complex diseases in humans. Journal of Human Genetics, 2021, 66, 11-23.	1.1	74
1625	Second primary malignancies in multiple myeloma: A review. Blood Reviews, 2021, 46, 100757.	2.8	30
1626	Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy. Journal of Geriatric Oncology, 2021, 12, 479-482.	0.5	2
1627	Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nature Reviews Cardiology, 2021, 18, 58-68.	6.1	187
1628	Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics, 2021, 16, 567-576.	1.3	9
1629	Pathogenic postzygotic mosaicism in the tyrosine receptor kinase pathway: potential unidentified human disease hidden away in a few cells. FEBS Journal, 2021, 288, 3108-3119.	2.2	7
1630	CHIPping away at Erdheim-Chester disease. Blood, 2021, 137, 434-436.	0.6	4
1631	Clonal hematopoiesis in adult pure red cell aplasia. Scientific Reports, 2021, 11, 2253.	1.6	12
1632	Diagnosis and Classification of AML: WHO 2016. Hematologic Malignancies, 2021, , 23-54.	0.2	1
1633	Clonal Cytopenia of Undetermined Significance in a Patient with Congenital Wilms' Tumor 1 and Acquired DNMT3A Gene Mutations. Internal Medicine, 2021, 60, 3785-3788.	0.3	0
1634	Stem cell epigenetics in medical therapy. , 2021, , 873-884.		0
1635	Genome editing in cardiovascular diseases. Progress in Molecular Biology and Translational Science, 2021, 181, 289-308.	0.9	53
1636	Lessons Learned from the Jackson Heart Study. Contemporary Cardiology, 2021, , 105-122.	0.0	0
1637	Stem Cell Biology in Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 29-42.	0.0	0
1638	Hereditary cancer syndrome-associated pathogenic variants are common in patients with hematologic malignancies subsequent to primary solid cancer. Journal of Cancer, 2021, 12, 4288-4294.	1.2	0
1639	The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome. Hematology, Transfusion and Cell Therapy, 2022, 44, 332-335.	0.1	6
1640	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics, 2021, 11, 292-303.	4.6	26
1641	Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category. Journal of Clinical and Experimental Hematopathology: JCEH, 2021, 61, 61-70.	0.3	3

#	Article	IF	Citations
1642	Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells, 2021, 10, 117.	1.8	75
1643	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	5.8	64
1644	Detectable chromosome X mosaicism in males is rarely tolerated in peripheral leukocytes. Scientific Reports, 2021, 11, 1193.	1.6	13
1645	Epigenetic modifiers in normal and aberrent erythropoeisis. Seminars in Hematology, 2021, 58, 15-26.	1.8	1
1646	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precision Oncology, 2021, 5, 265-274.	1.5	13
1647	Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy. International Journal of Hematology, 2021, 113, 936-940.	0.7	1
1648	Myelodysplastic syndromes with ring sideroblasts (<scp>MDSâ€RS</scp>) and <scp>MDS</scp>/myeloproliferative neoplasm with <scp>RS</scp> and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) â€“ â€œ<scp>2021</scp> update on diagnosis, riskâ€stratification, and managementâ€. American Journal of Hematology, 2021, 96, 379-394.	2.0	29
1649	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. JAMA Oncology, 2021, 7, 107.	3.4	90
1650	Acute Myeloid Leukemia. , 2021, , 275-304.		0
1651	Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?. Cancers, 2021, 13, 132.	1.7	20
1653	Tumors: Lymphomas. , 2021, , 1-10.		0
1654	Changes in full blood count parameters with age and sex: results of a survey of almost 900Â000 patient samples from primary care. British Journal of Haematology, 2021, 192, e102-e105.	1.2	8
1655	Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokineâ€“induced lncRNA Morrbid. Journal of Clinical Investigation, 2021, 131, .	3.9	18
1656	Lessons from mouse models of MPN. International Review of Cell and Molecular Biology, 2022, 366, 125-185.	1.6	2
1657	Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera. Scientific Reports, 2021, 11, 209.	1.6	2
1658	TP53 mutated myeloid malignancies and their treatment strategy. Journal of Hematopoietic Cell Transplantation, 2021, 10, 7-15.	0.1	0
1659	Acute Myeloid Leukemia. , 2021, , 110-141.		0
1660	Future Developments: Measurable Residual Disease. Hematologic Malignancies, 2021, , 317-337.	0.2	0

#	Article	IF	Citations
1661	Evolutionary perspectives on cancer and aging. , 2021, , 97-115.		0
1662	Haematopoietic ageing through the lens of single-cell technologies. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	6
1663	A New Perspective on the Origin of DNA Double-Strand Breaks and Its Implications for Ageing. Genes, 2021, 12, 163.	1.0	5
1664	TET-Mediated Epigenetic Regulation in Immune Cell Development and Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 623948.	1.8	27
1665	Poor mobilization of autologous CD34⁺ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. British Journal of Haematology, 2021, 193, 841-844.	1.2	6
1667	Cytokine Storm as a Cellular Response to dsDNA Breaks: A New Proposal. Frontiers in Immunology, 2021, 12, 622738.	2.2	8
1668	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. American Journal of Surgical Pathology, 2021, 45, 905-916.	2.1	24
1669	Comprehensive genomic analysis identifying heterogeneity in peripheral Tâ€cell lymphoma. Cancer Science, 2021, 112, 1339-1347.	1.7	4
1670	Clonal expansion in non-cancer tissues. Nature Reviews Cancer, 2021, 21, 239-256.	12.8	133
1671	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1â€mutated acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1054-1063.	1.2	28
1672	Clonal Hematopoiesis and Premature Menopause. Circulation, 2021, 143, 424-426.	1.6	1
1673	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	2.0	12
1674	Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 373-385.	0.8	11
1675	Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica, 2022, 107, 489-499.	1.7	20
1676	Nonâ€genetic heterogeneity, altered cell fate and differentiation therapy. EMBO Molecular Medicine, 2021, 13, e12670.	3.3	22
1677	Applications of next-generation sequencing in hematologic malignancies. Human Immunology, 2021, 82, 859-870.	1.2	8
1678	Circulating tumour DNA in Bâ€cell lymphomas: current state and future prospects. British Journal of Haematology, 2021, 193, 867-881.	1.2	11
1680	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. Biology, 2021, 10, 128.	1.3	5

#	Article	IF	Citations
1681	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. JCO Precision Oncology, 2021, 5, 378-388.	1.5	26
1682	Crucial role of hematopoietic <i>JAK2</i> V617F in the development of aortic aneurysms. Haematologica, 2021, 106, 1910-1922.	1.7	16
1683	Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?. International Journal of Molecular Sciences, 2021, 22, 2449.	1.8	30
1684	Mitochondrial DNA Content Is Linked to Cardiovascular Disease Patient Phenotypes. Journal of the American Heart Association, 2021, 10, e018776.	1.6	11
1685	High prevalence of clonal hematopoiesisâ€type genomic abnormalities in cellâ€free <scp>DNA</scp> in invasive gliomas after treatment. International Journal of Cancer, 2021, 148, 2839-2847.	2.3	19
1686	The vasculature: a therapeutic target in heart failure?. Cardiovascular Research, 2022, 118, 53-64.	1.8	26
1688	Insights into clonal hematopoiesis and its relation to cancer risk. Current Opinion in Genetics and Development, 2021, 66, 63-69.	1.5	20
1689	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nature Communications, 2021, 12, 1334.	5.8	103
1690	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
1691	The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?. HemaSphere, 2021, 5, e537.	1.2	0
1693	Molecular Medicine: Found in Translation. Med, 2021, 2, 122-136.	2.2	13
1694	Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2021, 384, 776-779.	13.9	12
1695	PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse. Leukemia, 2021, 35, 2693-2697.	3.3	2
1696	Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. Molecular Oncology, 2021, 15, 2253-2272.	2.1	10
1697	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. Cancers, 2021, 13, 748.	1.7	8
1698	Hallmarks of the aging Tâ€cell system. FEBS Journal, 2021, 288, 7123-7142.	2.2	70
1699	A Translational Research in Angioimmunoblastic T-cell Lymphoma. Journal of the Society of Japanese Women Scientists, 2021, 21, 1-12.	0.0	1
1700	When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. Journal of Clinical Medicine, 2021, 10, 1026.	1.0	6

#	Article	IF	Citations
1701	TETology: Epigenetic Mastermind in Action. Applied Biochemistry and Biotechnology, 2021, 193, 1701-1726.	1.4	22
1702	Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell, 2021, 184, 1348-1361.e22.	13.5	149
1703	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell, 2021, 28, 514-523.e9.	5.2	130
1705	Novel therapeutic targets for chronic myelomonocytic leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101244.	0.7	2
1706	Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 654817.	1.3	11
1707	Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nature Communications, 2021, 12, 1366.	5.8	69
1708	Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. Experimental Hematology, 2021, 95, 31-45.	0.2	15
1709	Full spectrum of clonal haematopoiesisâ€driver mutations in chronic heart failure and their associations with mortality. ESC Heart Failure, 2021, 8, 1873-1884.	1.4	26
1710	Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. Blood, 2021, 138, 662-673.	0.6	30
1711	Pre-Leukemic States: United by Difference. Cancers, 2021, 13, 1382.	1.7	0
1712	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	2.5	35
1713	Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature Communications, 2021, 12, 1826.	5.8	54
1714	Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	6
1715	Treatment options for older unfit patients with acute myeloid leukemia. Future Oncology, 2021, 17, 837-851.	1.1	0
1716	Somatic Genetic Mosaicism in the Apolipoprotein E-null Mouse Aorta. Thrombosis and Haemostasis, 2021, 121, 1541-1553.	1.8	0
1717	Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. International Journal of Molecular Sciences, 2021, 22, 2525.	1.8	2
1718	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	2.8	6
1719	Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome. Best Practice and Research in Clinical Haematology, 2021, 34, 101252.	0.7	2

#	Article	IF	Citations
1720	Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia. Cancers, 2021, 13, 1232.	1.7	9
1721	Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years. Leukemia and Lymphoma, 2021, 62, 1958-1966.	0.6	2
1722	Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discovery, 2021, 2, 226-237.	2.6	22
1723	When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncology and Therapy, 2021, 9, 89-110.	1.0	36
1724	The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy. Frontiers in Cell and Developmental Biology, 2021, 9, 635189.	1.8	13
1725	Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood, 2021, 137, 1628-1640.	0.6	25
1726	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia, 2021, 35, 1365-1379.	3.3	41
1727	The association between family history and genomic burden with schizophrenia mortality: a Swedish population-based register and genetic sample study. Translational Psychiatry, 2021, 11, 163.	2.4	0
1729	Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations. Expert Review of Molecular Diagnostics, 2021, 21, 299-310.	1.5	23
1730	Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia. , 0, , .		0
1731	The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. Annals of Hematology, 2021, , 1.	0.8	0
1732	Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. Cell Stem Cell, 2021, 28, 502-513.e6.	5.2	36
1733	Global DNA hypermethylation in peripheral blood mononuclear cells and cardiovascular disease risk: a population-based propensity score-matched cohort study. Journal of Epidemiology and Community Health, 2021, 75, 890-895.	2.0	6
1734	Healthy Lifestyle and Clonal Hematopoiesis of Indeterminate Potential: Results From the Women's Health Initiative. Journal of the American Heart Association, 2021, 10, e018789.	1.6	43
1735	Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular Disease. JACC: CardioOncology, 2021, 3, 134-136.	1.7	10
1736	Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease. Cancers, 2021, 13, 1968.	1.7	9
1737	Dnmt3a deficiency in the skin causes focal, canonical DNA hypomethylation and a cellular proliferation phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2022760118.	3.3	6
1738	Precision medicine in myeloid malignancies. Seminars in Cancer Biology, 2022, 84, 153-169.	4.3	18

#	Article	IF	Citations
1739	A feedback loop: Interactions between Inflammatory Signals and Clonal Hematopoiesis in Cardiovascular Disease. Molecular Biology Reports, 2021, 48, 3785-3798.	1.0	5
1740	Whatâ€™s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood, 2021, 138, 749-757.	0.6	23
1741	Murine Modeling of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 253-265.	0.9	0
1742	Clonal haematopoiesis and cardiovascular diseases: A growing relationship. Archives of Cardiovascular Diseases, 2021, 114, 316-324.	0.7	1
1743	Metabolic Regulation of Stem Cells in Aging. Current Stem Cell Reports, 2021, 7, 72-84.	0.7	3
1744	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. Biomedicines, 2021, 9, 388.	1.4	6
1745	Clonal Hematopoiesis and Risk of Progression of HeartÂFailure With Reduced Left Ventricular EjectionÂFraction. Journal of the American College of Cardiology, 2021, 77, 1747-1759.	1.2	111
1746	Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. JAMA Cardiology, 2021, 6, 379.	3.0	37
1747	Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged â‰¥80 years. Blood Advances, 2021, 5, 2115-2122.	2.5	44
1748	Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing. Leukemia and Lymphoma, 2021, 62, 1-12.	0.6	1
1749	Authorsâ€™ Reply to Moura et al.: â€œSafety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Riskâ€• Drugs and Aging, 2021, 38, 539-541.	1.3	0
1750	Stem cell concepts in myelodysplastic syndromes: lessons and challenges. Journal of Internal Medicine, 2021, 289, 650-661.	2.7	2
1751	Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a caseâ€“control and exploratory study. Rheumatology, 2022, 61, 775-780.	0.9	11
1752	Clonal haematopoiesis and atherosclerosis: a chicken or egg question?. Nature Reviews Cardiology, 2021, 18, 463-464.	6.1	15
1753	CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Blood, 2021, 137, 2209-2220.	0.6	18
1754	The changing landscape of atherosclerosis. Nature, 2021, 592, 524-533.	13.7	921
1755	Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients. Scientific Reports, 2021, 11, 8893.	1.6	4
1757	Importance of clonal hematopoiesis in heart failure. Trends in Cardiovascular Medicine, 2022, 32, 198-203.	2.3	7

#	Article	IF	Citations
1758	Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma. Blood Cancer Discovery, 2021, 2, 216-225.	2.6	22
1759	Disease modifying agents of myeloproliferative neoplasms: a review. Blood Research, 2021, 56, S26-S33.	0.5	8
1760	Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. Cancers, 2021, 13, 1746.	1.7	7
1762	Myeloid somatic mutation panel testing in myeloproliferative neoplasms. Pathology, 2021, 53, 339-348.	0.3	13
1763	Red cell distribution width is associated with mortality in nonâ€anemic patients with COVIDâ€19. Journal of Medical Virology, 2021, 93, 4130-4132.	2.5	9
1764	Yin and Yang: The dual effects of interferons on hematopoiesis. Experimental Hematology, 2021, 96, 1-12.	0.2	38
1765	The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood, 2021, 137, 2152-2160.	0.6	51
1766	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 2021, 135, 991-1007.	1.8	18
1767	Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 237-251.	0.9	4
1768	Induced pluripotent stem cell models of myeloid malignancies and clonal evolution. Stem Cell Research, 2021, 52, 102195.	0.3	4
1769	Epigenome Chaos: Stochastic and Deterministic DNA Methylation Events Drive Cancer Evolution. Cancers, 2021, 13, 1800.	1.7	13
1770	Clonal haematopoiesis of emerging significance. Pathology, 2021, 53, 300-311.	0.3	9
1771	How I Treat Adult Acute Myeloid Leukemia. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 182-189.	0.1	1
1772	Genetics of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 217-236.	0.9	13
1773	Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 305-324.	0.9	7
1774	Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining. Nature Communications, 2021, 12, 2455.	5.8	23
1775	An Evolutionary Approach to Clonally Complex Hematologic Disorders. Blood Cancer Discovery, 2021, 2, 201-215.	2.6	6
1776	Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms. Cancers, 2021, 13, 2120.	1.7	10

#	Article	IF	Citations
1777	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell, 2021, 39, 529-547.e7.	7.7	17
1778	Mutations in chronic myelomonocytic leukemia and their prognostic relevance. Clinical and Translational Oncology, 2021, 23, 1731-1742.	1.2	7
1779	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	2.5	19
1780	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Advances, 2021, 5, 2294-2304.	2.5	60
1781	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nature Communications, 2021, 12, 2833.	5.8	39
1782	Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. International Journal of Molecular Sciences, 2021, 22, 5042.	1.8	14
1783	Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World Journal of Gastrointestinal Oncology, 2021, 13, 332-350.	0.8	29
1784	Inflammation-Induced Tumorigenesis and Metastasis. International Journal of Molecular Sciences, 2021, 22, 5421.	1.8	88
1785	Aged hematopoietic stem cells are refractory to bloodborne systemic rejuvenation interventions. Journal of Experimental Medicine, 2021, 218, .	4.2	48
1786	Acute myeloid leukaemia in patients we judge as being older and/or unfit. Journal of Internal Medicine, 2021, 290, 279-293.	2.7	7
1787	Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. Hemato, 2021, 2, 305-328.	0.2	3
1788	FLT3â€‐TD mutations in acute myeloid leukaemia â€“ molecular characteristics, distribution and numerical variation. Molecular Oncology, 2021, 15, 2300-2317.	2.1	5
1791	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. International Journal of Molecular Sciences, 2021, 22, 5522.	1.8	12
1793	Somatic Mutations in â€œBenignâ€•Disease. New England Journal of Medicine, 2021, 384, 2039-2052.	13.9	111
1794	Genetic and Clinical Studies of Patients With Increased Multinucleated Megakaryocytes in Bone Marrow as an Isolated Finding. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1534-1540.	2.1	1
1795	The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. European Journal of Heart Failure, 2021, 23, 1712-1721.	2.9	19
1796	Whole-genome sequencing analysis of semi-supercentenarians. ELife, 2021, 10, .	2.8	37
1797	EnvIRONmental Aspects in Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2021, 22, 5202.	1.8	0

#	Article	IF	Citations
1798	Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. Journal of Physical Education and Sports Management, 2021, 7, a006090.	0.5	4
1799	Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell, 2021, 20, e13366.	3.0	72
1800	Editorial commentary: A heartbreaking relationship: Clonal hematopoiesis and heart failure. Trends in Cardiovascular Medicine, 2022, 32, 204-205.	2.3	0
1801	Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. Cancer Medicine, 2021, 10, 3165-3176.	1.3	8
1802	Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Scientific Reports, 2021, 11, 10761.	1.6	24
1803	Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis. Journal of Visualized Experiments, 2021, , .	0.2	10
1804	Interplay between inflammation and thrombosis in cardiovascular pathology. Nature Reviews Cardiology, 2021, 18, 666-682.	6.1	337
1805	DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. Journal of Experimental Medicine, 2021, 218, .	4.2	16
1806	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood, 2021, 137, 2992-2997.	0.6	19
1807	Splicing regulation in hematopoiesis. Current Opinion in Hematology, 2021, 28, 277-283.	1.2	2
1808	Indolent feature ofÂHelicobacter pylori-uninfected intramucosal signet ring cell carcinomas withÂCDH1Âmutations. Gastric Cancer, 2021, 24, 1102-1114.	2.7	13
1809	Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors. Leukemia, 2021, 35, 2199-2204.	3.3	11
1810	Germline risk of clonal haematopoiesis. Nature Reviews Genetics, 2021, 22, 603-617.	7.7	48
1811	Epigenetic Regulation of Genomic Stability by Vitamin C. Frontiers in Genetics, 2021, 12, 675780.	1.1	45
1812	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nature Cancer, 2021, 2, 527-544.	5.7	37
1813	Loss of a 7q gene,CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood, 2021, 138, 790-805.	0.6	13
1814	Liquid biopsy in lymphoma: Is it primed for clinical translation?. EJHaem, 2021, 2, 616-627.	0.4	6
1815	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. American Journal of Clinical Pathology, 2021, 156, 679-690.	0.4	10

#	Article	IF	Citations
1816	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia, 2021, 35, 3406-3420.	3.3	3
1817	Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. Journal of Experimental Medicine, 2021, 218, .	4.2	88
1818	Marrow failure and aging: The role of â€œInflammagingâ€• Best Practice and Research in Clinical Haematology, 2021, 34, 101283.	0.7	4
1819	Clonal hematopoiesis in patients with <scp>Covidâ€19</scp> is stable and not linked to an aggravated clinical course. American Journal of Hematology, 2021, 96, E331-E333.	2.0	14
1820	Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer, 2021, 20, 82.	7.9	58
1821	Immature acute leukaemias: lessons from the haematopoietic roadmap. FEBS Journal, 2022, 289, 4355-4370.	2.2	2
1822	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circulation Research, 2021, 128, 1973-1987.	2.0	10
1823	Mutations known from B-cell lymphoid malignancies are not found in CD34⁺ stem cells from patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2808-2811.	0.6	1
1824	Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. Journal of Experimental Medicine, 2021, 218, .	4.2	113
1825	CAR-HEMATOTOX: a model for CAR T-cellâ€“related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	0.6	160
1826	Epigenetic deregulation in myeloid malignancies. Blood, 2021, 138, 613-624.	0.6	8
1827	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2237-2251.	1.1	16
1828	Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Hamostaseologie, 2021, 41, 197-205.	0.9	2
1829	Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS ONE, 2021, 16, e0253386.	1.1	5
1830	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia, 2022, 36, 257-262.	3.3	19
1831	Genetic Determinants of Peripheral Artery Disease. Circulation Research, 2021, 128, 1805-1817.	2.0	9
1832	A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms. Cancer Discovery, 2021, 11, 3126-3141.	7.7	17
1833	Reference intervals of red blood cell parameters and platelet count for healthy adults in Japan. International Journal of Hematology, 2021, 114, 373-380.	0.7	4

#	Article	IF	Citations
1834	A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e328-e338.	1.8	2
1835	CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood, 2021, 138, 1727-1732.	0.6	58
1836	Next-Generation Sequencing of Cell-Free DNA Extracted From Pleural Effusion Supernatant: Applications and Challenges. Frontiers in Medicine, 2021, 8, 662312.	1.2	3
1837	Cohesin mutations in myeloid malignancies. Blood, 2021, 138, 649-661.	0.6	22
1838	Clinical implementation and current advancement of blood liquid biopsy in cancer. Journal of Human Genetics, 2021, 66, 909-926.	1.1	16
1839	Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. Best Practice and Research in Clinical Haematology, 2021, 34, 101280.	0.7	11
1840	Somatic mosaicism in inherited bone marrow failure syndromes. Best Practice and Research in Clinical Haematology, 2021, 34, 101279.	0.7	10
1841	Therapeutic implications of menin inhibition in acute leukemias. Leukemia, 2021, 35, 2482-2495.	3.3	76
1842	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nature Medicine, 2021, 27, 1012-1024.	15.2	109
1843	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood, 2021, 138, 1733-1739.	0.6	19
1844	Systematic analysis of exonic germline and postzygotic de novo mutations in bipolar disorder. Nature Communications, 2021, 12, 3750.	5.8	15
1845	Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia. Blood, 2021, 138, 1249-1257.	0.6	15
1847	Sibling donor-derived myeloid sarcoma after hematopoietic stem cell transplant. Human Pathology: Case Reports, 2021, 24, 200512.	0.2	2
1848	HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nature Medicine, 2021, 27, 1006-1011.	15.2	62
1849	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia, 2022, 36, 126-137.	3.3	10
1850	Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105.	0.6	37
1851	Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. Cancers, 2021, 13, 3296.	1.7	4
1852	Anemia in older adults as a geriatric syndrome: A review. Geriatrics and Gerontology International, 2021, 21, 549-554.	0.7	13

#	Article	IF	Citations
1853	British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. British Journal of Haematology, 2021, 194, 282-293.	1.2	10
1854	Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Advances, 2021, 5, 2539-2549.	2.5	9
1855	Molecular pathogenesis of the myeloproliferative neoplasms. Journal of Hematology and Oncology, 2021, 14, 103.	6.9	49
1856	Assessment of All-Cause Cancer Incidence Among Individuals With Preeclampsia or Eclampsia During First Pregnancy. JAMA Network Open, 2021, 4, e2114486.	2.8	7
1857	Post-myocardial infarction heart failure dysregulates the bone vascular niche. Nature Communications, 2021, 12, 3964.	5.8	23
1858	Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML. Cancers, 2021, 13, 3190.	1.7	5
1859	Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease. Cardiovascular Research, 2022, 118, 1413-1432.	1.8	12
1860	Assessment of the gene mosaicism burden in blood and its implications for immune disorders. Scientific Reports, 2021, 11, 12940.	1.6	5
1861	Splicing factor mutations in hematologic malignancies. Blood, 2021, 138, 599-612.	0.6	40
1862	Role of Tet2 in Regulating Adaptive and Innate Immunity. Frontiers in Cell and Developmental Biology, 2021, 9, 665897.	1.8	8
1863	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. Haematologica, 2022, 107, 887-898.	1.7	15
1864	Roles and Mechanisms of DNA Methylation in Vascular Aging and Related Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 699374.	1.8	17
1865	Prevalence and characteristics of clonal hematopoiesis in heart failure. Revista Espanola De Cardiologia (English Ed), 2021, 74, 996-999.	0.4	5
1866	Beyond morphology: to be or not to be an MDS. British Journal of Haematology, 2021, 194, 238-239.	1.2	1
1867	Multiplex technologies for the assessment of minimal residual disease and lowâ€level mutation detection in leukaemia: mass spectrometry versus nextâ€generation sequencing. British Journal of Haematology, 2022, 196, 19-30.	1.2	2
1868	Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness. Cancers, 2021, 13, 2755.	1.7	11
1869	Clinical and pathologic challenges of clonal cytopenia of undetermined significance. International Journal of Laboratory Hematology, 2021, 43, 82-85.	0.7	1
1870	Prevalencia y caracterÃsticas de la hematopoyesis clonal en insuficiencia cardiaca. Revista Espanola De Cardiologia, 2021, 74, 996-996.	0.6	1

#	Article	IF	Citations
1871	Stem Cells in the Myelodysplastic Syndromes. Frontiers in Aging, 2021, 2, .	1.2	4
1872	Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome. Nature Communications, 2021, 12, 4549.	5.8	21
1873	ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. Blood Cancer Discovery, 2021, 2, 500-517.	2.6	17
1874	Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. Cancers, 2021, 13, 3528.	1.7	5
1875	Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes. International Journal of Hematology, 2021, 114, 441-448.	0.7	5
1876	The Hematopoietic Bone Marrow Niche Ecosystem. Frontiers in Cell and Developmental Biology, 2021, 9, 705410.	1.8	34
1877	Subclinical cardiac damage in cancer patients before chemotherapy. Heart Failure Reviews, 2022, 27, 1091-1104.	1.7	9
1878	The Genetics of Myelodysplastic Syndromes: Clinical Relevance. Genes, 2021, 12, 1144.	1.0	14
1879	Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nature Medicine, 2021, 27, 1239-1249.	15.2	78
1880	Clonal Hematopoiesis and Incident HeartÂFailure Risk. Journal of the American College of Cardiology, 2021, 78, 53-55.	1.2	0
1881	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. Journal of Molecular Pathology, 2021, 2, 241-254.	0.5	6
1882	Assessment of medullary and extramedullary myelopoiesis in cardiovascular diseases. Pharmacological Research, 2021, 169, 105663.	3.1	3
1883	Red Cell Distribution Width: Commonly Performed Test Predicts Mortality in Primary Total Joint Arthroplasty. Journal of Arthroplasty, 2021, 36, 3646-3649.	1.5	1
1884	Inflammation in Myeloid Malignancies: From Bench to Bedside. Journal of Immunotherapy and Precision Oncology, 2021, 4, 160-167.	0.6	5
1885	DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model. Cancers, 2021, 13, 3587.	1.7	7
1886	Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification. Frontiers in Aging, 2021, 2, .	1.2	5
1887	TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight, 2021, 6, .	2.3	37
1888	The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. International Journal of Laboratory Hematology, 2021, 43, 1501-1509.	0.7	5

#	Article	IF	Citations
1889	Somatic mutation accumulation seen through a single-molecule lens. Cell Research, 2021, 31, 949-950.	5.7	0
1890	Pathophysiology of Myelodysplastic Syndromes. Hemato, 2021, 2, 477-495.	0.2	1
1891	Transcription Factors, R-Loops and Deubiquitinating Enzymes: Emerging Targets in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancers, 2021, 13, 3753.	1.7	2
1892	Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology. Seminars in Cancer Biology, 2022, 84, 23-31.	4.3	10
1893	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	2.6	10
1894	Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood, 2021, 138, 965-976.	0.6	58
1895	The role of vitamin C in epigenetic cancer therapy. Free Radical Biology and Medicine, 2021, 170, 179-193.	1.3	23
1898	Meta-Analysis of Circulating Cell-Free DNAâ€™s Role in the Prognosis of Pancreatic Cancer. Cancers, 2021, 13, 3378.	1.7	9
1899	Association of Clonal Hematopoiesis With Incident HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 42-52.	1.2	101
1900	Cell competition in hematopoietic cells: Quality control in homeostasis and its role in leukemia. Developmental Biology, 2021, 475, 1-9.	0.9	4
1901	Clonal hematopoiesis and its emerging effects on cellular therapies. Leukemia, 2021, 35, 2752-2758.	3.3	21
1902	Retrospective cell lineage reconstruction in humans by using short tandem repeats. Cell Reports Methods, 2021, 1, 100054.	1.4	9
1903	Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer. Molecular Medicine, 2021, 27, 68.	1.9	12
1904	Decoding and rejuvenating human ageing genomes: Lessons from mosaic chromosomal alterations. Ageing Research Reviews, 2021, 68, 101342.	5.0	21
1905	Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clinical Chemistry, 2021, 67, 1062-1070.	1.5	0
1906	Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. American Journal of Transplantation, 2021, 21, 3894-3906.	2.6	11
1907	Is Hematopoietic Clonality of Indetermined Potential a Risk Factor for Pulmonary Embolism?. TH Open, 2021, 05, e338-e342.	0.7	14
1908	Genetics of Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury, Mass), 2021, 27, 259-265.	1.0	1

#	Article	IF	Citations
1909	Incidental findings from cancer next generation sequencing panels. Npj Genomic Medicine, 2021, 6, 63.	1.7	11
1910	Current and emerging strategies for management of myelodysplastic syndromes. Blood Reviews, 2021, 48, 100791.	2.8	34
1911	Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank. Cell and Bioscience, 2021, 11, 143.	2.1	14
1912	From DNA damage to mutations: All roads lead to aging. Ageing Research Reviews, 2021, 68, 101316.	5.0	55
1913	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	1.5	4
1915	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. Cancer Biology and Therapy, 2021, 22, 455-464.	1.5	6
1916	Rates and Patterns of Clonal Oncogenic Mutations in the Normal Human Brain. Cancer Discovery, 2022, 12, 172-185.	7.7	19
1917	Hematopoiesis during Ontogenesis, Adult Life, and Aging. International Journal of Molecular Sciences, 2021, 22, 9231.	1.8	15
1918	Extracellular vesicles tell all: How vesicle-mediated cellular communication shapes hematopoietic stem cell biology with increasing age. Experimental Hematology, 2021, 101-102, 7-15.	0.2	5
1919	Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes. Cancers, 2021, 13, 4116.	1.7	11
1921	Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. Blood Advances, 2021, 5, 3266-3278.	2.5	6
1922	Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia, 2022, 36, 507-515.	3.3	49
1923	The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. British Journal of Haematology, 2021, 195, 338-351.	1.2	8
1924	Clonal Hematopoiesis: From Mechanisms to Clinical Intervention. Cancer Discovery, 2021, 11, 2987-2997.	7.7	30
1925	Dynamic regulation of mitochondrial-endoplasmic reticulum crosstalk during stem cell homeostasis and aging. Cell Death and Disease, 2021, 12, 794.	2.7	6
1926	Innate and adaptive immunity: the understudied driving force of heart valve disease. Cardiovascular Research, 2021, 117, 2506-2524.	1.8	30
1927	Somatic Mutations and Autoimmunity. Cells, 2021, 10, 2056.	1.8	7
1928	Interacting evolutionary pressures drive mutation dynamics and health outcomes in aging blood. Nature Communications, 2021, 12, 4921.	5.8	11

#	Article	IF	Citations
1929	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. Blood Advances, 2021, 5, 3066-3075.	2.5	12
1930	The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. Cancers, 2021, 13, 3923.	1.7	33
1931	Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse. Transplantation and Cellular Therapy, 2021, 27, 662.e1-662.e9.	0.6	14
1932	Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Advances, 2021, 5, 3203-3215.	2.5	114
1933	Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor. Cancer Discovery, 2022, 12, 220-235.	7.7	38
1934	Cardio-Oncology. JACC Basic To Translational Science, 2021, 6, 705-718.	1.9	21
1935	Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. Leukemia, 2022, 36, 394-402.	3.3	24
1936	Remarkable stability in clonal hematopoiesis involving leukemiaâ€driver genes in patients without underlying myeloid neoplasms. American Journal of Hematology, 2021, 96, E392-E396.	2.0	3
1937	Aging and Cancer: The Waning of Community Bonds. Cells, 2021, 10, 2269.	1.8	7
1938	Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis. Annals of Translational Medicine, 2021, 9, 1264-1264.	0.7	12
1939	TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	29
1941	Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential. Journal of Molecular Biology, 2022, 434, 167183.	2.0	22
1942	The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. Blood Advances, 2021, 5, 3216-3226.	2.5	21
1943	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	2.5	45
1944	How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. Biomedicines, 2021, 9, 953.	1.4	6
1945	Emerging Role of Acquired Mutations and Clonal Hematopoiesis in Atherosclerosisâ€â€â€• Beyond Conventional Cardiovascular Risk Factors â€•. Circulation Journal, 2023, 87, 394-400.	0.7	4
1946	Cell competition between wild-type and JAK2V617F mutant cells in a murine model of a myeloproliferative neoplasm. Experimental Hematology, 2021, 100, 52-62.	0.2	4
1947	Scopus Veri TabanÄ±na DayalÄ± Bibliyometrik DeÄŸerlendirme: Miyelodisplastik Sendrom Konulu YayÄ±nlarÄ±n Global Analizi ve TÃ¼rkiye KaynaklÄ± YayÄ±nlarÄ±n DeÄŸerlendirilmesi. Journal of Biotechnology and Strategic Health Research, 2021, 5, 125-131.	0.8	23

#	Article	IF	Citations
1948	Clonal hematopoiesis and myeloid malignancies. Current Opinion in Hematology, 2021, Publish Ahead of Print, 347-355.	1.2	4
1951	Clonal Hematopoiesis and Cardiovascular Diseases: The Connection. Current Problems in Cardiology, 2021, , 100962.	1.1	5
1952	Clonal Hematopoiesis Is Associated With Low CD4 Nadir and Increased Residual HIV Transcriptional Activity in Virally Suppressed Individuals With HIV. Journal of Infectious Diseases, 2022, 225, 1339-1347.	1.9	17
1953	Putative homeostatic role of cancer driver mutations. Trends in Cell Biology, 2022, 32, 8-17.	3.6	5
1954	Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. New England Journal of Medicine, 2021, 385, 834-843.	13.9	0
1955	Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay. Journal of Molecular Diagnostics, 2021, 23, 1292-1305.	1.2	8
1956	Balancing DNA repair to prevent ageing and cancer. Experimental Cell Research, 2021, 405, 112679.	1.2	14
1957	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	2.0	19
1958	SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 1-16.	0.2	20
1959	Clonal hematopoiesis and associated diseases: A review of recent findings. Cancer Science, 2021, 112, 3962-3971.	1.7	40
1960	Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. HemaSphere, 2021, 5, e632.	1.2	10
1961	Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Cancer Discovery, 2022, 12, 250-269.	7.7	14
1962	Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Clinical Epigenetics, 2021, 13, 169.	1.8	2
1963	Brain Somatic Mutation in Aging and Alzheimer's Disease. Annual Review of Genomics and Human Genetics, 2021, 22, 239-256.	2.5	32
1964	Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNÎ³ signaling. Cell Stem Cell, 2021, 28, 1428-1442.e6.	5.2	164
1965	Aged skeletal stem cells generate an inflammatory degenerative niche. Nature, 2021, 597, 256-262.	13.7	143
1966	Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins. Frontiers in Oncology, 2021, 11, 716830.	1.3	5
1967	Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 3348-3360.	0.6	11

#	Article	IF	Citations
1968	Gata2 haploinsufficiency promotes proliferation and functional decline of hematopoietic stem cells with myeloid bias during aging. Blood Advances, 2021, 5, 4285-4290.	2.5	11
1970	Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease. International Journal of Molecular Sciences, 2021, 22, 9867.	1.8	5
1971	Telomeres and Age-Related Diseases. Biomedicines, 2021, 9, 1335.	1.4	37
1972	Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. Frontiers in Oncology, 2021, 11, 748250.	1.3	7
1973	Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy. Current Opinion in Cardiology, 2021, Publish Ahead of Print, 776-783.	0.8	1
1974	Update on Clonal Hematopoiesis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S32-S33.	0.2	1
1975	Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients. Cell Stem Cell, 2021, 28, 1726-1739.e6.	5.2	28
1976	Megakaryopoiesis and Platelet Biology: Roles of Transcription Factors and Emerging Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 9615.	1.8	14
1977	The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood, 2022, 139, 894-906.	0.6	42
1978	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162.	2.8	32
1979	Molecular Pathology of Myeloid Neoplasms. Surgical Pathology Clinics, 2021, 14, 517-528.	0.7	3
1980	Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?. Leukemia, 2021, 35, 3364-3370.	3.3	4
1981	Clonal Hematopoiesis of Indeterminate Potential: an Expanding Genetic Cause of Cardiovascular Disease. Current Atherosclerosis Reports, 2021, 23, 66.	2.0	7
1982	Increased somatic mutation burdens in normal human cells due to defective DNA polymerases. Nature Genetics, 2021, 53, 1434-1442.	9.4	85
1983	Inflammation during the life cycle of the atherosclerotic plaque. Cardiovascular Research, 2021, 117, 2525-2536.	1.8	69
1984	Struggle within: evolution and ecology of somatic cell populations. Cellular and Molecular Life Sciences, 2021, 78, 6797-6806.	2.4	3
1985	Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis. Journal of Molecular and Cellular Cardiology, 2022, 163, 1-8.	0.9	32
1986	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. ELife, 2021, 10, .	2.8	19

#	Article	IF	Citations
1987	The biology of hematopoietic stem cells and its clinical implications. FEBS Journal, 2022, 289, 7740-7759.	2.2	6
1988	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances, 2021, 5, 4140-4148.	2.5	6
1989	Developmental and temporal characteristics of clonal sperm mosaicism. Cell, 2021, 184, 4772-4783.e15.	13.5	27
1990	Extramedullary Clonal Hematopoiesis with Indeterminate Potential. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e696-e698.	0.2	1
1992	Flow Cytometric Findings in Clonal Cytopenia of Undetermined Significance. American Journal of Clinical Pathology, 2021, , .	0.4	3
1993	Is There a Causal Link Between Periodontitis and Cardiovascular Disease? A Concise Review of Recent Findings. International Dental Journal, 2022, 72, 37-51.	1.0	15
1994	Synthetic biomarkers: a twenty-first century path to early cancer detection. Nature Reviews Cancer, 2021, 21, 655-668.	12.8	84
1995	Utility of plasma cell-free DNA for <i>de novo</i> detection and quantification of clonal hematopoiesis. Haematologica, 2022, 107, 1815-1826.	1.7	3
1996	Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 573-579.	0.2	4
1997	Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia. Cancers, 2021, 13, 4646.	1.7	8
1998	Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis. Acta Pharmaceutica Sinica B, 2022, 12, 678-691.	5.7	23
1999	The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large bâ€cell lymphoma. Clinical Case Reports (discontinued), 2021, 9, e03817.	0.2	2
2000	Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. Frontiers in Oncology, 2021, 11, 751668.	1.3	2
2001	Clonal hematopoiesis in sickle cell disease. Blood, 2021, 138, 2148-2152.	0.6	29
2002	The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice. Circulation Research, 2021, 129, 684-698.	2.0	42
2003	Peripheral Blood Cytopenia and Risk of Cardiovascular Disease and Mortality. Journal of the American Heart Association, 2021, 10, e020809.	1.6	3
2004	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Advances, 2021, 5, 4426-4434.	2.5	30
2005	Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. Leukemia Research, 2021, 108, 106613.	0.4	0

#	Article	IF	Citations
2006	The Myeloid-Kidney Interface in Health and Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 323-331.	2.2	5
2007	Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events. JAMA Cardiology, 2021, 6, 1069.	3.0	43
2008	Mammalian in vitro gametogenesis. Science, 2021, 374, eaaz6830.	6.0	77
2009	Somatic mutations provide important and unique insights into the biology of complex diseases. Trends in Genetics, 2021, 37, 872-881.	2.9	32
2010	Cell competition, cooperation, and cancer. Neoplasia, 2021, 23, 1029-1036.	2.3	6
2011	Late Onset of Chronic Granulomatous Disease Revealed by Paecilomyces lilacinus Cutaneous Infection. Journal of Clinical Immunology, 2022, 42, 60-63.	2.0	4
2012	Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape. Neoplasia, 2021, 23, 1101-1109.	2.3	6
2013	Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. Journal of Molecular and Cellular Cardiology, 2021, 161, 98-105.	0.9	82
2014	A case of hypereosinophilic syndrome with STAT5b N642H mutation. Oxford Medical Case Reports, 2021, 2021, omaa129.	0.2	5
2015	Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients. Annals of Hematology, 2021, 100, 1995-2004.	0.8	9
2016	Genomic Landscape and Clonal Evolution of AML. Hematologic Malignancies, 2021, , 103-118.	0.2	0
2017	Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDSâ€type molecular findings compared to CCUS without dysplasia. European Journal of Haematology, 2021, 106, 500-507.	1.1	8
2018	A Single-Cell Analysis of DNMT3A-Mediated Clonal Hematopoiesis in Heart Failure. Circulation Research, 2021, 128, 229-231.	2.0	4
2019	TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics. Seminars in Hematology, 2021, 58, 27-34.	1.8	9
2020	Oxidative Stress-Mediated Stem Cell Aging. , 2021, , 55-76.		1
2021	Whole Exome for the Identification of Mutations in CD8+ T-Cells. Methods in Molecular Biology, 2021, 2325, 155-182.	0.4	0
2022	Aging of human hematopoietic stem cells is linked to changes in Cdc42 activity. Haematologica, 2022, 107, 393-402.	1.7	23
2023	A field guide for cancer diagnostics using cellâ€free DNA: From principles to practice and clinical applications. Genes Chromosomes and Cancer, 2018, 57, 123-139.	1.5	155

#	Article	IF	Citations
2024	Genomic Instability of iPSCs and Challenges in Their Clinical Applications. Advances in Experimental Medicine and Biology, 2019, 1201, 23-47.	0.8	40
2025	The Impact of Aging on Cancer Progression and Treatment. , 2016, , 53-83.		2
2026	Hematopoietic Stem Cell Aging and Malignant Hemopathies. , 2018, , 1-13.		2
2027	Pediatric Myelodysplastic Syndromes. Pediatric Oncology, 2018, , 57-79.	0.5	1
2028	Genetic Theories of Aging. , 2020, , 1-9.		4
2029	Molecular and Cellular Aspects of Macrophage Aging. , 2019, , 1631-1663.		3
2030	Neoplastische BildungsstÃ¶rungen der HÃmatopoiese mit erhaltener Ausreifung. , 2019, , 47-87.		2
2031	Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia. Advances in Experimental Medicine and Biology, 2019, 1143, 95-128.	0.8	3
2032	Cancer Genomics in Precision Oncology: Applications, Challenges, and Prospects. , 2020, , 453-499.		9
2033	Current concepts and future directions for hemato-oncologic diagnostics. Critical Reviews in Oncology/Hematology, 2020, 151, 102977.	2.0	14
2034	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 2020, 151, 102978.	2.0	79
2035	Sex-Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor-Deficient Mice. JACC Basic To Translational Science, 2020, 5, 582-598.	1.9	36
2036	Mechanistic Biomarkers Informative ofÂBoth Cancer and Cardiovascular Disease. Journal of the American College of Cardiology, 2020, 75, 2726-2737.	1.2	51
2037	Application of Multiplex Bisulfite PCRâ€“Ligase Detection Reactionâ€“Real-Time Quantitative PCR Assay in Interrogating Bioinformatically Identified, Blood-Based Methylation Markers for Colorectal Cancer. Journal of Molecular Diagnostics, 2020, 22, 885-900.	1.2	5
2038	Picking Winners and Losers: Cell Competition in Tissue Development and Homeostasis. Trends in Genetics, 2020, 36, 490-498.	2.9	16
2039	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
2040	Extracellular serine controls epidermal stem cell fate and tumour initiation. Nature Cell Biology, 2020, 22, 779-790.	4.6	83
2041	The origin of leukemia: Genetic alterations and inflammatory factors in the development of premalignant clonal hematopoiesis. Seminars in Hematology, 2020, 57, 7-12.	1.8	4

#	Article	IF	Citations
2042	Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 383, 1358-1374.	13.9	274
2043	Molecular/Cytogenetic Education for Hematopathology Fellows. American Journal of Clinical Pathology, 2020, 154, 149-177.	0.4	6
2044	Common risk factors for heart failure and cancer. Cardiovascular Research, 2019, 115, 844-853.	1.8	175
2045	A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. HemaSphere, 2020, 4, e502.	1.2	10
2046	Clonal hematopoiesis in hematopoietic stem cell transplantation. Current Opinion in Hematology, 2021, 28, 94-100.	1.2	7
2080	Extensive heterogeneity in somatic mutation and selection in the human bladder. Science, 2020, 370, 75-82.	6.0	195
2081	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1361-1370.	3.2	25
2082	Aged marrow macrophages expand platelet-biased hematopoietic stem cells via interleukin-1B. JCI Insight, 2019, 4, .	2.3	82
2083	Aberrant X chromosome skewing and acquired clonal hematopoiesis in adult-onset common variable immunodeficiency. JCI Insight, 2019, 4, .	2.3	1
2084	Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction. JCI Insight, 2020, 5, .	2.3	103
2085	Transcription factor mutations as a cause of familial myeloid neoplasms. Journal of Clinical Investigation, 2019, 129, 476-488.	3.9	47
2086	Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. Journal of Clinical Investigation, 2019, 129, 4316-4331.	3.9	143
2087	Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. Journal of Clinical Investigation, 2015, 125, 4666-4680.	3.9	116
2088	Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. Journal of Clinical Investigation, 2017, 127, 3484-3495.	3.9	41
2089	Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. Journal of Clinical Investigation, 2017, 127, 3657-3674.	3.9	80
2090	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	0.9	34
2091	Mature lymphoid malignancies: origin, stem cells, and chronicity. Blood Advances, 2017, 1, 2444-2455.	2.5	13
2092	Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Advances, 2020, 4, 2261-2271.	2.5	61

#	Article	IF	Citations
2093	Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Advances, 2021, 5, 54-60.	2.5	11
2094	Clonal Hematopoiesis: The Seeds of Leukemia or Innocuous Bystander?. , 2016, 13, .		2
2095	Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematology American Society of Hematology Education Program, 2019, 2019, 97-104.	0.9	25
2096	The lethal sex gap: COVID-19. Immunity and Ageing, 2020, 17, 13.	1.8	68
2097	Recent advances in understanding the mechanisms determining longevity. F1000Research, 2019, 8, 1403.	0.8	7
2098	What do we know about the participation of hematopoietic stem cells in hematopoiesis?. F1000Research, 2015, 4, 1177.	0.8	1
2099	The Tatton-Brown-Rahman Syndrome: A clinical study of 55 individuals with de novo constitutive DNMT3A variants. Wellcome Open Research, 2018, 3, 46.	0.9	75
2100	Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments. PLoS Computational Biology, 2017, 13, e1005803.	1.5	26
2101	Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002206.	3.9	83
2102	Rare Circulating Cells in Familial WaldenstrÃ¶m Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. PLoS ONE, 2015, 10, e0136505.	1.1	6
2103	Role of interleukin 1 in the development of atherosclerosis. Nauchno-Prakticheskaya Revmatologiya, 0, 56, 28-34.	0.2	6
2104	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	8
2105	STAT5 activation in B-cell acute lymphoblastic leukemia: damned if you do, damned if you don't. Cancer Cell & Microenvironment, 2016, 3, .	0.8	4
2106	Constitutional Mosaic Epimutations â€“ a hidden cause of cancer?. Cell Stress, 2019, 3, 118-135.	1.4	22
2108	Reduced production of laminin by hepatic stellate cells contributes to impairment in oval cell response to liver injury in aged mice. Aging, 2018, 10, 3713-3735.	1.4	3
2109	DNA hydroxymethylation combined with carotid plaques as a novel biomarker for coronary atherosclerosis. Aging, 2019, 11, 3170-3181.	1.4	14
2110	Physical activity, a modulator of aging through effects on telomere biology. Aging, 2020, 12, 13803-13823.	1.4	30
2111	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	0.8	22

#	Article	IF	Citations
2112	Stat5 deficiency decreases transcriptional heterogeneity and supports emergence of hematopoietic sub-populations. Oncotarget, 2017, 8, 22477-22482.	0.8	2
2113	Chipping in on clonal hematopoiesis. Oncotarget, 2017, 8, 84637-84638.	0.8	1
2114	Rapid development of myeloproliferative neoplasm in mice with Ptpn11D61Y mutation and haploinsufficient for Dnmt3a. Oncotarget, 2018, 9, 6055-6061.	0.8	4
2115	Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia. Oncotarget, 2018, 9, 36613-36624.	0.8	26
2116	IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	0.8	92
2117	Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget, 2016, 7, 30084-30093.	0.8	42
2118	Altered neutrophil immunophenotypes in childhood B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 24664-24676.	0.8	8
2119	Targeting Immune Signaling Pathways in Clonal Hematopoiesis. Current Medicinal Chemistry, 2019, 26, 5262-5277.	1.2	6
2120	Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia. Current Drug Targets, 2017, 18, 296-303.	1.0	14
2121	Variants ofDNMT3Acause transcript-specific DNA methylation patterns and affect hematopoiesis. Life Science Alliance, 2018, 1, e201800153.	1.3	16
2122	Myelodysplastic syndromes: moving towards personalized management. Haematologica, 2020, 105, 1765-1779.	1.7	52
2123	Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA. Frontiers in Cell and Developmental Biology, 2020, 8, 604391.	1.8	10
2124	Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer. Cancers, 2021, 13, 39.	1.7	26
2125	Recent insights regarding the molecular basis of myeloproliferative neoplasms. Korean Journal of Internal Medicine, 2020, 35, 1-11.	0.7	25
2126	Dynamics of competing heterogeneous clones in blood cancers explains multiple observations - a mathematical modeling approach. Mathematical Biosciences and Engineering, 2020, 17, 7645-7670.	1.0	3
2127	The Molecular Pathogenesis of Multiple Myeloma. Hematology Reports, 2020, 12, 9054.	0.3	9
2128	Aging: A cell source limiting factor in tissue engineering. World Journal of Stem Cells, 2019, 11, 787-802.	1.3	19
2129	Therapy-related myeloid neoplasms - what have we learned so far?. World Journal of Stem Cells, 2016, 8, 231.	1.3	15

#	Article	IF	Citations
2130	The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies. Balkan Medical Journal, 2019, 36, 78-87.	0.3	3
2131	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
2132	NCCN Guidelines Insights: Survivorship, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1016-1023.	2.3	64
2133	A generalized theory of age-dependent carcinogenesis. ELife, 2019, 8, .	2.8	45
2134	Proteomic analysis of young and old mouse hematopoietic stem cells and their progenitors reveals post-transcriptional regulation in stem cells. ELife, 2020, 9, .	2.8	21
2135	Molecular testing for acute myeloid leukemia. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	3
2136	Advances in Diagnosis and Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cancer Treatment and Research, 2021, 181, 1-16.	0.2	1
2137	Loss OfÂ Tet2 ÂIn T Cells Drives Translocated Pathobiont Derived Aryl Hydrocarbon Receptor Agonist-Induced Tc1 Cell Autoimmune Hepatitis. SSRN Electronic Journal, 0, , .	0.4	0
2138	Impact of next generation sequencing results on clinical management in patients with hematological disorders. Leukemia and Lymphoma, 2021, 62, 1702-1710.	0.6	4
2139	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	4.1	23
2140	Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?. Seminars in Hematology, 2021, 58, 226-229.	1.8	22
2141	Epigenetic Clock and Circadian Rhythms in Stem Cell Aging and Rejuvenation. Journal of Personalized Medicine, 2021, 11, 1050.	1.1	11
2142	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. Frontiers in Cardiovascular Medicine, 2021, 8, 768119.	1.1	24
2143	How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?. Best Practice and Research in Clinical Haematology, 2021, 34, 101327.	0.7	2
2145	Inflammatory Modulation of Hematopoiesis: Linking Trained Immunity and Clonal Hematopoiesis with Chronic Disorders. Annual Review of Physiology, 2022, 84, 183-207.	5.6	21
2146	Somatic Mosaicism in Biology and Disease. Annual Review of Physiology, 2022, 84, 113-133.	5.6	5
2147	Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis. Cell Death Discovery, 2021, 7, 297.	2.0	8
2148	Frailty assessment in the care of older people with haematological malignancies. The Lancet Healthy Longevity, 2021, 2, e736-e745.	2.0	23

#	Article	IF	Citations
2149	Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Current Opinion in Hematology, 2022, 29, 1-7.	1.2	29
2150	Calibration-free NGS quantitation of mutations below 0.01% VAF. Nature Communications, 2021, 12, 6123.	5.8	13
2151	Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model. Cancer Science, 2021, 112, 4931-4943.	1.7	21
2152	Distinction of lymphoid and myeloid clonal hematopoiesis. Nature Medicine, 2021, 27, 1921-1927.	15.2	130
2153	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	3.4	44
2154	Mitochondrial Contributions to Hematopoietic Stem Cell Aging. International Journal of Molecular Sciences, 2021, 22, 11117.	1.8	17
2155	Advances in acute myeloid leukemia. BMJ, The, 2021, 375, n2026.	3.0	177
2156	TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. Nature Communications, 2021, 12, 6061.	5.8	47
2157	Cells with cancerâ€associated mutations overtake our tissues as we age. Aging and Cancer, 2021, 2, 82-97.	0.5	15
2158	VEXAS syndrome: An inflammatory and hematologic disease. Seminars in Hematology, 2021, 58, 201-203.	1.8	14
2159	Clonal hematopoiesis in CIN. Blood, 2021, 138, 1204-1206.	0.6	0
2160	Biomarkers in AL Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 10916.	1.8	7
2161	TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. International Journal of Molecular Sciences, 2021, 22, 10782.	1.8	25
2162	Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. Journal of Experimental Medicine, 2021, 218, .	4.2	81
2163	Cell-free Nucleic Acids in Cancer. Advances in Molecular Pathology, 2021, 4, 187-198.	0.2	1
2164	Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. Advances in Molecular Pathology, 2021, 4, 49-63.	0.2	2
2165	Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasms and Its Impact on Prognosis and Management. Advances in Molecular Pathology, 2021, 4, 65-79.	0.2	0
2166	The tumor suppression theory of aging. Mechanisms of Ageing and Development, 2021, 200, 111583.	2.2	8

#	Article	IF	Citations
2167	Therapy-Related AML and MDS: Who Really Has It?. , 2015, 12, .		1
2168	Pre-Leukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. , 2015, 12, .		0
2169	The Origin of Therapy-Related AML Lies Deep Within. , 2015, 12, .		0
2170	Age cutoff in lymphoma diagnosis. Aging, 2015, 7, 451-452.	1.4	0
2171	Ask the Hematopathologists: Diagnostic Approach to Monocytosis. , 2016, 13, .		0
2172	Genetics of Endocrinology. , 2016, , 49-68.		1
2173	Understanding and Controlling Cancer: The Hallmark Concept Revisited â€“ Chance, Evolution and Entropy. Journal of Science Humanities and Arts - JOSHA, 2015, 3, .	0.0	0
2174	Genetic Mutations in Acute Myeloid Leukemia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 245-256.	0.1	1
2175	Acquired Aplastic Anemia: Somatic Mutations and Eltrombopag Take the Spotlight. , 2016, 13, .		0
2176	http://ajbm.net/952016-2/. American Journal of BioMedicine, 2016, 4, 360-363.	0.0	0
2177	The Role of Cbx Proteins in Human Benign and Malignant Hematopoiesis. Blood, 2016, 128, 2651-2651.	0.6	0
2179	Donor Selection and Cell Dose in Haploidentical SCT. Pancreatic Islet Biology, 2017, , 9-16.	0.1	2
2181	Vitamin C Treatment Restores TET2 Deficiency and Confers Sensitivity to PARP Inhibition. , 2017, 14, .		0
2182	7. Current Treatment for Leukemia. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 546-551.	0.0	0
2183	Existing and Emerging Molecular Technologies in Myeloid Neoplasms. Molecular Pathology Library, 2018, , 369-412.	0.1	0
2185	Skin and Vascular Diseaseâ€"Inside-Out/Outside-In. JAMA Cardiology, 2017, 2, 944.	3.0	0
2186	The Myelodysplastic Syndromes. , 2018, , 483-508.		0
2187	Myeloid-Derived Suppressor Cells in Aged Humans. , 2018, , 1-12.		1

#	Article	IF	Citations
2189	The Biologic Interconnections Between Aging and Lymphoma. , 2018, , 1-12.		0
2191	Molecular and Cellular Aspects of Macrophage Aging. , 2018, , 1-32.		0
2192	Inherited Genetic Variants Increase the Likelihood of Developing Clonal Hematopoiesis: Something Akin to Pre-CHIP. , 2018, 15, .		0
2193	The Usual Suspects Aren't Always the Bad Guys! Molecular MRD Comes of Age in AML. , 2018, 15, .		1
2194	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. SSRN Electronic Journal, 0, , .	0.4	1
2195	Anemia in the Elderly. , 2018, , 82-85.		0
2196	Myelodysplastic Syndrome With Single Lineage Dysplasia. , 2018, , 576-579.		0
2197	Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection. Open Access Journal of Oncology and Medicine, 2018, 1, .	0.4	0
2198	Hematopoiesis and Aging. , 2018, , 1-24.		0
2199	2. Diagnosis and Treatment of Leukemia-Recent Advance-. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 493-498.	0.0	0
2208	MACROPHAGE FUNCTIONAL DISORDERS IN RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 486-493.	0.2	3
2210	Clonal Hematopoiesis and Cytopenias in theÂElderly. , 2019, , 195-212.		0
2215	Aging and Malignant Hemopathies: A Complex Multistep Process. , 2019, , 2267-2279.		0
2218	Myelodysplastic Syndrome. , 2019, , 1-21.		0
2219	Atherosclerosis Risk Factors. , 2019, , 9-45.		0
2220	Myeloid-Derived Suppressor Cells in Aged Humans. , 2019, , 733-744.		0
2221	Attack of the Clones: CHIP in the Clinic. , 2019, 16, .		0
2222	Myelodysplastic Syndrome: An Overview. , 2019, , 149-161.		0

#	Article	IF	Citations
2223	Lymphohematopoietic Stem Cells and Their Aging. , 2019, , 995-1009.		0
2224	The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system. OnCOReview, 2019, 9, 3-21.	0.1	0
2228	Chronic Myeloid Neoplasms. , 2020, , 235-251.		0
2235	Presentation of a diagnostically challenging case of chronic eosinophilic leukemia with marrow dysplasia and ringed sideroblasts. SAGE Open Medical Case Reports, 2020, 8, 2050313X2095744.	0.2	0
2237	A summary of the molecular testing recommended in acute myeloid leukemia. , 2020, 4, 012-017.		2
2238	4. NeuroImmuneMetabolic Control of Cardiac Homeostasis and Disease. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 177-180.	0.1	0
2240	A meghatÃ¡rozatlan jelentÅ‘sÃ©gÅ± klonÃ¡lis hemopoesis (CHIP) aktuÃ¡lis kÃ©rdÃ©sei â€“ irodalmi Ã¡ttekintÃ©s. Transfusio, 2020, 53, 106-110.	0.0	0
2244	Hematological Conditions. , 2020, , 405-430.		0
2245	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nature Communications, 2021, 12, 6177.	5.8	30
2246	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. Clinical Cancer Research, 2022, 28, 756-769.	3.2	9
2248	From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review. Diagnostics, 2021, 11, 1982.	1.3	6
2249	Enriched clonal hematopoiesis in seniors with dietary vitamin C inadequacy. Clinical Nutrition ESPEN, 2021, 46, 179-184.	0.5	8
2250	Loss of Y and clonal hematopoiesis in bloodâ€”two sides of the same coin?. Leukemia, 2022, 36, 889-891.	3.3	21
2251	The Biologic Interconnections Between Aging and Lymphoma. , 2020, , 141-152.		0
2252	Myelodysplastic Syndrome. , 2020, , 479-499.		0
2254	Bloedarmoede. , 2020, , 97-102.		0
2256	Epidemiology, Etiology, and Clinical Presentation of Myelodysplastic Syndromes. , 2020, , 3-17.		2
2257	CLL dedifferentiation to clonally related myeloid cells. Blood Advances, 2020, 4, 6169-6174.	2.5	1

#	Article	IF	Citations
2259	T(o) be, or (not) to B, or both? Somatically mutated clonal T cells in common variable immunodeficiency and related immunodeficiencies. Haematologica, 2020, 105, 2702-2703.	1.7	0
2260	Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. Current Opinion in Hematology, 2021, 28, 50-56.	1.2	6
2261	Longitudinal changes in red blood cell distribution width decades after radiation exposure in atomicâ€bomb survivors. British Journal of Haematology, 2021, 193, 406-409.	1.2	3
2262	Stem Cell Biology in Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 1-14.	0.0	0
2263	Some characteristics of patients with myelodysplastic syndrome. Medical Herald of the South of Russia, 2020, 11, 32-42.	0.2	0
2264	Identification and lineage restriction analyses of preleukemia cells in a sporadic biallelic CEBPA mutated acute myeloid leukemia patient. International Journal of Laboratory Hematology, 2021, 43, e145-e147.	0.7	1
2265	OUP accepted manuscript. Journal of Crohn's and Colitis, 2021, , .	0.6	6
2266	The JAK2 mutation. International Review of Cell and Molecular Biology, 2021, 365, 117-162.	1.6	4
2267	Hematopoietic Stem Cell Aging and Malignant Hemopathies. , 2020, , 169-181.		0
2268	CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations. , 2020, 17, .		0
2269	Molecular Genetics and Cell Biology for Hematopathology. , 2020, , 15-34.		0
2270	Molecular Landscape of MDS. , 2020, , 73-90.		0
2271	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant De Novo Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. Journal of Hematology (Brossard, Quebec), 2020, 9, 140-146.	0.4	6
2272	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
2273	LeukemieÃ«n en het myelodysplastisch syndroom. , 2020, , 595-613.		0
2274	Hematopoiesis and Aging. , 2020, , 305-328.		0
2276	The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time. Frontiers in Genetics, 2021, 12, 760039.	1.1	12
2277	Aged healthy mice acquire clonal hematopoiesis mutations. Blood, 2022, 139, 629-634.	0.6	13

#	Article	IF	Citations
2278	The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. Blood Advances, 2021, 5, 5584-5587.	2.5	8
2279	Prostate cancer research in the 21st century; report from the 2021 Coffeyâ€Holden prostate cancer academy meeting. Prostate, 2021, , .	1.2	2
2280	Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA,ÂPTENÂandÂRET mutations in solid tumors. Molecular and Clinical Oncology, 2021, 16, 1.	0.4	1
2281	Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2021, , .	2.0	2
2282	Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells. Cancers, 2021, 13, 5511.	1.7	4
2283	EXCELLENT PROGNOSIS OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DETECTABLE MYELOID-RELATED MUTATIONS. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
2284	Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science, 2021, 374, 768-772.	6.0	93
2285	Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues. Nature Genetics, 2021, 53, 1597-1605.	9.4	33
2286	Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	1.5	7
2287	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke, 2022, 53, 788-797.	1.0	88
2288	Is Myelodysplasia a Consequence of Normal Aging?. Current Oncology Reports, 2021, 23, 142.	1.8	5
2289	The Role and Impact of Minimal Residual Disease in NSCLC. Current Oncology Reports, 2021, 23, 136.	1.8	13
2290	A review of FLT3 inhibitors in acute myeloid leukemia. Blood Reviews, 2022, 52, 100905.	2.8	50
2291	Acute Myeloid Leukemia: Epidemiology and Etiology. Hematologic Malignancies, 2021, , 3-9.	0.2	2
2293	Deciphering the role of Wnt signaling in acute myeloid leukemia prognosis: how alterations in DNA methylation come into play in patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3097-3109.	1.2	4
2294	Seeds of cancer in normal skin. Nature, 2020, 586, 504-506.	13.7	1
2297	Leukemia Stem Cells: Concept and Implications. Methods in Molecular Biology, 2021, 2185, 25-37.	0.4	2
2298	No Differences in Outcomes Between JAK2 V617Fâ€“Positive Patients with Variant Allele FractionÂ< 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e569-e578.	0.2	3

#	Article	IF	Citations
2299	Aging Liver: Can Exercise be a Better Way to Delay the Process than Nutritional and Pharmacological Intervention? Focus on Lipid Metabolism. Current Pharmaceutical Design, 2020, 26, 4982-4991.	0.9	2
2303	Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biology and Medicine, 2016, 13, 41-54.	1.4	9
2304	THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. Transactions of the American Clinical and Climatological Association, 2016, 127, 127-139.	0.9	1
2305	Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology, 2016, 30, 330, 333.	0.4	0
2306	Perspective: Neuroregenerative Nutrition. Advances in Nutrition, 2017, 8, 546-557.	2.9	5
2307	Age-related Disease: A Revolution Is Coming. Integrative Medicine, 2018, 17, 12-15.	0.1	0
2308	Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches. Clinical Advances in Hematology and Oncology, 2018, 16, 56-66.	0.3	10
2316	Next generation sequencing guided treatment modulation and prognosis in Acute myeloid leukemia: Case vignettes. American Journal of Blood Research, 2020, 10, 134-144.	0.6	0
2317	Presidential address to the Ulster Medical Society on 3rd October 2019. Ulster Medical Journal, 2020, 89, 72-76.	0.2	0
2318	Aging and leukemic evolution of hematopoietic stem cells under various stress conditions. Inflammation and Regeneration, 2020, 40, 29.	1.5	6
2319	Therapy-related acute myeloid leukemia and its prevention. American Journal of Blood Research, 2020, 10, 416-433.	0.6	1
2320	Employing the CRISPR-Cas System for Clonal Hematopoiesis Research. International Journal of Physical Medicine & Rehabilitation, 2021, 9, .	0.5	1
2321	Myelodysplastic Syndromes and Metabolism. International Journal of Molecular Sciences, 2021, 22, .	1.8	0
2322	Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood, 2022, 139, 357-368.	0.6	106
2324	Myelodysplastic Syndromes and Metabolism. International Journal of Molecular Sciences, 2021, 22, 11250.	1.8	3
2325	The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. Cancers, 2021, 13, 5666.	1.7	11
2326	Aging, Bone Marrow and Next-Generation Sequencing (NGS): Recent Advances and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 12225.	1.8	11
2327	CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL. Cancers, 2021, 13, 5900.	1.7	6

#	Article	IF	Citations
2328	Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. Leukemia, 2022, 36, 1102-1110.	3.3	14
2329	Targeting Mitochondria by Plant Secondary Metabolites: A Promising Strategy in Combating Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 12570.	1.8	7
2330	Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis. JACC: CardioOncology, 2021, 3, 619-634.	1.7	49
2331	DNMT3Aovergrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults. Blood, 2022, 139, 461-464.	0.6	9
2332	Genetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and â€œMissingâ€•Heritability. Biomedicines, 2021, 9, 1728.	1.4	0
2333	Azacytidine Treatment for VEXAS Syndrome. HemaSphere, 2021, 5, e661.	1.2	45
2334	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. Journal of Clinical Oncology, 2022, 40, 189-201.	0.8	79
2335	Personalized Cell Therapy for Patients with Peripheral Arterial Diseases in the Context of Genetic Alterations: Artificial Intelligence-Based Responder and Non-Responder Prediction. Cells, 2021, 10, 3266.	1.8	2
2336	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2022, 6, 2230-2235.	2.5	10
2337	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Advances, 2022, 6, 100-107.	2.5	12
2338	The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing. Molecular Cytogenetics, 2021, 14, 52.	0.4	0
2339	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. Haematologica, 2022, 107, 2051-2063.	1.7	8
2340	TET2 Variants in Japanese Patients With Pulmonary ArterialÂHypertension. CJC Open, 2022, 4, 416-419.	0.7	6
2341	Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors. Cancer Research, 2022, 82, 199-209.	0.4	11
2342	The impact of DNA testing on management of patients with colorectal cancer. Annals of Gastroenterological Surgery, 2022, 6, 17-28.	1.2	3
2343	Dysregulated TET Family Genes and Aberrant 5mC Oxidation in Breast Cancer: Causes and Consequences. Cancers, 2021, 13, 6039.	1.7	6
2344	Why Single-Cell Sequencing Has Promise in MDS. Frontiers in Oncology, 2021, 11, 769753.	1.3	2
2345	Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients. Journal of Blood Medicine, 2021, Volume 12, 1019-1030.	0.7	5

#	Article	IF	Citations
2346	Impaired Redox Homeostasis and Cardiovascular Aging. Healthy Ageing and Longevity, 2022, , 65-86.	0.2	0
2347	Clonal hematopoiesis and its role in the development of hematological diseases. Gematologiya I Transfuziologiya, 2021, 66, 580-592.	0.1	0
2348	Variant interpretation using population databases: Lessons from gnomAD. Human Mutation, 2022, 43, 1012-1030.	1.1	184
2349	Prevalence of Monoclonal Gammopathies Including an Age-Related Monoclonal Gammopathy of Indeterminate Potential (MGIP) in a Racially Diverse US Population Screened by Mass Spectrometry. SSRN Electronic Journal, 0, , .	0.4	0
2350	Genetic Theories of Aging. , 2021, , 2025-2034.		0
2351	Skeletal Stem Cells as the Developmental Origin of Cellular Niches for Hematopoietic Stem and Progenitor Cells. Current Topics in Microbiology and Immunology, 2021, 434, 1-31.	0.7	3
2352	New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia. Central-European Journal of Immunology, 2021, 46, 524-530.	0.4	0
2353	Tumors: Lymphomas. , 2021, , 5251-5260.		0
2354	Stem cellsâ€™ potential to restore function in aging systems; are we there yet?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, , .	1.7	0
2355	Clonal hematopoiesis: Molecular and clinical implications. Leukemia Research, 2022, 113, 106787.	0.4	15
2356	Age influences on the molecular presentation of tumours. Nature Communications, 2022, 13, 208.	5.8	26
2357	Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes. Cancer Epidemiology, 2022, 76, 102090.	0.8	4
2358	KardiovaskulÃre Inflammation: Stand von Klinik und Forschung. , 0, , .		0
2359	Next-Generation Sequencing Analysis in Posttransplant Relapsed Acute Myeloid Leukemia Reveals Clonal Evolution and Donor-Derived Germline Variant Indicating Bone Marrow Chimerism. AJSP Review and Reports, 2019, 24, 260-262.	0.0	0
2360	18. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1983-1991.	0.0	0
2362	Molecular Diagnostics in Bone Marrow Haematopathology. , 2020, , 362-417.		0
2365	Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.	7.7	44
2366	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	3.4	32

#	Article	IF	Citations
2367	Clonal Expansion of Stem/Progenitor Cells in Cancer, Fibrotic Diseases, and Atherosclerosis, and CD47 Protection of Pathogenic Cells. Annual Review of Medicine, 2022, 73, 307-320.	5.0	5
2368	Anti-inflammatory strategies for atherosclerotic artery disease. Expert Opinion on Drug Safety, 2022, 21, 661-672.	1.0	4
2370	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances, 2022, 6, 1941-1946.	2.5	21
2372	Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2022, 28, 73-77.	1.0	6
2373	The Mechanism of Stem Cell Aging. Stem Cell Reviews and Reports, 2022, 18, 1281-1293.	1.7	18
2374	Clonal hematopoiesis in sickle cell disease. Journal of Clinical Investigation, 2022, 132, .	3.9	26
2375	Clonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers. Frontiers in Medicine, 2021, 8, 772166.	1.2	6
2376	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and metaâ€analysis. American Journal of Hematology, 2022, 97, 411-420.	2.0	11
2377	Cell-free DNA analysis in current cancer clinical trials: a review. British Journal of Cancer, 2022, 126, 391-400.	2.9	74
2378	Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. Seminars in Hematology, 2022, 59, 47-53.	1.8	3
2383	PIEZO1 mediates a mechanothrombotic pathway in diabetes. Science Translational Medicine, 2022, 14, eabk1707.	5.8	28
2385	The Complex Interplay of Inflammation, Metabolism, Epigenetics, and Sex in Calcific Disease of the Aortic Valve. Frontiers in Cardiovascular Medicine, 2021, 8, 791646.	1.1	8
2386	Genetic alterations in patients with chronic leucocytosis and persistent thrombocytosis. Journal of Genetics, 2022, 101, 1.	0.4	1
2387	An update on clinical applications of iPSCs from a genomic point of view. , 2022, , 147-175.		0
2388	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	3.2	4
2389	Single-Cell Epigenomics Reveals Mechanisms of Cancer Progression. Annual Review of Cancer Biology, 2022, 6, 167-185.	2.3	9
2390	Immune Mechanisms of Plaque Instability. Frontiers in Cardiovascular Medicine, 2021, 8, 797046.	1.1	14
2391	The German Uranium Minersâ€™ Biobankâ€”A Biobank for OMICs Radiation Research. Radiation, 2022, 2, 62-77.	0.6	1

#	Article	IF	Citations
2392	Immunity, Vascular Aging and Stroke. Current Medicinal Chemistry, 2022, 29, 5510-5521.	1.2	7
2393	Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 460-465.	1.3	4
2394	Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. Stem Cell Reviews and Reports, 2022, 18, 1211-1226.	1.7	8
2395	COPD makes CHIP less indeterminate. Blood, 2022, 139, 310-311.	0.6	0
2396	A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm. Laboratory Medicine, 2022, 53, e134-e138.	0.8	1
2397	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology, 2022, 49, 19-26.	0.8	5
2398	TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell, 2022, 29, 298-314.e9.	5.2	23
2399	Hypoxia signalling in the regulation of innate immune training. Biochemical Society Transactions, 2022, 50, 413-422.	1.6	1
2400	Size and density measurements of single sickle red blood cells using microfluidic magnetic levitation. Lab on A Chip, 2022, 22, 683-696.	3.1	16
2401	Somatic Mutations in Cardiovascular Disease. Circulation Research, 2022, 130, 149-161.	2.0	32
2403	Patience is a virtue. Blood, 2022, 139, 481-482.	0.6	0
2404	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Scientific Reports, 2022, 12, 577.	1.6	27
2405	Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature, 2022, 602, 162-168.	13.7	140
2406	Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study. Kidney International Reports, 2022, 7, 876-888.	0.4	13
2407	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. Expert Review of Clinical Pharmacology, 2022, , 1-13.	1.3	2
2408	Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments. Experimental Hematology, 2022, 107, 51-59.	0.2	1
2410	Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. Current Oncology, 2022, 29, 805-815.	0.9	3
2411	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2022, 139, 2347-2354.	0.6	131

#	Article	IF	Citations
2412	Emerging Concepts of Vascular Cell Clonal Expansion in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATVBAHA121316093.	1.1	12
2413	Bile cellâ€'free DNA: a game changer for management of biliary tract cancer?. ESMO Open, 2022, 7, 100389.	2.0	0
2414	The roles of sex and genetics in the MPN. International Review of Cell and Molecular Biology, 2022, 366, 1-24.	1.6	3
2415	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. International Review of Cell and Molecular Biology, 2022, 366, 83-124.	1.6	12
2416	Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review. Cells, 2022, 11, 580.	1.8	7
2417	JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm. Stem Cells, 2022, 40, 359-370.	1.4	4
2418	Highly specific functional equivalence of XN-HPC for optimum CD34+ cell count in harvested allogeneic bone marrow stem cell products. Hematology, 2022, 27, 232-238.	0.7	2
2419	Clonal hematopoiesis in cardiovascular disease and therapeutic implications. , 2022, 1, 116-124.		32
2420	Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors. Blood Advances, 2022, 6, 1981-1990.	2.5	5
2421	Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions. Cancer Letters, 2022, 532, 215597.	3.2	5
2422	Dissecting TET2 Regulatory Networks in Blood Differentiation and Cancer. Cancers, 2022, 14, 830.	1.7	9
2423	Clonal hematopoiesis and vascular disease. Seminars in Immunopathology, 2022, 44, 303-308.	2.8	6
2424	Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia. Cell Stem Cell, 2022, 29, 184-186.	5.2	2
2425	SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data. Bioinformatics, 2022, 38, 2088-2095.	1.8	4
2426	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes. Communications Biology, 2022, 5, 110.	2.0	8
2427	Clonal hematopoiesis of indeterminate potential in the companion dog. Leukemia, 2022, 36, 1401-1403.	3.3	2
2428	What Clonal Hematopoiesis Can Teach Us About MDS. Frontiers in Oncology, 2022, 12, 794021.	1.3	1
2429	Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F. Journal of Cardiology, 2023, 81, 3-9.	0.8	7

#	Article	IF	Citations
2430	Aging and Clonal Behavior of Hematopoietic Stem Cells. International Journal of Molecular Sciences, 2022, 23, 1948.	1.8	11
2431	Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein. Scientific Reports, 2021, 11, 24432.	1.6	51
2432	Aging and leukemic evolution of hematopoietic stem cells under various stress conditions. Inflammation and Regeneration, 2020, 40, 29.	1.5	16
2433	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A prospective cohort study. SSRN Electronic Journal, 0, , .	0.4	1
2434	Leukemic Stem Cell Research and Its Impact on Therapy Development. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 53a-58a.	0.0	0
2435	Clonal Hematopoiesis and Hematological Disorders. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 301-307.	0.0	0
2436	Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia. Stem Cells Translational Medicine, 2022, 11, 461-477.	1.6	8
2437	CD36-Mediated Fatty Acid Oxidation in Hematopoietic Stem Cells Is a Novel Mechanism of Emergency Hematopoiesis in Response to Infection. Immunometabolism, 2022, 4, .	0.7	4
2438	A Multilevel Approach to the Causes of Genetic Instability in Stem Cells. , 2022, , 1-55.		0
2439	Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis. Methods in Molecular Biology, 2022, 2419, 73-88.	0.4	3
2441	Clonal hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders. Human Molecular Genetics, 2022, 31, 2386-2395.	1.4	7
2442	Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2022, 33, 985-995.	3.0	45
2443	Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2022, 139, 1246-1250.	0.6	15
2444	Body mass index and adipose distribution have opposing genetic impacts on human blood traits. ELife, 2022, 11, .	2.8	4
2445	A BAX door to venetoclax resistance. Blood, 2022, 139, 1124-1126.	0.6	5
2446	A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis. Haematologica, 2022, , .	1.7	0
2447	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. Leukemia Research, 2022, 116, 106818.	0.4	5
2448	Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatology, 2022, 61, 4355-4363.	0.9	14

#	Article	IF	Citations
2449	Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium. Nature Communications, 2022, 13, 943.	5.8	24
2450	Pseudo-mutant P53 is a unique phenotype of <i>DNMT3A</i>-mutated pre-leukemia. Haematologica, 2022, 107, 2548-2561.	1.7	6
2451	DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers in Oncology, 2022, 12, 849376.	1.3	9
2453	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	1.5	33
2454	Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial. Blood, 2022, 139, 1593-1597.	0.6	21
2455	Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes. Hemato, 2022, 3, 268-286.	0.2	0
2456	Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations. JACC: CardioOncology, 2022, 4, 38-49.	1.7	14
2457	Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective. Leukemia, 2022, 36, 1203-1214.	3.3	8
2458	Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. International Journal of Molecular Sciences, 2022, 23, 3177.	1.8	5
2459	Cancer progression as a learning process. IScience, 2022, 25, 103924.	1.9	8
2460	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes and Development, 2022, 36, 259-277.	2.7	19
2461	A clinicianâ€™s handbook for using ctDNA throughout the patient journey. Molecular Cancer, 2022, 21, 81.	7.9	43
2462	Measures of Clonal Hematopoiesis: Are We Missing Something?. Frontiers in Medicine, 2022, 9, 836141.	1.2	1
2463	Thromboinflammation in Myeloproliferative Neoplasms (MPN)â€”A Puzzle Still to Be Solved. International Journal of Molecular Sciences, 2022, 23, 3206.	1.8	8
2464	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematology,the, 2022, 9, e340-e349.	2.2	27
2465	Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity. Haematologica, 2022, 107, 1703-1708.	1.7	8
2466	Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer. Frontiers in Cardiovascular Medicine, 2022, 9, 727487.	1.1	18
2467	Increasing Complexity of Molecular Landscapes in Human Hematopoietic Stem and Progenitor Cells during Development and Aging. International Journal of Molecular Sciences, 2022, 23, 3675.	1.8	5

#	Article	IF	Citations
2468	A Prospective Observational Study of Clinical, Biochemical, and Hematological Profile of Elderly Anemic Patients in a Tertiary Care Hospital. Biomedical and Pharmacology Journal, 2022, 15, 199-207.	0.2	0
2469	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia, 2022, 36, 1343-1350.	3.3	23
2472	Leukemia and Heart Disease. JACC: CardioOncology, 2022, 4, 50-52.	1.7	0
2473	How I diagnose and treat chronic myelomonocytic leukemia. Haematologica, 2022, 107, 1503-1517.	1.7	9
2474	Postnatal conservation of human blood- and marrow-specific CD34+ hematopoietic phenotypes. Experimental Hematology, 2022, , .	0.2	0
2475	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	2.9	41
2476	Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer. Chronic Diseases and Translational Medicine, 2022, 8, 83-90.	0.9	4
2477	RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells, 2022, 11, 854.	1.8	3
2478	Role of p53 in regulation of hematopoiesis in health and disease. Current Opinion in Hematology, 2022, 29, 194-200.	1.2	3
2479	Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations. Experimental Hematology, 2022, , .	0.2	2
2480	Advances in understanding the molecular basis of clonal hematopoiesis. Trends in Molecular Medicine, 2022, 28, 360-377.	3.5	5
2481	Maladaptive trained immunity and clonal hematopoiesis as potential mechanistic links between periodontitis and inflammatory comorbidities. Periodontology 2000, 2022, 89, 215-230.	6.3	13
2482	Somatic Mutations of Hematopoietic Cells Are an Additional Mechanism of Body Aging, Conducive to Comorbidity and Increasing Chronification of Inflammation. Biomedicines, 2022, 10, 782.	1.4	3
2483	TET2 Clonal Hematopoiesis Is Associated With Anthracycline-Induced Cardiotoxicity in Patients With Lymphoma. JACC: CardioOncology, 2022, 4, 141-143.	1.7	4
2484	Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans. Frontiers in Aging, 2022, 3, .	1.2	3
2485	Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool. Experimental Hematology, 2022, 109, 45-54.	0.2	0
2486	Clonal haematopoiesis as a risk factor for therapyâ€related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemoâ€(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	1.2	7
2487	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	15.2	19

#	Article	IF	Citations
2488	Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition. PLoS ONE, 2022, 17, e0266111.	1.1	4
2489	Mantle cell lymphoma and the evidence of an immature lymphoid component. Leukemia Research, 2022, 115, 106824.	0.4	1
2491	Myeloid Toxicity of Radionuclide Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 164-172.	0.7	2
2492	Txnip Enhances Fitness of Dnmt3a-Mutant Hematopoietic Stem Cells via p21. Blood Cancer Discovery, 2022, 3, 220-239.	2.6	7
2493	Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. EBioMedicine, 2022, 78, 103964.	2.7	30
2494	MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. Blood Advances, 2022, 6, 5702-5706.	2.5	3
2495	Somatic Dnmt3a inactivation leads to slow, canonical DNA methylation loss in murine hematopoietic cells. IScience, 2022, 25, 104004.	1.9	2
2496	The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Annals of Hematology, 2022, 101, 1227-1237.	0.8	5
2497	TET2-Driven Clonal Hematopoiesis and Response to Canakinumab. JAMA Cardiology, 2022, 7, 521.	3.0	125
2498	NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset. Blood Advances, 2022, 6, 2409-2413.	2.5	3
2499	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579.	4.7	36
2500	Interleukin-1 (IL-1) and the inflammasome in cancer. Cytokine, 2022, 153, 155850.	1.4	30
2501	The significance of CUX1 and chromosome 7 in myeloid malignancies. Current Opinion in Hematology, 2022, 29, 92-102.	1.2	6
2502	Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Research, 2022, 82, 749-763.	0.4	20
2503	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. Frontiers in Oncology, 2021, 11, 790004.	1.3	11
2504	Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond. Rheumatology, 2022, 61, 3149-3160.	0.9	16
2505	Have we reached a molecular era in myelodysplastic syndromes?. Hematology American Society of Hematology Education Program, 2021, 2021, 418-427.	0.9	23
2506	Driving mosaicism: somatic variants in reference population databases and effect on variant interpretation in rare genetic disease. Human Genomics, 2021, 15, 71.	1.4	5

#	Article	IF	Citations
2507	Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. ClÃ¤nica E InvestigaciÃ³n En Arteriosclerosis, 2023, 35, 35-41.	0.4	1
2508	A Vicious Circle of Clonal Haematopoiesis of Indeterminate Potential and Cardiovascular Disease. Hamostaseologie, 2021, 41, 443-446.	0.9	0
2509	CD8+ cell somatic mutations in multiple sclerosis patients and controlsâ€"Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies. PLoS ONE, 2021, 16, e0261002.	1.1	15
2510	Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia. Nature Communications, 2021, 12, 7244.	5.8	29
2511	<scp>ELN iMDS</scp> flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry. Cytometry Part B - Clinical Cytometry, 2023, 104, 66-76.	0.7	14
2512	SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	26
2513	When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?. Hematology American Society of Hematology Education Program, 2021, 2021, 399-404.	0.9	10
2515	Impaired myelopoiesis in congenital neutropenia: insights into clonal and malignant hematopoiesis. Hematology American Society of Hematology Education Program, 2021, 2021, 514-520.	0.9	2
2517	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HemaSphere, 2022, 6, e676.	1.2	35
2519	Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies. Life, 2021, 11, 1351.	1.1	1
2521	Molecular damage in aging. Nature Aging, 2021, 1, 1096-1106.	5.3	51
2522	Epigenetic and Transcriptional Regulation of Innate Immunity in Cancer. Cancer Research, 2022, 82, 2047-2056.	0.4	5
2523	A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms. Cancer Research Communications, 2022, 2, 258-276.	0.7	0
2524	Clinical application of liquid biopsy in cancer patients. BMC Cancer, 2022, 22, 413.	1.1	3
2525	Aging and â€œrejuvenationâ€•of resident stem cells â€" a new way to active longevity?. Journal of Clinical Practice, 2022, 13, 79-91.	0.2	0
2526	Cell originâ€"dependent cooperativity of mutant Dnmt3a and Npm1 inÂclonal hematopoiesis and myeloid malignancy. Blood Advances, 2022, 6, 3666-3677.	2.5	8
2527	Somatic mutation rates scale with lifespan across mammals. Nature, 2022, 604, 517-524.	13.7	211
2528	Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. Cancer Discovery, 2022, 12, 1760-1781.	7.7	15

#	Article	IF	Citations
2529	Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720â€2A>G variant. Journal of Clinical Laboratory Analysis, 2022, , e24388.	0.9	3
2530	A predictive model for bone marrow disease in cytopenia based on noninvasive procedures. Blood Advances, 2022, 6, 3541-3550.	2.5	2
2531	Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk. Thrombosis and Haemostasis, 2022, 122, 1435-1442.	1.8	3
2532	Niche Regulation of Hematopoiesis: The Environment Is â€œMicro,â€•but the Influence Is Large. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 691-699.	1.1	3
2533	Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications. International Journal of Molecular Sciences, 2022, 23, 4573.	1.8	7
2534	Bone Marrow Niches of Hematopoietic Stem and Progenitor Cells. International Journal of Molecular Sciences, 2022, 23, 4462.	1.8	19
2535	Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nature Reviews Cardiology, 2022, 19, 414-425.	6.1	23
2536	Nonresolving inflammation redux. Immunity, 2022, 55, 592-605.	6.6	35
2537	Next Generation Risk Markers in Preventive Cardio-oncology. Current Atherosclerosis Reports, 2022, , 1.	2.0	2
2538	Cardiovascular disease and the biology of aging. Journal of Molecular and Cellular Cardiology, 2022, 167, 109-117.	0.9	11
2543	Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. JAMA Oncology, 2022, 8, 835.	3.4	25
2544	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies. Cancer Letters, 2022, 538, 215691.	3.2	4
2545	Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clinical Science, 2022, 136, 405-423.	1.8	24
2547	Inflammation and myeloid malignancy: quenching the flame. Blood, 2022, 140, 1067-1074.	0.6	22
2548	Clonal Hematopoiesis and CKD Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 878-879.	3.0	2
2558	Screening of early-staged colorectal neoplasia by clonal hematopoiesis-based liquid biopsy and machine-learning.. American Journal of Cancer Research, 2022, 12, 1088-1101.	1.4	0
2560	Cardiovascular Risk Assessment Using Artificial Intelligence-Enabled Event Adjudication and Hematologic Predictors. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008007.	0.9	5
2561	The Presence of Clonal Hematopoiesis Is Negatively Associated with Diabetic Peripheral Neuropathy in Type 2 Diabetes. Endocrinology and Metabolism, 2022, 37, 243-248.	1.3	3

#	Article	IF	Citations
2563	Dissecting the Genetic and Non-Genetic Heterogeneity of Acute Myeloid Leukemia Using Next-Generation Sequencing and In Vivo Models. Cancers, 2022, 14, 2182.	1.7	4
2564	Somatic Mutations Detected in Parkinson Disease Could Affect Genes With a Role in Synaptic and Neuronal Processes. Frontiers in Aging, 2022, 3, .	1.2	7
2565	Bone Marrow Aging and the Leukaemia-Induced Senescence of Mesenchymal Stem/Stromal Cells: Exploring Similarities. Journal of Personalized Medicine, 2022, 12, 716.	1.1	8
2566	Human acute myeloid leukemia stem cells: evolution of concept. Blood Research, 2022, 57, S67-S74.	0.5	8
2567	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 279-298.	1.8	11
2569	The disordered N-terminal domain of DNMT3A recognizes H2AK119ub and is required for postnatal development. Nature Genetics, 2022, 54, 625-636.	9.4	31
2570	Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Advances, 2022, 6, 3767-3778.	2.5	13
2571	Ageing and cancer: a research gap to fill. Molecular Oncology, 2022, 16, 3220-3237.	2.1	7
2572	Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Molecular Cancer Therapeutics, 2022, , .	1.9	5
2573	Higher red cell distribution width and poorer hospitalizationâ€related outcomes in elderly patients. Journal of the American Geriatrics Society, 2022, 70, 2354-2362.	1.3	6
2574	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 395.e1-395.e11.	0.6	6
2575	The translational challenges of precision oncology. Cancer Cell, 2022, 40, 458-478.	7.7	38
2576	The Cell Typeâ€“Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia. Blood Cancer Discovery, 2022, 3, 346-367.	2.6	16
2577	Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell, 2022, 29, 760-775.e10.	5.2	29
2578	Quiescence regulation by normal haematopoietic stem cells and leukaemia stem cells. FEBS Journal, 2023, 290, 3708-3722.	2.2	3
2579	Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. Current Hematologic Malignancy Reports, 2022, 17, 61-68.	1.2	14
2580	Immune and Inflammatory Networks in Myocardial Infarction: Current Research and Its Potential Implications for the Clinic. International Journal of Molecular Sciences, 2022, 23, 5214.	1.8	18
2581	DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022030.	0.5	2

#	Article	IF	Citations
2582	Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals. Blood Advances, 2022, 6, 4174-4184.	2.5	8
2583	Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells. Nature Communications, 2022, 13, 2691.	5.8	22
2584	Single Cell Biology: Exploring Somatic Cell Behaviors, Competition and Selection in Chronic Disease. Frontiers in Pharmacology, 2022, 13, .	1.6	1
2585	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. Basic Research in Cardiology, 2022, 117, 28.	2.5	9
2586	Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus on Prevention. Contemporary Cardiology, 2022, , 247-270.	0.0	3
2589	The Role of Telomeres in Human Disease. Annual Review of Genomics and Human Genetics, 2022, 23, 363-381.	2.5	39
2590	Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics. Immunity and Ageing, 2022, 19, .	1.8	20
2591	Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL). Cancers, 2022, 14, 2474.	1.7	2
2593	Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. Thrombosis Research, 2022, 213, S107-S112.	0.8	4
2596	Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis. Cancers, 2022, 14, 2487.	1.7	4
2597	Modern Concepts in Cardiovascular Disease: Inflamm-Aging. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	12
2598	Clonal hematopoiesis: Mutation-specific adaptation to environmental change. Cell Stem Cell, 2022, 29, 882-904.	5.2	34
2599	Modeling the temporal dynamics of clonal hematopoiesis. , 0, , .		0
2600	Bloodâ€™s life history traced through genomic scars. Nature, 0, , .	13.7	0
2601	The longitudinal dynamics and natural history of clonal haematopoiesis. Nature, 2022, 606, 335-342.	13.7	136
2602	Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk. Current Cardiology Reports, 2022, 24, 1049-1058.	1.3	9
2603	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1621-1629.	1.1	2
2604	Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease. Journal of Clinical Medicine, 2022, 11, 3160.	1.0	2

#	Article	IF	Citations
2605	Clonal dynamics of haematopoiesis across the human lifespan. Nature, 2022, 606, 343-350.	13.7	160
2606	Acute and chronic leukemias. , 2023, , 403-411.		0
2607	Specification of hematopoietic stem cells in mammalian embryos: A rare or frequent event?. Blood, 0, , .	0.6	1
2609	Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy. Current Issues in Molecular Biology, 2022, 44, 2695-2709.	1.0	11
2610	CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis. Leukemia Research Reports, 2022, 17, 100334.	0.2	1
2611	TET2-mutant clonal hematopoiesis and risk of gout. Blood, 2022, 140, 1094-1103.	0.6	57
2612	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
2613	Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis. Aids, 2022, 36, 1521-1531.	1.0	10
2614	Sporadic, late-onset, and multistage diseases. , 2022, 1, .		5
2615	Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends. Archives of Pathology and Laboratory Medicine, 2023, 147, 425-433.	1.2	1
2616	Clonal hematopoiesis in clinical practice: walking a tightrope. Leukemia and Lymphoma, 2022, 63, 2536-2544.	0.6	1
2617	Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation. Transplantation and Cellular Therapy, 2022, , .	0.6	1
2618	A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility forÂtesting interventions. Blood, 2022, 140, 1774-1789.	0.6	13
2619	Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors. Clinical Research in Cardiology, 2023, 112, 506-517.	1.5	1
2621	Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome. GeroScience, 2023, 45, 1231-1236.	2.1	3
2622	A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence. Cancers, 2022, 14, 2871.	1.7	5
2623	Mechanisms that regulate the activities of TET proteins. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	27
2624	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2022, , .	1.2	0

#	Article	IF	Citations
2627	Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock. European Journal of Heart Failure, 2022, 24, 1573-1582.	2.9	20
2629	Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. Blood Reviews, 2022, 56, 100986.	2.8	6
2630	Therapy-Related Clonal Hematopoiesis. Heart Failure Clinics, 2022, 18, 349-359.	1.0	1
2631	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Advanced Heart Failure. , 2022, 2, 218-221.		0
2632	Detection of ASXL1 Codon 646 Variant Using Amplicon-Based Next-Generation Sequencing. , 2022, 44, 76-81.		0
2633	Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone,. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022058.	0.5	0
2634	<scp>AGS</scp> and <scp>NIA</scp> benchâ€to bedside conference summary: Cancer and cardiovascular disease. Journal of the American Geriatrics Society, 2022, 70, 2764-2774.	1.3	4
2635	Evaluation the role of MicroRNAs in diagnosis and prognosis of acute myeloid leukemia. International Journal of Health Sciences, 0, , .	0.0	0
2636	Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer. Haematologica, 2023, 108, 161-170.	1.7	2
2637	Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma. Cancers, 2022, 14, 3222.	1.7	5
2638	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO Precision Oncology, 2022, , .	1.5	9
2639	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
2640	Myelodysplastic syndrome: epidemiology, diagnostics and epigenetic disorders. Medical Herald of the South of Russia, 2022, 13, 179-190.	0.2	0
2641	Myelodysplastic Syndrome: Diagnosis and Screening. Diagnostics, 2022, 12, 1581.	1.3	4
2642	Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells, 2022, 11, 2107.	1.8	7
2643	Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. Diagnostics, 2022, 12, 1659.	1.3	1
2644	PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation. Blood Cancer Discovery, 2022, 3, 444-467.	2.6	10
2645	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. Journal of Internal Medicine, 2022, 292, 262-277.	2.7	7

#	Article	IF	Citations
2646	Aging: Lifespan and the evolution of somatic mutation rates. Current Biology, 2022, 32, R753-R755.	1.8	0
2647	Clonal haematopoiesis mutations in cardiogenic shock: a beginning of a new era?. European Journal of Heart Failure, 2022, 24, 1583-1585.	2.9	0
2648	Microâ€environment alterations through time leading to myeloid malignancies. British Journal of Pharmacology, 2024, 181, 283-294.	2.7	2
2649	Recent advances in â€œsickle and nicheâ€•research - Tribute to Dr. Paul S Frenette -. Stem Cell Reports, 2022, 17, 1509-1535.	2.3	8
2650	Beyond Pathogenic RUNX1 Germline Variants: The Spectrum of Somatic Alterations in RUNX1-Familial Platelet Disorder with Predisposition to Hematologic Malignancies. Cancers, 2022, 14, 3431.	1.7	5
2651	Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects. Nature Medicine, 2022, 28, 1439-1446.	15.2	36
2653	Somatic mutations in acquired pure red cell aplasia. Seminars in Hematology, 2022, , .	1.8	4
2654	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	0.6	204
2655	Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Pancreatology, 2022, , .	0.5	2
2656	Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease. Diagnostics, 2022, 12, 1613.	1.3	4
2657	Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI Insight, 2022, 7, .	2.3	16
2658	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655.	0.6	10
2659	Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nature Genetics, 2022, 54, 1155-1166.	9.4	109
2660	Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study. Npj Breast Cancer, 2022, 8, .	2.3	6
2661	The Need for Individualized Risk Assessment in Cardiovascular Disease. Journal of Personalized Medicine, 2022, 12, 1140.	1.1	4
2662	Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?. Lancet Haematology,the, 2022, 9, e523-e534.	2.2	14
2663	Targeted sequencing of candidate gene regions for myelofibrosis in dogs. Journal of Veterinary Internal Medicine, 0, , .	0.6	2
2664	Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews, 2023, 57, 100991.	2.8	5

#	Article	IF	Citations
2665	Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell, 2022, 40, 850-864.e9.	7.7	82
2666	Ageing and rejuvenation of tissue stem cells and their niches. Nature Reviews Molecular Cell Biology, 2023, 24, 45-62.	16.1	96
2667	A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology. Cancers, 2022, 14, 3663.	1.7	3
2668	Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy. , 2022, 1, .		0
2669	ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia, 2022, 36, 2242-2249.	3.3	14
2670	CAR T-cell Therapy Meets Clonal Hematopoiesis. Blood Cancer Discovery, 2022, 3, 382-384.	2.6	4
2671	Cardiovascular Disease in Myeloproliferative Neoplasms. JACC: CardioOncology, 2022, 4, 166-182.	1.7	23
2672	Hematopoyesis Clonal de Potencial Indeterminado (HCPI): mÃ¡s allÃ¡ de un modelo de campo de cancerizaciÃ³n. Revista Colombiana De CancerologÀa, 2021, 25, 210-221.	0.0	0
2674	Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia, 2022, 36, 2151-2164.	3.3	24
2675	Evaluation the role of MicroRNAs in diagnosis and prognosis of acute myeloid leukemia. International Journal of Health Sciences, 0, , 276-293.	0.0	0
2677	Comparison of High-Resolution Melting (HRM) Analysis with Direct Sequencing for the Detection of DNMT3A Mutations in AML Patients. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2185-2190.	0.5	2
2678	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers, 2022, 14, 3674.	1.7	3
2679	Religious fasting and the vascular health. Indian Heart Journal, 2022, , .	0.2	0
2680	Discovering the drivers of clonal hematopoiesis. Nature Communications, 2022, 13, .	5.8	33
2682	Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	8
2683	Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. Life, 2022, 12, 1135.	1.1	6
2684	The role of inflammation in hematopoiesis and bone marrow failure: What can we learn from mouse models?. Frontiers in Immunology, 0, 13, .	2.2	7
2685	Clonal Hematopoiesis and Epigenetic Age Acceleration in Elderly Danish Twins. HemaSphere, 2022, 6, e768.	1.2	3

#	Article	IF	Citations
2686	Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovascular Research, 2023, 118, 3451-3466.	1.8	9
2687	Effect of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIV. Experimental Hematology, 2022, 114, 18-21.	0.2	7
2688	Clonal haematopoiesis of indeterminate potential and impaired kidney functionâ€"A Danish general population study with 11â€‰years followâ€up. European Journal of Haematology, 2022, 109, 576-585.	1.1	8
2689	Clonal hematopoiesis of indeterminate potential: clinical relevance of an incidental finding in liquid profiling. Laboratoriums Medizin, 2022, 46, 301-310.	0.1	3
2690	Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas. Diagnostics, 2022, 12, 2001.	1.3	5
2691	Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Reviews, 2023, 57, 100996.	2.8	12
2692	CHIPing away the progression potential of CHIP: A new reality in the making. Blood Reviews, 2023, 58, 101001.	2.8	6
2694	Considerations for carcinogenesis countermeasure development using mouse models. Life Sciences in Space Research, 2022, , .	1.2	1
2696	Clonal haematopoiesis of indeterminate potentialâ€related mutations and outcome in dilated and ischaemic cardiomyopathy. ESC Heart Failure, 2022, 9, 3954-3960.	1.4	3
2697	Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?. Seminars in Hematology, 2022, 59, 150-155.	1.8	3
2698	Single-cell genomics in AML: extending the frontiers of AML research. Blood, 2023, 141, 345-355.	0.6	14
2699	The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discovery, 2022, 12, 2392-2413.	7.7	28
2700	DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. Immunity, 2022, 55, 1386-1401.e10.	6.6	27
2701	Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq). Journal of Molecular Diagnostics, 2022, , .	1.2	1
2702	Somatic mutations in VEXAS Syndrome and Erdheim-Chester disease: Inflammatory myeloid diseases. Seminars in Hematology, 2022, 59, 156-166.	1.8	4
2703	Somatic compensation of inherited bone marrow failure. Seminars in Hematology, 2022, 59, 167-173.	1.8	3
2704	Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. Human Molecular Genetics, 2023, 32, 489-495.	1.4	1
2706	Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells. Nature Genetics, 2022, 54, 1406-1416.	9.4	31

#	Article	IF	Citations
2707	The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome. Seminars in Hematology, 2022, 59, 123-130.	1.8	7
2708	Germline Testing for the Evaluation of Hereditary Cancer Predisposition. Clinics in Laboratory Medicine, 2022, 42, 497-506.	0.7	0
2709	Donorâ€derived Acute Myeloid Leukemia in solid organ transplantation. American Journal of Transplantation, 0, , .	2.6	1
2710	Turning the clock forward: Inflammation accelerates the aging of hematopoietic stem cells. Cell Stem Cell, 2022, 29, 1156-1158.	5.2	1
2711	Mechanisms involved in hematopoietic stem cell aging. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	6
2712	miR-196bâ€“TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML. Clinical Cancer Research, 2022, 28, 4574-4586.	3.2	5
2713	Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts. Communications Biology, 2022, 5, .	2.0	14
2714	How Azanucleosides Affect Myeloid Cell Fate. Cells, 2022, 11, 2589.	1.8	3
2716	Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients. American Journal of Transplantation, 2022, 22, 3078-3086.	2.6	7
2717	Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. Blood Cancer Journal, 2022, 12, .	2.8	8
2718	Cancer-driving mutations are enriched in genic regions intolerant to germline variation. Science Advances, 2022, 8, .	4.7	2
2719	Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. Lancet Haematology,the, 2022, 9, e605-e614.	2.2	6
2720	Non-neutral clonal selection and its potential role in mammalian germline stem cell dysfunction with advancing age. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
2721	Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants. Blood Advances, 2022, 6, 5732-5736.	2.5	3
2722	Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels. Cancer Genetics, 2022, 266-267, 86-89.	0.2	0
2723	Clonal germinal center B cells function as a niche forÂT-cell lymphoma. Blood, 2022, 140, 1937-1950.	0.6	17
2724	HIV accelerates clonal hematopoiesis and cardiovascular aging. Aids, 2022, 36, 1599-1601.	1.0	0
2725	Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection. Trends in Immunology, 2022, 43, 693-695.	2.9	1

#	Article	IF	Citations
2726	Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer, 2022, 172, 19-28.	0.9	9
2727	Geographic disparities in cardiovascular mortality among patients with myelodysplastic syndromes: A population-based analysis.. Cancer Epidemiology, 2022, 80, 102238.	0.8	1
2729	Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Journal of Clinical Oncology, 2023, 41, 132-142.	0.8	27
2730	Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma. American Journal of Hematology, 2022, 97, 1538-1547.	2.0	3
2731	Genome-Based Medicine for Acute Myeloid Leukemia: Study and Targeting of Molecular Alterations and Use of Minimal Residual Disease as a Biomarker. Hemato, 2022, 3, 543-568.	0.2	0
2732	The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. , 0, , 1-21.		10
2733	The development of therapy related myeloid neoplasms in childhood cancer survivors. Trends in Cancer, 2022, 8, 790-791.	3.8	0
2734	In Response to Lymphohematopoietic Clones. , 2022, 19, .		0
2735	Role of DNA Damage, Somatic Mutations, Telomere Shortening, and Epigenetic Alterations in Aging and Age-Related Disease. , 2022, , .		0
2736	Inflammation as a Driver of Disease. , 2022, , .		0
2737	Myeloproliferative Neoplasms. , 2022, , .		0
2738	Somatic mutations in â€œbenignâ€•blood diseases. Seminars in Hematology, 2022, 59, 121-122.	1.8	0
2739	Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical Cancer Research, 2023, 29, 81-91.	3.2	19
2740	Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies. Cancer Research, 2022, 82, 4107-4113.	0.4	8
2741	The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis. Experimental Hematology and Oncology, 2022, 11, .	2.0	3
2742	TERT and TET2 Genetic Variants Affect Leukocyte Telomere Length and Clinical Outcome in Coronary Artery Disease Patientsâ€”A Possible Link to Clonal Hematopoiesis. Biomedicines, 2022, 10, 2027.	1.4	3
2743	CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022069.	0.5	1
2744	Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5

#	Article	IF	Citations
2747	Clonal hematopoiesis of indeterminate potential andÂrisk of death from COVID-19. Blood, 2022, 140, 1993-1997.	0.6	8
2748	Clonal hematopoiesis and differential outcomes after immune checkpoint blockade. Cancer Cell, 2022, 40, 1071-1072.	7.7	4
2749	Age-related somatic mutation burden in human tissues. Frontiers in Aging, 0, 3, .	1.2	16
2750	Patient perspectives on testing for clonal hematopoiesis ofÂindeterminate potential. Blood Advances, 2022, 6, 6151-6161.	2.5	3
2751	Genomic profiling for clinical decision making inÂmyeloid neoplasms and acute leukemia. Blood, 2022, 140, 2228-2247.	0.6	72
2752	Sleep exerts lasting effects on hematopoietic stem cell function and diversity. Journal of Experimental Medicine, 2022, 219, .	4.2	26
2754	Inferring the initiation and development of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	12
2756	Molecular Diagnostic Testing for Hematopoietic Neoplasms. Clinics in Laboratory Medicine, 2022, 42, 325-347.	0.7	5
2758	Diagnosis and Treatment of Myelodysplastic Syndromes. JAMA - Journal of the American Medical Association, 2022, 328, 872.	3.8	44
2759	Somatic mutation contributing to clonal haematopoiesis is a risk factor of recurrent stroke in first-ever acute ischaemic stroke: a prospective cohort study. Stroke and Vascular Neurology, 2023, 8, 103-110.	1.5	6
2760	Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. Cancer Discovery, 2022, 12, 2800-2819.	7.7	16
2761	Somatic variation in normal tissues: friend or foe of cancer early detection?. Annals of Oncology, 2022, 33, 1239-1249.	0.6	12
2762	International expert group collaboration for developing an adverse outcome pathway for radiation induced leukemia. International Journal of Radiation Biology, 0, , 1-14.	1.0	2
2763	Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nature Genetics, 2022, 54, 1514-1526.	9.4	50
2764	Clonal hematopoiesis of indeterminate potential and cardiovascular disease. Translational Research, 2023, 255, 152-158.	2.2	3
2765	Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease. Nature Communications, 2022, 13, .	5.8	25
2766	The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Annals of Oncology, 2022, 33, 1269-1283.	0.6	44
2767	The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Molecular Cancer, 2022, 21, .	7.9	4

#	Article	IF	Citations
2768	Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells. Nature Communications, 2022, 13, .	5.8	20
2769	Distinct Tumor Necrosis Factor Alpha Receptors Dictate Stem Cell Fitness versus Lineage Output in Dnmt3a-Mutant Clonal Hematopoiesis. Cancer Discovery, 2022, 12, 2763-2773.	7.7	23
2770	Cell competition in development, homeostasis and cancer. Nature Reviews Molecular Cell Biology, 2023, 24, 221-236.	16.1	33
2771	ASXL1/2 mutations and myeloid malignancies. Journal of Hematology and Oncology, 2022, 15, .	6.9	8
2772	Role of ASXL1 in Hematopoiesis and Myeloid Diseases. Experimental Hematology, 2022, , .	0.2	4
2774	Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nature Reviews Nephrology, 2022, 18, 762-778.	4.1	51
2776	Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. Nature Communications, 2022, 13, .	5.8	18
2777	Hypothesis: can transfer of primary neoplasm-derived extracellular vesicles and mitochondria contribute to the development of donor cellâ€“derived hematologic neoplasms after allogeneic hematopoietic cell transplantation?. Cytotherapy, 2022, 24, 1169-1180.	0.3	1
2778	Compartment-specific mutational landscape of clonal hematopoiesis. Leukemia, 2022, 36, 2647-2655.	3.3	6
2779	The role of aging in cancer. Molecular Oncology, 2022, 16, 3213-3219.	2.1	7
2780	Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. Experimental Hematology and Oncology, 2022, 11, .	2.0	4
2781	Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiological Reviews, 2023, 103, 649-716.	13.1	21
2782	All that glitters is not LGL Leukemia. Leukemia, 2022, 36, 2551-2557.	3.3	8
2785	Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed TomographyÂ(SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). Journal of Cardiovascular Computed Tomography, 2023, 17, 66-83.	0.7	21
2788	Usefulness of Genetic Aberration and Shorter Telomere Length in Myelodysplastic Syndrome: A Pilot Study. Laboratory Medicine, 0, , .	0.8	0
2789	Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations. Molecular Therapy, 2022, 30, 3106-3117.	3.7	23
2790	Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60Âyears. GeroScience, 2023, 45, 543-553.	2.1	5
2791	Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	6

#	Article	IF	Citations
2792	Leukemic Stem Cell Research and Its Impact on Therapy Development. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1735-1742.	0.0	0
2793	Mutational Landscape of Patients Referred for Elevated Hemoglobin Level. Current Oncology, 2022, 29, 7209-7217.	0.9	0
2794	Increased prevalence of clonal hematopoiesis of indeterminate potential in hospitalized patients with COVID-19. Frontiers in Immunology, 0, 13, .	2.2	3
2795	Prior Cancer Is Associated with Lower Atherosclerotic Cardiovascular Disease Risk at First Acute Myocardial Infarction. Biomedicines, 2022, 10, 2681.	1.4	0
2796	Massive expansion of multiple clones in the mouse hematopoietic system long after whole-body X-irradiation. Scientific Reports, 2022, 12, .	1.6	2
2797	Ropeginterferon-alfa2b resolves angina pectoris and reduces JAK2V617F in a patient with clonal hematopoiesis of indeterminate potential: A case report. , 0, 1, .		1
2798	Impact of Clonal Hematopoiesis in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 80, 1545-1556.	1.2	20
2799	IPSS-M has greater survival predictive accuracy compared with IPSS-R in personsâ€‰â‰¥â€‰60Âyears with myelodysplastic syndromes. Experimental Hematology and Oncology, 2022, 11, .	2.0	17
2800	SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia, 2022, 36, 2894-2902.	3.3	12
2801	Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities. JCI Insight, 2022, 7, .	2.3	5
2802	The International Consensus Classification of myelodysplastic syndromes and related entities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 39-51.	1.4	6
2804	Somatic genetic variation in healthy tissue and non-cancer diseases. European Journal of Human Genetics, 2023, 31, 48-54.	1.4	2
2805	Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers. European Journal of Heart Failure, 2023, 25, 4-13.	2.9	11
2807	Evaluating the Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in patients with Non-Small Cell Lung Cancer (NSCLC). International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
2808	Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study. Blood Advances, 0, , .	2.5	0
2809	Clonal Hematopoiesis in Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 80, 1557-1559.	1.2	0
2811	Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	5
2812	An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances, 2023, 7, 2709-2714.	2.5	6

#	Article	IF	Citations
2813	Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. International Journal of Molecular Sciences, 2022, 23, 12054.	1.8	9
2814	Clonal hematopoiesis transcending species barriers. Blood, 2022, 140, 1748-1750.	0.6	1
2817	Neutrophils in aging and agingâ€related pathologies. Immunological Reviews, 2023, 314, 357-375.	2.8	17
2818	The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. Frontiers in Oncology, 0, 12, .	1.3	4
2819	Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia, 2022, 36, 2939-2946.	3.3	14
2820	Acute deletion of TET enzymes results in aneuploidy in mouse embryonic stem cells through decreased expression of Khdc3. Nature Communications, 2022, 13, .	5.8	3
2821	The Role of Inflammation in Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 12906.	1.8	86
2822	Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood, 2023, 141, 380-390.	0.6	4
2823	Clonal hematopoiesis, multi-omics and coronary artery disease. , 2022, 1, 965-967.		1
2824	Clinical, Mutational, and Transcriptomic Characteristics in Elderly Korean Individuals With Clonal Hematopoiesis Driver Mutations. Annals of Laboratory Medicine, 2023, 43, 145-152.	1.2	4
2825	A Multilevel Approach to the Causes of Genetic Instability in Stem Cells. , 2022, , 1445-1498.		0
2826	Cellular heterogeneity and clonal hematopoiesis of immune system cells in atherosclerosis. Russian Journal of Cardiology, 2022, 27, 5228.	0.4	0
2827	Aging drives Tet2 +/â^' clonal hematopoiesis via IL-1 signaling. Blood, 2023, 141, 886-903.	0.6	29
2828	Integrative analysis of multi-omics data for liquid biopsy. British Journal of Cancer, 2023, 128, 505-518.	2.9	8
2829	Immuno-cardio-oncology: Killing two birds with one stone?. Frontiers in Immunology, 0, 13, .	2.2	3
2830	Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood, 2023, 141, 1909-1921.	0.6	31
2831	Clonal hematopoiesis and bone marrow inflammation. Translational Research, 2023, 255, 159-170.	2.2	3
2832	Factors associated with clonal hematopoiesis and interaction with marrow environment. Journal of Bone and Mineral Metabolism, 0, , .	1.3	0

#	Article	IF	Citations
2833	Molecular Pathogenesis of Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2022, 17, 319-329.	1.2	11
2834	Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 3-14.	1.1	10
2836	Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment. Cancers, 2022, 14, 5531.	1.7	4
2837	Clonal hematopoiesis and cardiovascular disease: deciphering interconnections. Basic Research in Cardiology, 2022, 117, .	2.5	11
2838	Recurrent missense variants in clonal hematopoiesisâ€related genes present in the general population. Clinical Genetics, 2023, 103, 247-251.	1.0	2
2839	A novel costimulatory molecule gene-modified leukemia cell-derived exosome-targeted CD4+ T cell vaccine efficiently enhances anti-leukemia immunity. Frontiers in Immunology, 0, 13, .	2.2	3
2840	Association of postâ€vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with highâ€risk cardiovascular disease: the <scp>INVESTED</scp> trial. European Journal of Heart Failure, 2023, 25, 299-310.	2.9	6
2841	Genetic Modifiers of Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2022, 36, 1097-1124.	0.9	4
2842	Cell-free Nucleic Acids in Cancer. Clinics in Laboratory Medicine, 2022, 42, 669-686.	0.7	0
2843	EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Advances, 2023, 7, 1308-1311.	2.5	3
2844	Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. Cancers, 2022, 14, 5656.	1.7	9
2845	Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations. Translational Research, 2023, 255, 171-180.	2.2	5
2846	Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211439.	1.4	3
2847	Somatic Mutations in Myelodysplastic Syndrome Patients in the Context of Allogeneic Stem Cell Transplantation. European Medical Journal Oncology, 0, , 122-129.	0.0	0
2848	The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms. Cancers, 2022, 14, 5690.	1.7	3
2849	A Case Report of HER2-Amplification in the Breast Without Histological Abnormality. International Journal of Surgical Pathology, 2023, 31, 801-804.	0.4	0
2850	Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma. Cancers, 2022, 14, 5699.	1.7	2
2851	Clonal Hematopoiesis and Its Impact on Human Health. Annual Review of Medicine, 2023, 74, 249-260.	5.0	18

#	Article	IF	Citations
2852	Transcriptomic profiling of calcified aortic valves in clonal hematopoiesis of indeterminate potential carriers. Scientific Reports, 2022, 12, .	1.6	1
2853	Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke. Blood, 2023, 141, 787-799.	0.6	21
2854	Age acquired skewed X chromosome inactivation is associated with adverse health outcomes in humans. ELife, 0, 11, .	2.8	9
2855	Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. Science Translational Medicine, 2022, 14, .	5.8	16
2856	Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia. Wiener Medizinische Wochenschrift, 0, , .	0.5	0
2857	An Epigenetic LINE-1-Based Mechanism in Cancer. International Journal of Molecular Sciences, 2022, 23, 14610.	1.8	7
2859	Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes. Hematological Oncology, 2023, 41, 463-473.	0.8	0
2860	Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. Biomedicines, 2022, 10, 3008.	1.4	0
2861	Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts. Annals of Hematology, 0, , .	0.8	1
2862	Analyzing rare mutations in metagenomes assembled using long and accurate reads. Genome Research, 0, , .	2.4	2
2863	Common and rare variant associations with clonal haematopoiesis phenotypes. Nature, 2022, 612, 301-309.	13.7	74
2864	Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer Journal, 2022, 12, .	2.8	8
2865	The Role of Cell-Free DNA in Cancer Treatment Decision Making. Cancers, 2022, 14, 6115.	1.7	10
2866	Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature Communications, 2022, 13, .	5.8	2
2867	Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2023, 19, .	0.7	3
2868	Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms. Leukemia, 0, , .	3.3	0
2869	Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. Clinical Cancer Research, 2023, 29, 899-909.	3.2	14
2870	Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis. Frontiers in Immunology, 0, 13, .	2.2	3

#	Article	IF	Citations
2871	Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias. Seminars in Oncology, 2022, 49, 465-475.	0.8	5
2872	Spatial biology of cancer evolution. Nature Reviews Genetics, 2023, 24, 295-313.	7.7	42
2873	Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors. Leukemia, 0, , .	3.3	1
2874	The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia. British Journal of Haematology, 0, , .	1.2	0
2875	Clonal Hematopoiesis and Risk of Incident Lung Cancer. Journal of Clinical Oncology, 2023, 41, 1423-1433.	0.8	10
2876	Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood, 2023, 141, 1922-1933.	0.6	15
2877	CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. Clinical Cancer Research, 2023, 29, 1403-1411.	3.2	9
2878	Genetic causes and cardiovascular consequences of clonal hematopoiesis in the UK Biobank. , 2023, 2, 13-15.		2
2879	Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation. Cancers, 2022, 14, 5989.	1.7	0
2880	Myeloid cells promote interferon signaling-associated deterioration of the hematopoietic system. Nature Communications, 2022, 13, .	5.8	3
2881	Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease. Hematology American Society of Hematology Education Program, 2022, 2022, 266-271.	0.9	5
2882	Targeting inflammation in lower-risk MDS. Hematology American Society of Hematology Education Program, 2022, 2022, 382-387.	0.9	5
2883	Cancer Genomics. Archives of Medical Research, 2022, 53, 723-731.	1.5	5
2885	The attack of the clones to the cardiovascular system. European Journal of Heart Failure, 2023, 25, 14-16.	2.9	0
2886	Endothelial Dysfunction and Chronic Inflammation: The Cornerstones of Vascular Alterations in Age-Related Diseases. International Journal of Molecular Sciences, 2022, 23, 15722.	1.8	12
2888	Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. GeroScience, 2023, 45, 727-746.	2.1	7
2889	Genetic landscape of chronic myeloid leukemia. International Journal of Hematology, 2023, 117, 30-36.	0.7	12
2890	Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Advances, 0, , .	2.5	2

#	Article	IF	Citations
2891	Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry. Prostate, 2023, 83, 454-461.	1.2	1
2894	Loss of Y in leukocytes as a risk factor for critical COVID-19 in men. Genome Medicine, 2022, 14, .	3.6	6
2895	Is it the time to integrate novel sequencing technologies into clinical practice?. Current Opinion in Hematology, 0, Publish Ahead of Print, .	1.2	0
2896	A new risk factor associated with cardiovascular disease: clonal hematopoiesis of indeterminate potential. Molecular Biology Reports, 0, , .	1.0	0
2898	TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease. , 2023, 2, 144-158.		25
2899	MYB insufficiency disrupts proteostasis in hematopoietic stem cells leading to age-related neoplasia. Blood, 0, , .	0.6	3
2900	Clonal heamatopoiesis and associated cardiovascular diseases. Japanese Journal of Clinical Oncology, 0, , .	0.6	0
2901	Clonal Hematopoiesis in Nonhuman Primates: Harnessing Shared Evolution to Model Clonal Selection in Human Disease. , 2023, 20, .		0
2903	Myocardial infarction in women under 50: Possible implication of clonal haematopoiesis of indetermined potential. Archives of Cardiovascular Diseases, 2023, 116, 106-108.	0.7	0
2904	Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from PreleukemicTP53-Mutant Clonal Hematopoiesis. Blood Cancer Discovery, 2023, 4, 134-149.	2.6	4
2906	State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2023, , .	0.2	1
2907	Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution. ELife, 0, 12, .	2.8	9
2908	Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. Current Oncology, 2023, 30, 1146-1150.	0.9	2
2909	Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. International Journal of Hematology, 2023, 117, 919-924.	0.7	4
2910	Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell, 2023, 41, 210-225.e5.	7.7	32
2911	A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features. Modern Pathology, 2023, 36, 100068.	2.9	0
2914	Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies. Scientific Reports, 2023, 13, .	1.6	6
2915	Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. Leukemia Research, 2023, 125, 107007.	0.4	6

#	Article	IF	Citations
2916	Where diagnosis for myelodysplastic neoplasms (<scp>MDS</scp>) stands today and where it will go: The role of flow cytometry in evaluation of <scp>MDS</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 12-14.	0.7	1
2917	The Association Between Red Cell Distribution Width and Grip Strength in Older Adults. Cureus, 2022, , .	0.2	0
2918	Clonal hematopoiesis and inflammation â€“ the perpetual cycle. Trends in Cell Biology, 2023, 33, 695-707.	3.6	5
2920	Emerging evidence on the role of clonal hematopoiesis of indeterminate potential in chronic kidney disease. Translational Research, 2023, 256, 87-94.	2.2	3
2921	Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia. Current Opinion in Hematology, 2023, 30, 38-44.	1.2	3
2922	Genomics of PDGFR-rearranged hypereosinophilic syndrome. Blood Advances, 0, , .	2.5	0
2923	Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment. Blood Cancer Journal, 2023, 13, .	2.8	8
2924	The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting. Frontiers in Oncology, 0, 13, .	1.3	0
2925	DNA barcoding and nutritional profiling of underutilized native indigenous plant species of Karnataka, India. Molecular Biology Reports, 2023, 50, 3111-3118.	1.0	0
2926	Long-term risk associated with clonal hematopoiesis in patients with severe aortic valve stenosis undergoing TAVR. Clinical Research in Cardiology, 2023, 112, 585-593.	1.5	3
2927	The Immunology of DLBCL. Cancers, 2023, 15, 835.	1.7	10
2929	Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event. Leukemia Research, 2023, 127, 107023.	0.4	1
2930	Causes of Clonal Hematopoiesis: a Review. Current Oncology Reports, 2023, 25, 211-220.	1.8	1
2931	Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	7
2932	The NOTCH-RIPK4-IRF6-ELOVL4 Axis Suppresses Squamous Cell Carcinoma. Cancers, 2023, 15, 737.	1.7	3
2933	Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population. HemaSphere, 2023, 7, e821.	1.2	3
2934	DNA repair deficiency as circulating biomarker in prostate cancer. Frontiers in Oncology, 0, 13, .	1.3	8
2935	Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-transplant Follow-Up: The Role of Next-Generation Sequencing. Biomedicines, 2023, 11, 359.	1.4	0

#	Article	IF	Citations
2936	Increased Inflammasome Activation Is Associated with Aging and Chronic Myelomonocytic Leukemia Disease Severity. Journal of Immunology, 2023, 210, 580-589.	0.4	8
2938	Telomere integrated scoring system of myelodysplastic syndrome. Journal of Clinical Laboratory Analysis, 2023, 37, .	0.9	1
2940	Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis. International Journal of Molecular Sciences, 2023, 24, 2262.	1.8	5
2942	Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene, 2023, 42, 881-893.	2.6	4
2943	Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60â€‰years with acute myeloid leukemia: Assessment of different risk scores. American Journal of Hematology, 0, , .	2.0	0
2944	Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation. Journal of the American College of Cardiology, 2023, 81, 1263-1278.	1.2	8
2945	Intestinal Microbes and Hematological Malignancies. Cancers, 2023, 15, 2284.	1.7	1
2946	Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature, 2023, 616, 755-763.	13.7	19
2947	Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation. JCI Insight, 2023, 8, .	2.3	6
2948	Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease. EBioMedicine, 2023, 91, 104553.	2.7	12
2949	Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions. Current Oncology Reports, 2023, 25, 539-547.	1.8	2
2950	Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. Current Treatment Options in Oncology, 0, , .	1.3	1
2951	Inflammatory signals from fatty bone marrow support DNMT3AÂdriven clonal hematopoiesis. Nature Communications, 2023, 14, .	5.8	13
2952	Clonal haematopoiesis and risk of chronic liver disease. Nature, 2023, 616, 747-754.	13.7	40
2953	Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research, 2023, 129, 107076.	0.4	2
2954	Bleeding in the Setting of Lymphoma, with aÂFocus on WaldenstrÃ¶m Macroglobulinaemia. , 2022, , .		0
2955	On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer. Annual Review of Cancer Biology, 2023, 7, 291-311.	2.3	5
2956	Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes â€“ A potential prognostic marker?. Frontiers in Oncology, 0, 12, .	1.3	0

#	Article	IF	Citations
2957	Germline TP53 pathogenic variants and breast cancer: A narrative review. Cancer Treatment Reviews, 2023, 114, 102522.	3.4	5
2958	A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood Advances, 2023, 7, 5549-5553.	2.5	2
2959	Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica, 2023, 108, 353-366.	1.7	26
2960	The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications. Current Opinion in Hematology, 2023, 30, 53-63.	1.2	2
2961	Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers. JAMA Network Open, 2023, 6, e2254221.	2.8	1
2962	Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up. Haematologica, 2023, 108, 1817-1826.	1.7	4
2963	JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood, 2023, 141, 1934-1942.	0.6	17
2964	Synthetic lethal targeting of <scp> TET2 </scp> â€mutant haematopoietic stem and progenitor cells by <scp>XPO1</scp> inhibitors. British Journal of Haematology, 2023, 201, 489-501.	1.2	0
2965	Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. Cells, 2023, 12, 531.	1.8	1
2966	Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer. Cancer Discovery, 2023, 13, 844-857.	7.7	12
2967	Evolving field of cardio-oncology. , 2023, 1, 141-145.		1
2968	From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers. Leukemia Research, 2023, 127, 107038.	0.4	5
2969	Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Reviews, 2023, 60, 101056.	2.8	2
2970	Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes. Scientific Reports, 2023, 13, .	1.6	1
2971	TP53 in AML and MDS: The new (old) kid on the block. Blood Reviews, 2023, 60, 101055.	2.8	1
2972	Clonal hematopoiesis and ischemic stroke. Blood, 2023, 141, 693-694.	0.6	1
2973	Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease. International Journal of Molecular Sciences, 2023, 24, 3962.	1.8	2
2974	Inflammatory Monocytes: Fanning the Flames of Clonal Hematopoiesis. , 2023, 20, .		0

#	Article	IF	Citations
2975	Clonal Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Adaptive Origins With Maladaptive Consequences?. , 2023, 20, .		0
2976	The etiology of clonal mosaicism in human aging and disease. Aging and Cancer, 2023, 4, 3-20.	0.5	2
2977	Clonal Hematopoiesis: Connecting Aging and Inflammation in Atherosclerosis. Current Atherosclerosis Reports, 2023, 25, 105-111.	2.0	1
2978	Clonal hematopoiesis with DNMT3A mutation is associated with lower white matter hyperintensity volume. CNS Neuroscience and Therapeutics, 2023, 29, 1243-1253.	1.9	1
2979	Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?. Cancers, 2023, 15, 1348.	1.7	1
2980	Clonal hematopoiesis: the nonhereditary genetics of age-associated cardiovascular disease. Current Opinion in Cardiology, 2023, 38, 201-206.	0.8	0
2981	Human Immunodeficiency Virus and Clonal Hematopoiesis. Cells, 2023, 12, 686.	1.8	2
2982	Clonal hematopoiesis and atherosclerotic cardiovascular disease: A primer. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2023, 35, 35-41.	0.1	0
2983	NETworking with cancer: The bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell, 2023, 41, 505-526.	7.7	29
2984	The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw. Cancers, 2023, 15, 1483.	1.7	2
2985	Types of Liquid Biopsies: Understanding the Different Lenses Through Which They Can Detect Cancer. Oncologist, 2023, 28, 281-282.	1.9	0
2987	B-lineage acute lymphoblastic leukemia causes cell autonomous defects in long-term hematopoietic stem cell function.. Haematologica, 0, , .	1.7	2
2988	Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. JCO Precision Oncology, 2023, , .	1.5	4
2989	Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences, 2023, 24, 4790.	1.8	5
2990	Molecular characterization and prognosis of mutant <scp>TP53</scp> acute myeloid leukemia and myelodysplastic syndrome with excess blasts. International Journal of Laboratory Hematology, 0, , .	0.7	0
2991	Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?. Blood Reviews, 2023, 60, 101071.	2.8	1
2992	In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction. International Journal of Molecular Sciences, 2023, 24, 4903.	1.8	1
2993	Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation. Journal of Physical Education and Sports Management, 2023, 9, a006251.	0.5	2

#	Article	IF	Citations
2994	Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes. Blood Advances, 0, , .	2.5	0
2995		0.0	0
2996	White cell deficiency and TET2 and SRSF2 gene mutations. , 2022, 38, 193-196.		0
2997	<scp>ER</scp>+, <scp>HER2</scp>â˜' advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology, 2023, 17, 2000-2016.	2.1	0
2998	Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews, 2023, 60, 101072.	2.8	7
2999	Clinical Circulating Tumor DNA Testing for Precision Oncology. Cancer Research and Treatment, 2023, 55, 351-366.	1.3	6
3000	Clonal Hematopoiesis and the Heart: a Toxic Relationship. Current Oncology Reports, 2023, 25, 455-463.	1.8	0
3001	Mosaic chromosomal alterations detected in men living with HIV and the relationship to non-Hodgkin lymphoma. Aids, 0, Publish Ahead of Print, .	1.0	0
3002	Patterns of mosaicism for sequence and copy-number variants discovered through clinical deep sequencing of disease-related genes in one million individuals. American Journal of Human Genetics, 2023, 110, 551-564.	2.6	3
3003	Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals. Blood Advances, 2023, 7, 3232-3243.	2.5	1
3004	Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception Strategies. Cancer Prevention Research, 2023, 16, 369-378.	0.7	3
3005	Mosaic loss of Y chromosome in monocytes is associated with lower survival after transcatheter aortic valve replacement. European Heart Journal, 2023, 44, 1943-1952.	1.0	11
3006	Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors. Cancer Discovery, 2023, 13, 1310-1323.	7.7	9
3007	Hematopoietic Stem Cells and the Immune System in Development and Aging. International Journal of Molecular Sciences, 2023, 24, 5862.	1.8	7
3008	COVID-19 and the Genetics of Inflammation. Critical Care Medicine, 2023, 51, 817-825.	0.4	3
3009	Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. American Journal of Hematology, 2023, 98, 951-964.	2.0	2
3010	A review of research on the intersection between breast cancer and cardiovascular research in the Womenâ€™s Health Initiative (WHI). Frontiers in Oncology, 0, 12, .	1.3	4
3011	Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 774-783.	1.1	5

#	Article	IF	Citations
3012	An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. International Journal of Molecular Sciences, 2023, 24, 6031.	1.8	1
3013	Association of Lung Function Decline with All-cause and Cancer-cause Mortality after World Trade Center Dust Exposure. Annals of the American Thoracic Society, 0, , .	1.5	0
3014	Recent advances in targeted therapies in acute myeloid leukemia. Journal of Hematology and Oncology, 2023, 16, .	6.9	23
3015	Clonal haematopoiesis and dysregulation of the immune system. Nature Reviews Immunology, 2023, 23, 595-610.	10.6	18
3016	Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke. Stroke, 2023, 54, 938-946.	1.0	5
3018	Mosaic chromosomal alterations and human longevity. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	1.7	0
3019	Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Modern Pathology, 2023, 36, 100166.	2.9	0
3020	Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors. Cancer Epidemiology Biomarkers and Prevention, 2023, 32, 776-783.	1.1	1
3021	Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway. JCI Insight, 0, , .	2.3	1
3022	Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Advances, 2023, 7, 3624-3636.	2.5	9
3023	Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Science Translational Medicine, 2023, 15, .	5.8	6
3025	The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action. HemaSphere, 2023, 7, e872.	1.2	6
3026	Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. Biomedicines, 2023, 11, 1069.	1.4	1
3027	Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia, 2023, 37, 957-963.	3.3	2
3028	Toward a systems-level probing of tumor clonality. IScience, 2023, 26, 106574.	1.9	1
3029	DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nature Cell Biology, 2023, 25, 528-539.	4.6	9
3030	Updates in molecular genetics of acute myeloid leukemia. Seminars in Diagnostic Pathology, 2023, , .	1.0	1
3031	Microbiota influences on hematopoiesis and blood cancers: New Horizons?. Blood Cancer Discovery, 0, , .	2.6	0

#	Article	IF	Citations
3032	Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. Journal of the National Cancer Institute, 2023, 115, 981-988.	3.0	3
3033	Innate Immunity System in Patients With Cardiovascular and Kidney Disease. Circulation Research, 2023, 132, 915-932.	2.0	8
3034	TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Biomedicines, 2023, 11, 1152.	1.4	2
3035	The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms. Blood Cancer Discovery, 2023, 4, 254-266.	2.6	4
3036	The origins and functional effects of postzygotic mutations throughout the human life span. Science, 2023, 380, .	6.0	6
3037	Epigenetic regulation by ASXL1 in myeloid malignancies. International Journal of Hematology, 2023, 117, 791-806.	0.7	4
3038	DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age. Nature Communications, 2023, 14, .	5.8	2
3039	Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs. Journal of Experimental Medicine, 2023, 220, .	4.2	1
3040	Obesity-induced inflammation exacerbates clonal hematopoiesis. Journal of Clinical Investigation, 2023, 133, .	3.9	16
3041	Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing. JCO Precision Oncology, 2023, , .	1.5	2
3042	Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies. Experimental Hematology, 2023, 122, 10-18.	0.2	1
3043	Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort. Annals of Hematology, 2023, 102, 1409-1420.	0.8	7
3044	Clinical implications of myeloid malignancyâ€‘related somatic mutations in aplastic anemia. Clinical and Experimental Medicine, 2023, 23, 4473-4482.	1.9	1
3050	Hallmarks of cardiovascular ageing. Nature Reviews Cardiology, 2023, 20, 754-777.	6.1	28
3065	Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis. Frontiers in Oncology, 0, 13, .	1.3	1
3066	Methylation and hydroxymethylation in cancer. , 2023, , 11-37.		0
3109	Clonal haematopoiesis and atherosclerotic cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 437-438.	6.1	1
3121	Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution. Leukemia, 2023, 37, 1561-1566.	3.3	2

#	Article	IF	Citations
3127	Atherosklerose-Risikofaktoren. , 2023, , 9-47.		0
3155	Cancers make their own luck: theories of cancer origins. Nature Reviews Cancer, 2023, 23, 710-724.	12.8	14
3165	Case report: Rare case of donor cellâ€derived Tâ€cell acute lymphoblastic leukaemia in a female patient after receiving an alloâ€transplant from her male sibling. British Journal of Haematology, 2023, 203, 282-287.	1.2	1
3197	Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly. Cell Death Discovery, 2023, 9, .	2.0	0
3199	Effects of lifestyle factors on leukocytes in cardiovascular health and disease. Nature Reviews Cardiology, 2024, 21, 157-169.	6.1	0
3200	Infection risk associated with clonal hematopoiesis of indeterminate potential is partly mediated by hematologic cancer transformation in the UK Biobank. Leukemia, 2023, 37, 2306-2308.	3.3	1
3203	Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications. Genome Instability & Disease, 2023, 4, 227-238.	0.5	0
3211	Molecular tumour boards â€" current and future considerations for precision oncology. Nature Reviews Clinical Oncology, 2023, 20, 843-863.	12.5	6
3220	Maternal Secondary Genomic Findings Detected by Fetal Genetic Testing. , 2023, , 333-355.		0
3230	Colorimetric Barcoding to Track, Isolate, and Analyze Hematopoietic Stem Cell Clones. Methods in Molecular Biology, 2024, , 265-277.	0.4	0
3241	Hematologic Malignancies. , 2023, , 1-14.		0
3244	Bone Marrowâ€"Resident Stem Cells. , 2024, , 357-379.		0
3247	GamÃ©togenÃ¨se invitro. , 2023, , 419-430.		0
3253	Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention. International Review of Neurobiology, 2023, , 237-284.	0.9	0
3255	Molecular Techniques in the Diagnosis and Monitoring of Acute and Chronic Leukaemias. , 2023, , 23-45.		0
3256	Treatment Algorithm of Essential Thrombocythemia. , 2023, , 523-538.		0
3257	Basic Hematopoiesis and Leukemia Stem Cells. , 2023, , 1-12.		0
3258	Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia. , 2023, , 61-89.		0

#	Article	IF	Citations
3259	Therapy-Related MDS/AML and the Role of Environmental Factors. , 2023, , 409-420.		0
3261	Clonal Hematopoiesis and Its Functional Implications in MDS/AML. , 2023, , 405-407.		0
3263	Hematologic Disorders. , 2023, , 1-31.		0
3275	Molecular testing in myeloproliferative neoplasms. , 2024, , 569-587.		1
3277	Molecular testing in myelodysplastic syndromes. , 2024, , 589-596.		0
3278	Molecular testing in acute myeloid leukemia. , 2024, , 597-615.		0
3284	Macrophage and T cell networks in adipose tissue. Nature Reviews Endocrinology, 0, , .	4.3	0
3287	Clonal haematopoiesis, ageing and kidney disease. Nature Reviews Nephrology, 2024, 20, 161-174.	4.1	1
3289	Precision Nutrition and Cancer. , 2024, , 277-298.		1
3291	Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis, 2023, 12, .	2.1	3
3295	DNA methylation controls hematopoietic stem cell aging. Nature Aging, 2023, 3, 1320-1322.	5.3	0
3308	ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms. Leukemia, 0, , .	3.3	0
3312	Liquid Biopsies for Pancreatic Cancer: Is It Ready for Prime Time?. , 2023, , 147-157.		0
3322	Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 0, , .	0.7	0
3356	Ten-Eleven-Translocation Genes in Cancer. Cancer Treatment and Research, 2023, , 363-373.	0.2	0
3365	Vascular damage in systemic lupus erythematosus. Nature Reviews Nephrology, 2024, 20, 251-265.	4.1	1
3397	Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis. Advances in Experimental Medicine and Biology, 2023, , 29-44.	0.8	0
3400	Immune System Influence on Hematopoietic Stem Cells and Leukemia Development. Advances in Experimental Medicine and Biology, 2023, , 125-135.	0.8	0

#	Article	IF	Citations
3403	Aging, Causes, and Rejuvenation of Hematopoietic Stem Cells. Advances in Experimental Medicine and Biology, 2023, , 201-210.	0.8	0
3404	The Origin of Clonal Hematopoiesis and Its Implication in Human Diseases. Advances in Experimental Medicine and Biology, 2023, , 65-83.	0.8	0
3423	Waldenstrom Macroglobulinemia. , 2024, , .		0
3433	TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clinical and Experimental Medicine, 2024, 24, .	1.9	0
3435	Incidental finding of leukaemia in circulating tumour DNAâ€" the importance of a molecular tumour board. , 2024, 2, .		0
3439	Myelodysplastic Syndrome. , 2024, , .		0
3440	Approaches of Biochar in Ecosystem Management: current scenario and future perspectives. , 0, , .		0
3441	Hematologic Disorders. , 2024, , 511-541.		0
3442	Hematologic Malignancies. , 2024, , 919-932.		0
3444	Biomarkers of minimal residual disease and treatment. Advances in Clinical Chemistry, 2024, , 33-70.	1.8	0
3446	Role of Phenolics in Establishing Mycorrhizal Association in Plants for Management of Biotic Stress. , 2024, , 35-74.		0
3471	Alternative DNA structures in hematopoiesis and adaptive immunity. Advances in Immunology, 2024, , .	1.1	0